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La presente tesis doctoral titulada “Nuevas sondas, portadores y pro-
fármacos dirigidos a células senescentes in vivo” se centra en el diseño, 
preparación, caracterización y evaluación de sondas basadas en fluoróforos 
funcionalizados o en nanopartículas, así como en el desarrollo de profármacos, 
aplicadas al campo de la senescencia celular. 
En el primer capítulo se introducen, a nivel general, los diferentes conceptos 
relacionados con el reconocimiento molecular y la detección de biomarcadores. 
Seguidamente se introducen conceptos básicos de senescencia celular y 
envejecimiento, así como el papel que juegan las células senescentes a nivel 
fisiológico, en enfermedades asociadas al envejecimiento celular y en el cáncer. 
Por último, se aborda también la creciente necesidad de desarrollar nuevas 
herramientas de diagnóstico y terapias centradas en la detección y tratamiento de 
dichas enfermedades.  
En el segundo capítulo se exponen los objetivos generales de la presente tesis 
doctoral, así como los objetivos concretos que son abordados en los diferentes 
capítulos experimentales. 
En el tercer capítulo se describe una nueva sonda molecular para la detección 
de senescencia in vivo. En concreto, se describe el diseño de una sonda de dos 
fotones basada en un fluoróforo de naftalimida conectada, mediante un éster 
metílico de L-histidina, con una galactosa acetilada que esta unida a uno de los 
átomos de nitrógeno aromático de la L-histidina a través de un enlace N-
glicosídico hidrolizable (AHGa). La sonda inicial presenta una baja emsión pero en 
células senescentes se transforma en un fluoróforo con alto rendimiento cuantico 
que permite visualizar estas células debido a la hidrólisis del enlace N-glicosidico 
por la enzima -galactosidasa sobreexpresada en este tipo de células. La sonda es 




quimioterapia inductora de senescencia frente a células control. Adicionalmente, 
se validó la detección in vivo de senescencia en ratones con xenoinjertos 
tumorales tratados con quimioterapia inductora de senescencia. 
Basándonos en los resultados obtenidos en el capítulo tres, en el capítulo 
cuatro se describe un sistema similar cuyas características confieren al fluoróforo 
una mayor longitud de onda de excitación (HeckGal). La nueva sonda es capaz de 
detectar células senescentes debido a la sobreexpresión de la enzima -
galactosidasa asociada a senescencia en gran variedad de líneas celulares con 
diversos métodos de inducción de senescencia. Esta sonda se validó también in 
vivo en un modelo ortotópico de cáncer de mama de ratón tratado con 
quimioterapia inductora de senescencia, y en un modelo de ratón de fibrosis 
renal.  
Seguidamente, el capítulo cinco, se centra en un nuevo concepto de sondas 
moleculares no invasivas, que proporcionan una señal fácilmente legible a través 
de simples medidas de fluorescencia de la orina. Esta idea se llevó a cabo 
mediante la funcionalización de una sonda con grupos que le confieren 
características diuréticas (rápida eliminación renal) y el concepto se aplicó al 
diseño de una sonda para a la detección en orina de la carga senescente en 
diversos modelos. La sonda (Cy7Gal) está basada en la cianina-7 que es 
hidrolizada por la enzima -galactosidasa en un fluoróforo altamente emisivo Cy7. 
Cy7Gal y Cy7 contienen restos de ácido sulfónico que aumentan su solubilidad en 
agua y desencadenan su rápida excreción por el sistema urinario. El grado de 
senescencia se cuantificó por medición directa de fluorescencia en orina en tres 
modelos de senescencia en ratones: (i) un modelo ortotópico de cáncer de mama 
en ratones BALB/cByJ con senescencia inducida por quimioterapia; (ii) ratones 
BALB / cByJ envejecidos de forma natural; y (iii) ratones con senescencia 
acelerada (SAMP8, del inglés Senescence Accelerated Mouse-Prone 8). Además, 
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las imágenes IVIS ex vivo permiten la evaluación de senescencia en diversos 
órganos. La sonda Cy7Gal es el primer ejemplo para la detección y cuantificación 
no invasiva en orina de la presencia in vivo de células senescentes y puede servir 
como base en el desarrollo de nuevas sondas moleculares para el diagnóstico 
rápido en orina de diferentes enfermedades, así como para el seguimiento de 
tratamientos terapéuticos. 
Por último, en lo que a detección de senescencia celular se refiere, se 
presenta en el capítulo seis la detección óptica in vivo de senescencia celular 
mediante el uso de nanopartículas de sílice mesoporosas (S3) cargadas con el 
fluoróforo Nile Blue (NB) y funcionalizadas en su superficie externa con un 
galactohexasacárido. El NB está aprobado por la FDA para su uso en humanos y 
presenta emisión en el infrarrojo cercano (NIR). La emisión a 672 nm de NB se 
encuentra prácticamente desactivada dentro de los poros de las nanopartículas 
S3, debido a la planaridad de la molécula y su capacidad para dar interacciones de 
apilamiento-π. Las nanopartículas S3 están funcionalizadas con un 
galactohexasacárido que les confiere una selectividad específica hacia células 
senescentes. En presencia de estas células y de -galactosidasa, el galactosacárido 
es hidrolizado, produciéndose la liberación de NB que vuelve a emitir 
fluorescencia. La eficacia de la sonda para detectar ópticamente senescencia 
celular se validó in vivo en células senescentes SK-Mel-103 y 4T1, y en ratones 
BALB/cByJ con tumores ortotópicos de cáncer de mama tratados con 
quimioterapia in vivo.  
Una vez alcanzados los objetivos planificados en lo referente al diagnóstico, 
en el capítulo siete se abordó la mejora de uno de los senolíticos más potentes y 
ampliamente conocido en el campo de la senescencia celular que existe a día de 
hoy en el mercado: el Navitoclax, también conocido como ABT-263. Muchas 




especificidad subóptima de los fármacos senolíticos para las células senescentes y 
las altas toxicidades que reducen sus ventanas terapéuticas. El senolítico 
Navitoclax es un inhibidor selectivo de las proteínas antiapoptoticas BCL-2, BCL-XL 
y BCL-W, y su principal efecto secundario en humanos es que induce la muerte 
apoptótica de las plaquetas (trombocitopenia) al depender éstas de BCL-XL para 
su supervivencia. El efecto senolítico de este compuesto proviene de la 
sobreexpresión de proteínas de la familia BCL-2 en células senescentes. Teniendo 
en cuenta lo anterior, se diseñó y preparó un pro-fármaco a través de la 
funcionalización de Navitoclax con un residuo galactosídico (Nav-gal), con el fin de 
que éste no fuese capaz de inhibir las proteínas antiapoptóticas de la familia BCL-
2 cuando está unido al azúcar, evitando así la muerte de células no senescentes. 
Al entrar en el lisosoma de células senescentes, el enlace glicosídico se hidroliza 
por acción de la enzima -galactosidasa (SAβGal), obteniendo Navitoclax libre que 
mata a la célula. La pro-droga Nav-gal se validó en células senescentes de cáncer 
de pulmón humanas (A549) y de ratón (L1475 (luc)); líneas celulares de cáncer de 
melanoma humano (SK-Mel-103) y glándula mamaria de ratón (4T1); células de 
carcinoma colorrectal (HCT116); fibroblastos de pulmón de ratón (células MLg) y 
fibroblastos de pulmón humano (ER: células Mek IMR90) observando un IC50 
similar a el Navitoclax en células senescentes, pero protegiendo a las células no 
senescentes. Además, los estudios in vivo tras el tratamiento con un inductor 
quimioterapéutico de senescencia y Nav-gal produjeron la reducción de células 
senescentes en un modelo ortotópico de cáncer de pulmón y la disminución del 
tamaño tumoral en ratones xenoinjertados con células de cáncer de pulmón 
humanas. Por otra parte, se reduce significativamente la trombocitopenia a las 




Por último, en el capítulo ocho, se presentan las conclusiones principales 
extraídas de los estudios con los diferentes sistemas desarrollados, así como las 
conclusiones generales extraídas de esta tesis doctoral. El desarrollo de sondas, 
nanomateriales y profármacos para detectar y eliminar selectivamente células 
senescentes in vivo se presenta como una nueva estrategia con gran potencial en 
el campo de las enfermedades relacionadas con el envejecimiento. Se espera que 
los resultados obtenidos en esta tesis puedan servir como base para el desarrollo 
de nuevas sondas moleculares y senolíticos para el diagnóstico y tratamiento 
temprano de diferentes enfermedades, así como para el seguimiento en pacientes 
















La present tesi doctoral titulada “Noves sondes, portadors i pro-fàrmacs 
dirigits a cèl·lules senescents in vivo” es centra en el disseny, preparació, 
caracterització i avaluació de sondes basades en fluorófores funcionalitzats o 
nanoparticles, així com en el desenvolupament de profàrmacs, aplicades a el 
camp de la senescència cel·lular. 
En el primer capítol s'introdueixen, a nivell general, els diferents conceptes 
relacionats amb el reconeixement molecular i la detecció de biomarcadors. 
Seguidament s'introdueixen conceptes bàsics de senescència cel·lular i 
envelliment, així com el paper que juguen les cèl·lules senescentes a nivell 
fisiològic, en les malalties associades a l'envelliment cel·lular i en el càncer. 
Finalment, s’aborda la creixent necessitat de desenvolupar noves eines de 
diagnòstic i teràpies centrades en la detecció i tractament d'aquestes malalties. 
En el segon capítol, s'exposen els objectius generals de la present tesi doctoral 
així com els objectius concrets que són abordats en els diferents capítols 
experimentals. 
En el tercer capítol es descriu una nova sonda molecular per a la detecció de 
senescència in vivo. En concret, es descriu el disseny d'una sonda de dos fotons 
basada en un fluorófor de naftalimida conectat, mitjançant un èster metílic de L-
histidina, amb una galactosa acetilada que està unida a un dels àtoms de nitrogen 
aromàtic de la L-histidina a través d'un enllaç N-glicosídic hidrolizable (AHGa). La 
sonda inicial presenta una baixa emsión però en cèl·lules senescents es 
transforma en un fluorófor amb alt rendiment quantinc que permet visualitzar 
aquestes cèl·lules a causa de la hidròlisi de l'enllaç N-glicosídic per l'enzim β-
galactosidasa sobreexpressada en aquest tipus de cèl·lules. La sonda és capaç de 
detectar in vitro cèl·lules de melanoma humà SK-Mel-103 tractades amb 




Addicionalment, es va validar la detecció in vivo de senescència en ratolins amb 
xenoinjerts tumorals tractats amb quimioteràpia inductora de senescència. 
Basant-nos en els resultats obtinguts en el capítol tres, en el capítol quatre es 
descriu un sistema similar però en aquest cas amb un fluorófor amb una major 
longitud d'ona d'excitació i d'emissió (HeckGal).  
La nova sonda és capaç de detectar cèl·lules senescents causa de la 
sobreexpressió de l'enzim β-galactosidasa associada a senescència en gran 
varietat de línies cel·lulars amb diversos mètodes d'inducció de senescència. 
Aquesta sonda es va validar també in vivo en un model ortotòpic de càncer de 
mama de ratolí tractat amb quimioteràpia inductora de senescència, i en un 
model de ratolí de fibrosi renal. 
Seguidament, en el capítol cinc, ens centrem en un nou concepte de sondes 
moleculars no invasives, que proporcionen un senyal fàcilment llegible a través de 
simples mesures de fluorescència de l'orina pel fet que existeix una creixent 
necessitat de mètodes de diagnòstic no invasius, barats i versàtils. Aquesta idea es 
va dur a terme mitjançant la funcionalización d'un fluorófore comú amb grups que 
li confereixen característiques diürètiques (ràpida eliminació renal) i el concepte 
es va aplicar a el disseny d'una sonda per a la detecció en orina de la càrrega 
senescente en diversos models. La sonda (Cy7Gal) està basada en la cianina-7 que 
és hidrolitzada per l'enzim β-galactosidasa en un fluoròfor altament emissiu Cy7. 
Cy7Gal i Cy7 contenen restes d'àcid sulfònic que augmenten la seua solubilitat en 
aigua i desencadenen la seua ràpida excreció pel sistema urinari. El grau de 
senescència es va quantificar per mesurament directe de fluorescència en orina 
en tres models de senescència en ratolins: (i) un model ortotópico de càncer de 
mama de ratolí en ratolins BALB/cByJ amb senescència induïda per quimioteràpia; 
(ii) ratolins BALB/cByJ envellits de manera natural; i (iii) ratolins amb senescència 
accelerada (SAMP8, de l'anglés Senescence Accelerated Mouse-Prone 8). A més, 
les imatges IVIS ex viu permeten l'avaluació de senescència en diversos òrgans. La 
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sonda Cy7Gal és el primer exemple per a la detecció i quantificació no invasiva en 
orina de la presència in vivo de cèl·lules senescents i pot servir com a base en el 
desenvolupament de noves sondes moleculars per al diagnòstic ràpid en orina de 
diferents malalties, així com per al seguiment de tractaments terapèutics. 
Finalment en el que a detecció de senescència cel·lular es refereix, es 
presenta en el capítol sis la detecció òptica in vivo de senescència cel·lular 
mitjançant l'ús de nanopartícules de sílice mesoporoses (S3) carregades amb el 
fluorófor Nile Blue (NB) i funcionalizadas en la seua superfície externa amb un 
galactohexasacárido. El NB està aprovat per la FDA i presenta emissió en 
l'infraroig pròxim (NIR). L'emissió a 672 nm de NB es troba pràcticament 
desactivada dins dels porus de les nanopartícules S3, degut a la planaridad de la 
molècula i la seua capacitat per a donar interaccions d'apilament-π. Les 
nanopartícules S3 estan cobertes amb un galactohexasacàrid que els confereix 
una selectivitat específica per les cèl·lules senescents. En presència de aquestes 
cèl·lules i de -galactosidasa, el galactohexasacàrid és hidrolitzat, produint-se 
l'alliberament de NB que torna a emetre fluorescència. L'eficàcia de la sonda per a 
detectar òpticament la senescència cel·lular es va validar in vitro en cèl·lules 
senescentes SK-Mel-103 i 4T1, i en ratolins BALB/cByJ amb tumors ortotòpics de 
càncer de mama tractats amb quimioteràpia in vivo.  
Una vegada aconseguits els objectius planificats referent al diagnòstic, en el 
capítol set, es va abordar la millora d'un dels senolíticos més potents i àmpliament 
conegut en el camp de la senescència cel·lular que existeix hui dia en el mercat: el 
Navitoclax, també conegut com ABT-263. Moltes potencials teràpies senolíticas a 
humans es veuen obstaculitzades per l'especificitat subòptima dels fàrmacs 
senolíticos per a les cèl·lules senescentes i les altes toxicitats que redueixen les 
seues finestres terapèutiques. El senolítico Navitoclax és un inhibidor selectiu de 
les proteïnes antiapoptoticas BCL-2, BCL-XL i BCL-W, i el seu principal efecte 
secundari en humans és que indueix la mort apoptótica de les plaquetes 
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(trombocitopenia) en dependre aquestes de BCL-XL per a la seua supervivència. 
L'efecte senolítico d'aquest compost prové de la sobreexpresión de proteïnes de 
la família BCL-2 en cèl·lules senescentes. Tenint en compte l'anterior, es dissenye i 
va preparar un pro-fàrmac a través de la funcionalización de Navitoclax amb un 
residu galactosídico (Nav-gal), amb la finalitat que aquest no fóra capaç d'inhibir 
les proteïnes antiapoptóticas de la família BCL-2 quan està unit al sucre, evitant 
així la mort de cèl·lules no senescentes. En entrar en el lisosoma de cèl·lules 
senescentes, l'enllaç glicosídic s'hidrolitza per acció de l'enzim β-galactosidasa 
(SAβGal), obtenint Navitoclax lliure que mata a la cèl·lula. La pro-droga Nav-gal es 
va validar en cèl·lules senescentes de càncer de pulmó humanes (A549) i de ratolí 
(L1475 (luc)); línies cel·lulars de càncer de melanoma humà (SK-Mel-103) i 
glàndula mamària de ratolí (4T1); cèl·lules de carcinoma colorectal (HCT116); 
fibroblastos de pulmó de ratolí (cèl·lules MLg) i fibroblastos de pulmó humà (ER: 
cèl·lules Mek IMR90) observant un IC50 similar al Navitoclax en cèl·lules 
senescentes però protegint a les cèl·lules no senescentes. A més els estudis in vivo 
després del tractament amb un inductor quimioterapéutico de senescència i Nav-
gal van produir la reducció de cèl·lules senescentes en un model ortotópico de 
càncer de pulmó i la disminució de la grandària tumoral en ratolins xenoinjertados 
amb cèl·lules de càncer de pulmó humanes. A més es redueix significativament la 
trombocitopenia a les dosis de tractament, aconseguint-se així una millora en el 
perfil terapèutic del fàrmac. 
Finalment, en el capítol huit, es presenten les conclusions principals extretes 
dels estudis amb els diferents sistemes desenvolupats així com les conclusions 
generals extretes d'aquesta tesi doctoral. El desenvolupament de sondes, 
nanomaterials i profármacos per a detectar i eliminar selectivament cèl·lules 
senescentes in vivo es presenta com una nova estratègia amb gran potencial en el 
camp de les malalties relacionades amb l'envelliment. S'espera que els resultats 
obtinguts en aquesta tesi puguen servir com a base per al desenvolupament de 
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noves sondes moleculars i senolíticos per al diagnòstic i tractament primerenc de 







This PhD thesis entitled "New probes, carriers and pro-drugs to target 
senescent cells in vivo" focuses on the design, preparation, characterization and 
validation of probes based on functionalized fluorophores or nanoparticles coated 
with biomolecules, as well as on the development of prodrugs, applied to the field 
of cellular senescence. The first chapter introduces, at a general level, the 
different concepts related to molecular recognition and the detection of 
biomarkers. Next, basic concepts of cellular senescence and aging are introduced, 
as well as the role that senescent cells play at a physiological level, in diseases 
associated with cellular aging and in cancer. Finally, the growing need to develop 
new diagnostic tools and therapies focused on the detection and treatment of 
these diseases is also addressed. 
The second chapter sets out the general objectives of this doctoral thesis as 
well as the specific objectives that are addressed in the different experimental 
chapters. 
The third chapter describes a new molecular probe for the detection of 
senescence in vivo. Specifically, the design of a two-photon probe based on a 
naphthalimide fluorophore connected, by means of a methyl ester of L-histidine, 
with an acetylated galactose that is attached to one of the aromatic nitrogen 
atoms of L-histidine through a hydrolyzable N-glycosidic bond (AHGa) is 
described. The initial probe has a low emission but it is transformed in senescent 
cells into a fluorophore with high quantum yield due to the hydrolysis of the N-
glycosidic bond by the enzyme β-galactosidase overexpressed in senescent cells. 
The probe is capable of detecting SK-Mel-103 human melanoma cells treated with 
senescence-inducing chemotherapy in vitro against control cells. Additionally, the 
in vivo detection of senescence was validated in mice with tumor xenografts 
treated with senescence-inducing chemotherapy. 
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Based on the results obtained in chapter three, chapter four describes a 
similar fluorophore with a longer excitation wavelength (HeckGal). The new probe 
was capable of detecting senescent cells due to the overexpression of the enzyme 
β-galactosidase associated with senescence in a wide variety of cell lines and 
using various methods of inducing senescence. This probe was also validated in 
vivo in a mouse orthotopic model of breast cancer treated with senescence-
inducing chemotherapy, and in a mouse model of renal fibrosis. 
Chapter five focuses on a new concept of molecular probes, which provide an 
easily readable signal through simple measurements of fluorescence in urine. This 
idea was carried out by functionalizing a probe with groups that confer diuretic 
characteristics (rapid renal clearance) and the concept was applied to the design 
of a probe to detect cellular senescence burden in various senescence models. 
The probe (Cy7Gal) is based on cyanine-7 which is hydrolyzed by the enzyme β-
galactosidase into a highly emissive Cy7 fluorophore. Cy7Gal and Cy7 contain 
sulfonic acid residues that increase their solubility in water and trigger their rapid 
excretion through the urinary system. The degree of senescence was quantified 
by direct measurement of fluorescence in urine in three models of senescence in 
mice: (i) an orthotopic model of breast cancer in BALB / cByJ mice with 
chemotherapy-induced senescence; (ii) naturally aged BALB / cByJ mice; and (iii) 
mice with accelerated senescence (SAMP8, Senescence Accelerated Mouse-Prone 
8). In addition, IVIS ex vivo images allow the assessment of senescence in various 
organs. Our findings demonstrate that renal clearable fluorogenic probes are a 
versatile modular tool that opens new opportunities to develop simple diagnoses 
in urine for a variety of diseases where the abnormal enzymatic activity is a 
biomarker. 
Finally, regarding the detection of cellular senescence, chapter six reports the 
in vivo optical detection of cellular senescence through the use of mesoporous 
silica nanoparticles (S3) loaded with the Nile Blue (NB) fluorophore and 
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functionalized on the outer surface with a galactohexasaccharide. NB is FDA 
approved for use in humans and displays a Near Infrared (NIR) emission. The 
emission at 672 nm of NB is practically deactivated within the pores of the S3 
nanoparticles, due to the planarity of the molecule and its ability to give stacking-
π interactions. S3 nanoparticles are functionalized with a galactohexasaccharide 
that gives them a specific selectivity towards senescent cells. In the presence of 
these cells, β-galactosidase hydrolizes the capping galactosaccharide resulting in 
the release of the NB fluorophore. The efficacy of the probe to optically detect 
cellular senescence was validated in vitro in senescent SK-Mel-103 and 4T1 cells, 
and in vivo in BALB / cByJ mice with orthotopic breast cancer tumors treated with 
chemotherapy. 
Once the planned objectives related with diagnosis were achieved, chapter 
seven addressed the chemical modification and uses of a powerful and widely 
known senolytic: Navitoclax, also known as ABT-263. Many potential human 
senolytic therapies are hampered by the suboptimal specificity of senolytic drugs 
for senescent cells and the high toxicities that reduce their therapeutic windows. 
The senolytic Navitoclax is a selective inhibitor of the antiapoptotic proteins BCL-
2, BCL-XL and BCL-W, and its main side effect in humans is that it induces 
apoptotic death of platelets (thrombocytopenia). The senolytic effect of 
navitoclax comes from the overexpression of proteins of the BCL-2 family in 
senescent cells. Taking into account the above, a pro-drug was designed and 
prepared through the functionalization of Navitoclax with a galactosidic residue 
(Nav-gal). Upon entering the lysosome of senescent cells, the glycosidic bond is 
hydrolyzed by the action of the enzyme β-galactosidase, obtaining free Navitoclax 
that kills the cell. The prodrug Nav-gal was validated in human (A549) and mouse 
(L1475 (luc)) lung cancer senescent cells; human melanoma cancer cell lines (SK-
Mel-103) and mouse mammary gland (4T1); colorectal carcinoma cells (HCT116); 
mouse lung fibroblasts (MLg cells) and human lung fibroblasts (ER: Mek IMR90 
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cells) observing an IC50 similar to Navitoclax in senescent cells but protecting non-
senescent cells. Furthermore, in vivo studies after treatment with a 
chemotherapeutic senescence inducer and Nav-gal produced a reduction of 
senescent cells in an orthotopic model of lung cancer and a decrease in tumor size 
in xenografted mice with human lung cancer cells. In addition, thrombocytopenia 
was significantly reduced at treatment doses, thus achieving an improvement in 
the therapeutic profile of the drug. 
Finally, in chapter eight, the main conclusions obtained from the studies with 
the different systems developed are presented, as well as the general conclusions 
drawn from this doctoral thesis. The development of probes, nanomaterials and 
prodrugs to selectively detect and eliminate senescent cells in vivo is presented as 
a new strategy with great potential in the field of diseases related to aging. It is 
expected that the results obtained in this thesis can serve as the basis for the 
development of new molecular and senolytic probes for the early diagnosis and 
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1.1  Molecular recognition 
The term “molecular recognition” can be defined as the specific interaction 
between two or more molecules through non-covalent bonds (hydrogen bonds, 
metal coordination, hydrophobic forces, van der Waals forces, π-π, halogen, 
electrostatic and/or electromagnetic interactions, etc).1 The guest and the host 
involved in molecular recognition exhibit molecular complementarity in terms of 
geometric and electronic features. Molecular recognition plays an important role 
in biological systems and is observed between receptor-ligand, antigen-antibody, 
DNA-protein, sugar-lectin, RNA-ribosome interactions.2 
In 1894 Dr. Emil Fisher proposed the first model of molecular recognition: the 
lock and key principle, a concept closely related with host-guest interactions, 
applied to enzymes and substrates.3 In this case, enzymes are “the lock” and their 
substrates are “the key” that should present a complementary size and shape as 
shown in Figure 1. Although the “lock-key” principle simplifies the mechanism of 
action of most biological systems, it can explain their high selectivity and 
specificity. Selectivity is the ability of the host to distinguish among different 
guests, while specificity is related to the precision of the molecular recognition.4 
1 J. M. Lehn, “Supramolecular Chemistry – Scope and Perspectives”. Nobel Lecture, 1987 
2 a) M. R. Lockett, H. Lange, B. Breiten, A. Heroux, W. Sherman, D. Rappoport, P. O. Yau,  P. W. Snyder and G. M. 
Whitesides, "The Binding of Benzoarylsulfonamide Ligands to Human Carbonic Anhydrase is Insensitive to Formal 
Fluorination of the Ligand". Angew. Chem. Int. Ed. 2003, 52, 7714–7717 b) B. Breiten, M. R. Lockett, W. Sherman, 
S. Fujita, M. Al-Sayah, H. Lange, C. M. Bowers, A. Heroux, G. Krilov and G. M. Whitesides, "Water Networks 
Contribute to Enthalpy/Entropy Compensation in Protein–Ligand Binding". J. Am. Chem. Soc. 2013, 135, 15579–
15584 
3 H. E. Fischer, “Chemistry”. Nobel Lecture, 1966 
4 G. Bergmann, B. Von and O. P. Zinn, “Improvement in the definitions of sensitivity and selectivity”. Anal. Chem. 
1987, 59, 2522-2526 
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Figure 1. Schematic representation of the “lock-key” principle, which governs molecular recognition. 
1.1.1 Molecular probes 
Molecular recognition has been widely applied in the development of 
molecular sensors, also known as probes, chemical sensors or chemosensors. The 
IUPAC definine a chemosensor as ”a device that transforms chemical information 
ranging from the concentration of a specific sample component to total 
composition analysis into an analytically useful signal”.5 
Molecular probes are -normally- organic molecules which, when interacting 
with target (bio)molecules, change one or more of their physicochemical features. 
These molecular probes have been extensively used in many research fields, such 
as molecular or chemical biology, drugs detection, monitoring of diseases, etc. 
Molecular probes are mainly formed by two subunits: the “signaling subunit” and 
the “binding site” (Figure 2). The binding site is responsible of the selective 
interaction with one specific guest. This selective recognition of one molecule 
among different analytes can be achieved by an accurate design of the binding 
site in order to introduce a high degree of complementarity (matching size, shape, 
charge, etc.) with the target analyte. On the other hand, the signaling subunit is a 
5 a) A. Hulanicki, S. Geab and F. Ingman, “Chemical sensors definitions and classification”. Pure. Appl. Chem. 
1991, 63, 1247-1250; b) U. E. Spichiger-Keller, “Chemical Sensors for Medical and Biological Applications”. Wiley-
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molecular entity able to transduce the molecular interaction of the target analyte 
with the binding site into a measurable macroscopic signal generally related with 
the concentration of the former. Traditionally, changes in the optical properties 
(color or fluorescence) or a modification in the electrochemical features (redox 
potential) has been used as signal outputs.6 
The design of molecular probes for the chromo-fluorogenic detection of 
different biomarkers or analytes is an alternative to traditional analytical 
techniques with advantages such as their chemical simplicity, ease of use, rapid 
response suitable for real time on-site detection, easy detection to the naked eye, 
etc. In spite of these remarkable features, the development of chromo-
fluorogenic sensors for the selective and sensitive detection of certain analytes, 
especially biomolecules, is still poorly explored.7 
Figure 2. Schematic representation of a molecular probe. 
6 a) R. Martínez-Máñez and F. Sancenón, “Fluorogenic and Chromogenic Chemosensors and Reagents for 
Anions”. Chem. Rev. 2003, 103, 4419-4476; b) L. E. Santos-Figueroa, M. E. Moragues, E. Climent, A. Agostini, R. 
Martínez-Máñez and F. Sancenón, “Chromogenic and fluorogenic chemosensors and reagents for anions. A 
comprehensive review of the years 2010–2011”. Chem. Soc. Rev. 2013, 42, 3489-3613.  
7 E. Garrido, L. Pla, B. Lozano‐Torres, S. El Sayed, R. Martínez‐Máñez and F. Sancenón, “Chromogenic and 
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 1.1.2 Nanotecnology 
The functionalization of inorganic materials with molecular or supramolecular 
assemblies has led, in the recent years, to the preparation of hybrid materials, 
within the nanoscale range, with advanced functionalities.8 The grafting of organic 
(bio)molecules or supramolecules onto selected inorganic solids (with different 
natures, sizes and shapes) promotes the development of smart nanodevices with 
applications in several scientific fields.9 Inside the realm of smart nanodevices, 
one appealing concept is related with the design of gated materials. These 
materials are constructed for the purpose of finely tuning the delivery of 
(bio)chemical species from the voids of porous supports to a solution in response 
to an external stimulus.10 These nanodevices are generally composed by two 
subunits: (i) a porous inorganic support in which a cargo is entrapped and (ii) 
selected molecular and/or supramolecular entities, grafted onto the external 
surface, which control mass transport from the pores (Figure 3). Dealing with both 
components, one of the most used inorganic supports are mesoporous solids 
(mainly silica-based in the form of micro- or nanoparticles)11 whereas the gating 
mechanisms takes advantage of electrostatic 
8 a) L. Nicole, C. Laberty-Robert, L. Rozes and C. Sanchez, “Hybrid materials science: a promised land for the 
integrative design of multifunctional materials”. Nanoscale. 2014, 6, 6267-6292. b) A. B. Descalzo, R. Martínez-
Máñez, F. Sancenón, K. Hoffmann and K. Rurack, “The supramolecular chemistry of organic-inorganic hybrid 
materials.” Angew. Chem. Int. Ed. 2006, 45, 5924-5948. 
9 a) Q. Zhang, E. Uchaker, S. L. Candelariaza and G. Gao, “Nanomaterials for energy conversion and storage”. 
Chem. Soc. Rev. 2013, 42, 3127-3171. b) N. Linares, A. M. Silvestre-Albero E. Serrano, J. Silvestre-Albero and J. 
Carcía-Martínez, “Mesoporous materials for clean energy technologies”. Chem. Soc. Rev. 2014, 43, 7681-7717. c) 
T. Wagner, S. Haffer, C. Weinberger, D. Klaus, M. Tiemann, “Mesoporous materials as gas sensors”. Chem. Soc. 
Rev. 2013, 42, 4036-4053. d) C. Perego, R. Millini, Chem. Soc. Rev., 2013, 42, 3956-3976. d) A. E. Garcia-Bennett, 
“Synthesis, toxicology and potential of ordered mesoporous materials in nanomedicine”. Nanomedicine. 2011, 6, 
867-877.  
10 E. Aznar, M. Oroval, Ll. Pascual, J. R. Murguía, R. Martínez-Máñez and F. Sancenón, “Gated Materials for On-
Command Release of Guest Molecules”. Chem. Rev. 2016, 116, 561-718. 
11 a) A. Stein, “Advances in Microporous and Mesoporous Solids—Highlights of Recent Progress”. Adv. Mater. 
2003, 15, 763-775. b) G. J. A. A. Soler-Illia and O. Azzaroni, “Multifunctional hybrids by combining ordered 
mesoporous materials and macromolecular building blocks”. Chem. Soc. Rev. 2011, 40, 1107-1150. c) A. P. Wight 
and M. E. Davis, “Design and Preparation of Organic−Inorganic Hybrid Catalysts”. Chem. Rev. 2002, 102, 3589-
3614. d) G. Kickelbick, “Hybrid inorganic-organic mesoporous materials”. Angew. Chem. Int. Ed. 2004, 43, 3102-
3104. 
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or supramolecular interactions, the rupture/formation of covalent bonds, or 
changes in the physical properties of molecules or macromolecules.12 These gated 
materials presented high potential applications in the field of controlled release 
and in the development of new sensing/recognition protocols.13 
Figure 3. Schematic representation of a molecular gate for on-command controlled release. 
One of the most interesting triggers used in the development of gated 
materials are enzymes.10,13 Using enzymes for uncapping gated materials is 
appealing if we take into account the large amount of different tailor-made 
specific compounds that can be selectively hydrolysed using enzymes. This 
technology may provide exquisite selectivity in the design of advanced gated 
devices for on-command delivery of drugs, biomolecules, or fluorophores in 
realistic biological environments.  
12 a) E. Aznar, R. Martínez-Máñez and F. Sancenón, “Controlled release using mesoporous materials containing 
gate-like scaffoldings”, Expert Opin. Drug Deliv. 2009, 6, 643-655. b) Y. –W. Yang, “Towards biocompatible 
nanovalves based on mesoporous silicananoparticles”. Med. Chem. Commun. 2011, 2, 1033-1049.  
13 F. Sancenón, Ll. Pascual, M. Oroval, E. Aznar and R. Martínez-Máñez, “Gated silica mesoporous materials in 
sensing applications”. ChemOpen, 2015, 4, 418-437. 
Cargo Molecular gate
SpacerSupport
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1.2  Cellular senescence 
Senescence is a state of permanent cell cycle arrest. This state was noticed by 
Hayflick and co-workers in 1961 while studying the serial cultivation of human 
diploid cells,14 which, rather than being immortal, ceased to replicate after a finite 
number of passages, (‘Hayflick’s limit’). The cells, including their nuclei, also 
experienced changes in morphology. Nowadays, we refer to this type of 
senescence as replicative senescence, which is associated with the shortening of 
the chromosomal termini, termed telomeres (Figure 4).15  
Other factors, including the activation of oncogenes, inhibition of tumour 
suppressor genes, accumulation of DNA damage, presence of reactive oxygen 
species (ROS), metabolic and epigenetic changes, and spindle or nucleolar stress, 
contribute to another type of senescence known as stress-induced premature 
senescence (SIPS).15 SIPS is a way to protect the body from cells that accumulate 
damage and proliferative defects but cannot undergo apoptosis. A third type of 
senescence is programmed senescence, which occurs during development. 
Intensive research efforts have led to our present understanding of the 
molecular mechanisms involved in triggering senescence. The mammalian cell 
cycle consists of two main phases — one involving DNA synthesis (S phase) and 
another involving cell division (mitosis; M phase). These phases are separated by 
two gaps (G1 and G2), and passage through the different phases is controlled by 
cyclin-dependent kinases (CDKs).16,17,18 Depending on what the trigger of  
14 L. Hayflick, and P. S. Moorhead, “ The serial cultivation of human diploid cell strains”. Exp. Cell Res. 1961, 25, 
585–621  
15 a) A. G. Bodnar, et al. “Extension of life-span by introduction of telomerase into normal human cells”. Science. 
1998, 279, 349–352. b) C. B. Harley, A. B. Futcher and C. W., “GreiderTelomeres shorten during ageing of human 
fibroblasts”. Nature. 1990, 345, 458–460. c) A. M. Olovnikov, “Telomeres, telomerase, and aging: origin of the 
theory”. Exp. Gerontol. 1996, 31, 443–448. d) G.-L. Yu, J. D. Bradley, L. D. Attardi and E. H. Blackburn, “In vivo 
alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs”. Nature. 
1990, 344, 126–132. 
16 J. Bloom and F. R. Cross, “Multiple levels of cyclin specificity in cell-cycle control”.  Nat. Rev. Mol. Cell Biol. 
2007, 8, 149–160. 
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Figure 4. Different types of cellular senescence. Depending on how senescence is triggered, it can be 
classified as either replicative senescence, stress-induced premature senescence (SIPS) or 
physiological senescence. Senescence, in particular SIPS, can also be triggered by natural or 
synthetic drugs. CDK, cyclin-dependent kinases; HAT, histone acetyltransferase; HDAC, histone 
deacetylase; PKC, protein kinase C; ROS, reactive oxygen species. 
senescence is, certain molecular pathways that result in the overexpression of 
CDK inhibitor proteins, such as p16, p21, p15 or p27, will be activated (Figure 5). 
Inhibited CDKs cannot phosphorylate retinoblastoma protein (Rb), which 
permanently sequesters the transcription factor E2F, a protein that controls the 
expression of genes that are needed for cell cycle progression.  Arrested cells face 
17 D. S. Peeper, et al. “A- and B-type cyclins differentially modulate substrate specificity of 534 cyclin-cdk 
complexes”. EMBO J. 1993, 12, 1947–1954. 
18 M. Malumbres and M. Barbacid, “Cell cycle, CDKs and cancer: a changing paradigm”.  Nat. Rev. Cancer. 2009, 
9, 153–166. 
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one of three fates: (i) undergo apoptosis; (ii) repair the damage and re-enter the 
cell cycle; or (iii) remain permanently arrested and become senescent (Figure 5). 
Cellular senescence has physiological roles in tissue remodelling during 
development and after injury.19,20,21 However, the chronic accumulation of 
senescent cells can negatively affect tissue regeneration and function, rendering 
the tissue more vulnerable to inflammation and aging-related diseases.17 This 
introduction describes the fundamental characteristics of senescent cells and how 
these can be exploited for therapeutic targeting. For example, the induction of 
senescence via small molecules could constitute the basis of new antitumor 
treatments.22,23 Alternatively, it is possible to decrease the number of senescent 
cells by using a senolytic drug to kill them or a senomorphic drug to reduce the 
senescence-associated secretory phenotype (SASP). These approaches are 
promising strategies to treat aging-related diseases24,25 but developments on this 
front require us to be able to identify senescent cells in vitro and in vivo. This will 
allow us to better understand the characteristics of senescence and evaluate 
medicinal treatments aimed at inducing or eliminating cellular senescence. 
19 X. Kong, et al. “Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice”. 
Hepatology. 2012, 56, 1150–1159. 
20 B. Ritschka, et al. The senescence- associated secretory phenotype induces cellular plasticity and tissue 
regeneration”. Genes Dev. 2017,  31, 172–183. 
21 L. Mosteiro, C. Pantoja, A. de Martino and M. Serrano, “Senescence promotes in vivo reprogramming through 
p16INK4a and IL-6”. Aging Cell  2018, 17, 12711–12722. 
22 A. Hernandez- Segura, J. Nehme, and M. Demaria, “Hallmarks of cellular senescence”. Trends Cell Biol. 2018, 
28 
436–453. 
23 R. L. Sutherland and E. A.  Musgrove, “CDK inhibitors as potential breast cancer therapeutics: new evidence 
for enhanced efficacy in ER+ disease”. Breast Cancer Res. 2009, 11, 112–113. 
24 J. L. Kirkland, T. Tchkonia, Y.  Zhu, L. J. Niedernhofer and P. D. Robbins, “The clinical potential of senolytic 
drugs”. J. Am. Geriatr. Soc. 2017, 65, 2297–2301. 
25 V. Myrianthopoulos, “ The emerging field of senotherapeutic drugs”. Future Med. Chem. 2018, 10, 2369–
2372. 
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Figure 5. The molecular pathways involved in senescence cell cycle arrest. Various senescence 
triggers can gate signalling pathways that converge in the overexpression of cell cycle inhibitors, 
such as p21 and p16Ink4a. These proteins stop cyclin-dependent kinases (CDK)–cyclin complexes from 
phosphorylating the retinoblastoma protein (Rb). As a result, the transcription factor E2F, which is 
normally responsible for the expression of the genes needed for cell cycle progression, is 
sequestered by Rb. The ensuing cell cycle arrest can be transient if cell damage is repaired, or 
can lead to cell death by apoptosis or to permanent arrest, known as senescence. ATM, ataxia–
telangiectasia mutated; ATR, ATM and Rad3-related homologue; ROS, reactive oxygen species; SASP, 
senescence-associated secretory phenotype. 
1.2.1 Senescence in health and disease 
Senescent cells differ from other cells in terms of their chemistry and 
morphology. Moreover, senescent cells have a characteristic SASP, which sees 
them produce high concentrations of signalling molecules that cause changes in 
the tissue microenvironment.26 The secretome of senescent cells activates the 
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innate and adaptive immune systems by recruiting cells such as natural killer cells, 
macrophages, neutrophils, CD4+ T lymphocytes, CD8+ T lymphocytes and B 
lymphocytes. Under normal conditions, these cells perform immune clearance 
and eliminate senescent cells from the body.27,28 Indeed, preventing damaged or 
stressed cells from proliferating is the main biological role of cellular 
senescence.29 Senescence is responsible for maintaining the tissue homeostasis 
that is necessary for embryonic development, wound healing or tissue 
remodeling;19-21,30,31,32,33 for example, senescence regulates skeletal bone growth 
during puberty, after which the growth rate eventually decreases.31 Further 
examples of senescence function include the development of the kidneys, the 
endolymphatic sac in the inner ear32,34 and the placenta.35 Although senescence is 
important in tissue repair and remodelling, inefficient elimination of senescent 
cells can occur if there is continuous damage or ageing. Thus, senescent cells tend 
to accumulate in tissues by promoting local inflammation, tissue ageing and 
destruction.24 Cellular senescence is related to multiple degenerative and 
hyperplastic pathologies of ageing, and the accumulation of senescent cells is 
involved in the pathophysiology of many diseases, such as metabolic disorders,36 
Secretion”. Nat. Cell Biol. 2009, 11, 973–979. 
27 A. Sagiv, et al.” NKG2D ligands mediate immunosurveillance of senescent cells”. Aging. 2016, 8, 328–344. 
28 T.-W. Kang et al.” Senescence surveillance of pre-malignant hepatocytes limits liver cancer development”. 
Nature. 2011, 479, 547–551. 
29 D. Muñoz- Espín and M. Serrano. “Cellular senescence: from physiology to pathology”. Nat. Rev. Mol. Cell. 
Biol. 2014, 15, 482–496. 
30 M. Demaria et al. An essential role for senescent cells in optimal wound healing through secretion of 
PDGF-AA. Dev. Cell 31, 722–733 (2014). 
31 C. Li et al. “Programmed cell senescence in skeleton during late puberty”. Nat. Commun. 2017, 8, 1312. 
32 Storer, M. et al. “Senescence is a developmental mechanism that contributes to embryonic growth and 
patterning”. Cell 2013, 155, 1119–1130.
33W. O’Brien, G. Stenman and R. Sager. “Suppression of tumor growth by senescence in virally transformed 
human fibroblasts”. Proc. Natl Acad. Sci. USA 1986, 83, 8659–8663. 
34 D. Muñoz- Espín, et al. “Programmed cell senescence during mammalian embryonic development”. Cell 2013, 
155, 1104–1118. 
35 Z. Sultana, K. Maiti, L. Dedman and R. Smith. “Is there a role for placental senescence in the genesis of 
obstetric complications and fetal growth restriction?”. Am. J. Obstet. Gynecol. 2018, 218, S762–S773. 
36 M. J.Schafer, J. D.  Miller and  N. K. LeBrasseur, “Cellular senescence: implications for metabolic disease”. Mol. 
Cell. Endocrinol. 2017, 455, 93–102.  
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osteoporosis,37,38 pulmonary39 and liver fibrosis,40 cardiac41and brain disorders,42 
and kidney disease.43,44 
Senescence gives rise to dual and sometimes contradictory consequences, a 
property it has in common with other physiological processes, such as 
inflammation. Senescence is necessary for tissue and organ homeostasis but its 
de-regulation causes diseases.45 For example, senescent activated stellate cells 
facilitate the resolution of liver fibrosis46 but also cause age-dependent steatosis.47 
With respect to diabetes, senescence acts as a balance. On one hand, the 
increase in the expression of p16Ink4 in insulin-producing pancreatic β-cells leads 
to a decrease in cellular replication, thus lowering the number of cells that 
produce insulin, which results in the increased risk of type 2 diabetes due to the 
global decrease in insulin production.48,49 On the other hand, it has been shown 
that, in mice affected by diabetes, the increase in p16Ink4 leads to an improved 
glucose homeostasis and to a consequent improvement in insulin secretion from 
each single cell; this unexpected functional benefit can be seen as a way to 
37 S. Khosla, J. N. Farr and J. L. Kirkland, “Inhibiting cellular senescence: a new therapeutic paradigm for age- 
related osteoporosis”. J. Clin. Endocrinol. Metab. 2018, 103, 1282–1290. 
38 J. N. Farr, et al. “Targeting cellular senescence prevents age- related bone loss in mice”. Nat. Med. 2017, 23, 
1072–1079.  
39 M. J. Schafer, et al. “Cellular senescence mediates fibrotic pulmonary disease”. Nat. Commun. 2017, 8, 14532. 
40 F. Wandrer, et al. “Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection”. 
Aliment. Pharmacol. Ther. 2018, 48, 270–280. 
41 R. Sun, et al. “Senescence as a novel mechanism involved in β-adrenergic receptor mediated cardiac 
hypertrophy”. PLoS One 2017, 12, e0182668. 
42 D. J. Baker and R. C. Petersen, “Cellular senescence in brain aging and neurodegenerative diseases: evidence 
and perspectives”. J. Clin. Invest. 2018, 128, 1208–1216. 
43 H.  Yang and A. B. Fogo, “Cell senescence in the aging kidney”. J. Am. Soc. Nephrol. 2010, 21, 1436–1439. 
44  R. Jimenez, et al. “Replicative senescence in patients with chronic kidney failure”. Kidney Int. 2005, 68, S11–
S15. 
45 S. He and N. E. Sharpless, “Senescence in health and disease”. Cell. 2017, 169, 1000–1011. 
46 V. Krizhanovsky et al. “Senescence of activated stellate cells limits liver fibrosis”. Cell 2008, 134, 657–667. 
47 M. Ogrodnik et al. “Cellular senescence drives age-dependent hepatic steatosis”. Nat. Commun. 2017, 8, 
15691. 
48 O. Tavana and C. Zhu. “Too many breaks (brakes): pancreatic β- cell senescence leads to diabetes”. Cell Cycle. 
2011, 10, 2471–2484. 
49 J. Krishnamurthy et al. “p16INK4a induces an agedependent decline in islet regenerative potential”. 
Nature.2006, 443, 453–457. 
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compensate for the loss of regenerative capacity.50 Senescence in the placenta is a 
normal physiological process35 but aberrant senescence can lead to preeclampsia 
or pre-term birth.51,52 Similarly, the role of senescence in tumourigenesis is 
complex and inducing senescence in tumour cells is an opportunity to alert and 
activate the immune system to detect and eliminate them.53,54,55,56 These 
observations have led to the development of pro-senescence therapies, one of 
which uses palbociclib, an inhibitor of CDK4 and CDK6 (Figure 6), to treat 
advanced breast cancer.23,24 Again, the accumulation of senescent cells shows 
their ‘dark side’ by promoting tumour progression and metastasis. Cancer 
stemness is promoted by senescence induction57 and senescent endothelial cells 
facilitate tumour cell migration and metastasis.58 These pro-tumourigenic effects 
have further stimulated research interest in killing senescent cells.58,59,60 The 
selective induction of cell death in senescent cells, known as senolysis, has 
emerged as a new strategy to manage the adverse effects of senescent cells. 
Senolytic drugs have attracted great interest as a means to fight cancer as well as 
the many ageing related diseases that are associated with the accumulation of 
50 A. Helman et al. “p16Ink4a- induced senescence of pancreatic beta cells enhances insulin secretion. Nat. Med. 
2016, 22, 412–420. 
51 T. D. Cindrova, N. M. E. Fogarty, C. J. P. Jones, J. Kingdom and G. J. Burton. “Evidence of oxidative stress- 
induced senescence in mature, post- mature and pathological human placentas”. Placenta. 2018, 68, 15–22. 
52 L. S. Cox and C. Redman. “The role of cellular senescence in ageing of the placenta”. Placenta 2017, 52, 139–
145. 
53 M. Collado et al. “Senescence in premalignant tumours”. Nature. 2005, 436, 642. 
54 Z. Chen et al. “Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient 
tumorigenesis”. Nature 2005, 436, 725–730. 
55 C. Michaloglouet al. “BRAFE600-associated senescence like cell cycle arrest of human naevi”. Nature 2005, 
436, 720–724. 
56 M. Braig et al. “Oncogene- induced senescence as an initial barrier in lymphoma development”. Nature. 2005, 
436, 660–665. 
57 M. Schosserer, J. Grillari and M. Breitenbach. “The dual role of cellular senescence in developing tumors and 
their response to cancer therapy”. Front. Oncol. 2017, 7, 2781–2793. 
58 E. Wieland et al. “Endothelial Notch1 activity facilitates metastasis”. Cancer Cell. 2017,.31, 355–367  
59 M. Milanovic et al. “Senescence- associated reprogramming promotes cancer stemness”. Nature. 2017, 553, 
96–100  
60 S. Parrinello, J.-P. Coppe, A. Krtolica and J. Campisi. “Stromal–epithelial interactions in aging and cancer: 
senescent fibroblasts alter epithelial cell differentiation”. J. Cell Sci. 2005, 118, 485–496.  
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senescent cells.49,61 In landmark studies, it was shown that eliminating cells that 
express high levels of the CDK inhibitor p16Ink4a ameliorated ageing related 
disorders in mice. Because p16Ink4a is also a senescence marker, we can infer that 
selectively removing senescent cells would also have beneficial effects, further 
motivating the search for new senolytics.62,63 
1.2.2 Senescence induction methods 
The approaches to induce SIPS using drugs are described below. Senescent 
phenotypes are dynamic and can change depending on how senescence was 
induced (chemical or natural stimuli) and what cell type is involved (normal or 
tumour cells, different cell lines). Furthermore, individual senescent cells can be 
heterogeneous in their gene expression signatures even though the cellular 
population appears homogeneous.64,65 
The use of low molecular weight compounds to induce senescence has been 
reviewed previously,66 and the treatments typically involve prolonged exposure to 
the drug(s), which can be classified into eight groups (Figure 6). One common 
method to trigger senescence is to use DNA replication stress inducers, such as 
aphidicolin (a DNA polymerase-α inhibitor),67 hydroxyurea (a ribonucleotide 
61 C. López- Otín, M. A. Blasco, L.  Partridge, M. Serrano and G. Kroemer. “The hallmarks of aging”. Cell. 2013, 
153, 1194–1217. 
62 D. J. Baker et al. “Clearance of p16Ink4a- positive senescent cells delays ageing- associated disorders”. Nature. 
2011, 479, 232–236. 
63 D. J. Baker et al. “Naturally occurring p16Ink4a-positive cells shorten healthy lifespan”. Nature. 2016, 530, 
184–189. 
64 A. Hernandez- Segura et al. “Unmasking transcriptional heterogeneity in senescent cells”. Curr. Biol. 2017, 27, 
2652–2660  
65 C. D. Wiley et al. “Analysis of individual cells identifies cell- to-cell variability following induction of cellular 
senescence”. Aging Cell. 2017, 16, 1043–1050. 
66 N. V. Petrova, A. K. Velichko, S. V. Razin and O. L. Kantidze. “Small molecule compounds that induce cellular 
senescence”. Aging Cell. 2016, 15, 999–1017. 
67 A. Marusyk, L. J. Wheeler, C. K. Mathews and J. DeGregori. “p53 mediates senescence- like arrest induced by 
chronic replicational stress”. Mol. Cell. Biol. 2007, 27, 5336–5351. 
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reductase inhibitor),68 thymidine (a compound that attenuates deoxycytidine 
triphosphate synthesis),69 bromodeoxyuridine (a DNA replication suppressor),70 
difluorodeoxycytidine (also known as gemcitabine, a ribonucleotide reductase and 
CTP synthetase inhibitor)71 and cyclopentenyl cytosine (a CTP synthetase 
inhibitor).72 Senescence can also be triggered by damaging DNA with 
doxorubicin,73 etoposide,74 daunorubicin,75 mitoxantrone,76 camptothecin,77
cisplatin,78 actinomycin D,79 bleomycin or temozolomide80. As we have noted, 
telomere shortening and dysfunction elicit a senescence response. This response 
can be triggered by inhibiting telomerase, an enzyme that maintains the length of  
68 E. J. Yeo et al. “Senescence- like changes induced by hydroxyurea in human diploid fibroblasts”. Exp. Gerontol. 
2000, 35, 553–571. 
69 E. Sumikawa, Y. Matsumoto, R. Sakemura, M. Fujii and D. Ayusawa. “Prolonged unbalanced growth induces 
cellular senescence markers linked with mechano transduction in normal and tumor cells”. Biochem. Biophys. 
Res. Commun. 2005, 335, 558–565. 
70 E. Michishita et al. “5-Bromodeoxyuridine induces senescence- like phenomena in mammalian cells regardless 
of cell type or species”. J. Biochem. 1999, 126, 1052–1059. 
71 D. E. Modrak, E. Leon, D. M. Goldenberg and D. V. Gold. “Ceramide regulates gemcitabine- induced 
senescence 
and apoptosis in human pancreatic cancer cell lines”. Mol. Cancer Res. 2009, 7, 890–896. 
72 M. Huang, P. Whang, P. Lewicki and B. S. Mitchell. “Cyclopentenyl cytosine induces senescence in breast 
cancer cells through the nucleolar stress response and activation of p53”. Mol. Pharmacol. 2011, 80, 40–48. 
73 B. D. Chang et al. “A senescence- like phenotype distinguishes tumor cells that undergo terminal proliferation 
arrest after exposure to anticancer agents”. Cancer Res. 1999, 59, 3761–3767. 
74 R. H. te Poele, A. L. Okorokov, L. Jardine, J. Cummings and S. P. Joel. “DNA damage is able to induce 
senescence in tumor cells in vitro and in vivo”. Cancer Res. 2002, 62, 1876–1883. 
75 S. Mansilla, B. Piña and J. Portugal. “Daunorubicininduced variations in gene transcription: commitment to 
proliferation arrest, senescence and apoptosis”. Biochem. J. 2003, 372, 703–711. 
76 J.-P. Coppé et al. “Senescence- associated secretory phenotypes reveal cell- nonautonomous functions of 
oncogenic RAS and the p53 tumor suppressor”. PLoS Biol. 2008, 6, e301. 
77 Z. Han et al. “Role of p21 in apoptosis and senescence of human colon cancer cells treated with 
camptothecin”. J. Biol. Chem. 2002, 277, 17154–17160. 
78 X. Wang et al. “Evidence of cisplatin- induced senescent-like growth arrest in nasopharyngeal carcinoma 
cells”. Cancer Res. 1998, 58, 5019–5022. 
79 S. J. Robles and G. R. Adami. “Agents that cause DNA double strand breaks lead to p16INK4a enrichment and 
the premature senescence of normal fibroblasts”. Oncogene. 1998, 16, 1113–1123. 
80 Y. Hirose, M. S. Berger and R. O. Pieper. “p53 effects both the duration of G2/M arrest and the fate of 
temozolomide- treated human glioblastoma cells”. Cancer Res. 2001, 61, 1957–1963. 
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 Figure 6. There are many ways to induce senescence. The representative senescence-inducing 
species are classified according to their mechanism of action. The compounds that act in cell nuclei 
are presented in blue boxes, while those that are active in the cytosol are shown in an orange box. 
ROS, reactive oxygen species. 
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these DNA regions. Telomerase inhibitors developed for this purpose include 
SYUIQ-5,81 BMVC4,82 pyridostatin,83 compound 115405,84 perylene and indole 
derivatives,85 harmine,86 BIBR1532 and azidothymidine.  Beyond just DNA, we can 
also consider how the phenotype of senescent cells differs from that of normal 
cells in terms of chromatin organization and the epigenome. Thus, inhibitors of 
DNA methyltransferases, histone deacetylases, histone acetyltransferases, and 
histone methyltransferases are frequently used to induce senescence.87 Drugs 
that cause overexpression of the genes encoding p53, Rb, p21 or p16Ink4a or 
activate these proteins can induce senescence by activating the p53–p21 and/or 
p16Ink4a–Rb tumour suppressor pathways. The tumour suppressor p53, referred to 
as the guardian of the genome, is key to cell cycle arrest, DNA repair and 
apoptosis.88  
Activators of p53, such as nutlin-3a (an MDM2 antagonist), can induce 
senescence. Similarly, FL118 also induces p53-dependent senescence by 
promoting proteasomal degradation of MDM2,89 although senescence might 
81 J.-M. Zhou, et al. “Senescence and telomere shortening induced by novel potent G- quadruplex interactive 
agents, quindoline derivatives, in human cancer cell lines”. Oncogene. 2006, 25, 503–511. 
82 F.-C. Huang, C.-C. Chang, J.-M. Wang, T.-C. Chang and J.-J. Lin. “Induction of senescence in cancer cells by the 
G- quadruplex stabilizer, BMVC4, is independent of its telomerase inhibitory activity”. Br. J. Pharmacol. 2012, 
167, 393–406. 
83 S. Müller et al. “Pyridostatin analogues promote telomere dysfunction and long- term growth inhibition in 
human cancer cells”. Org. Biomol. Chem. 2012, 10, 6537–6546. 
84 J. F. Riou et al. “Cell senescence and telomere shortening induced by a new series of specific G-quadruplex 
DNA ligands”. Proc. Natl Acad. Sci. USA. 2002, 99, 2672–2677. 
85 C. N. Marconett et al. “Indole-3-carbinol downregulation of telomerase gene expression requires the 
inhibition of estrogen receptor- alpha and Sp1 transcription factor interactions within the hTERT promoter and 
mediates the G1 cell cycle arrest of human breast cancer cells”. Carcinogenesis 2011, 32, 1315–1323. 
86 L. Zhao and M. Wink. “The β- carboline alkaloid harmine inhibits telomerase activity of MCF-7 cells by 
downregulating hTERT mRNA expression accompanied by an accelerated senescent phenotype”. PeerJ. 2013, 1, 
e174 (). 
87 M. Vogt, C. Haggblom, J. Yeargin, T. Christiansen-Weber and M. Haas. “Independent induction of senescence 
by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts”. Cell Growth Differ. 1998, 9, 139–
146. 
88 E. R. Kastenhuber and S. W. Lowe. “Putting p53 in context”. Cell. 2017, 170, 1062–1078. 
89 A. Efeyan et al. “Induction of p53-dependent senescence by the mdm2 antagonist nutlin-3a in mouse cells of 
fibroblast origin”. Cancer Res. 2007, 67, 7350–7357. 
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instead be a result of FL118 inhibiting topoisomerase I.90 The cell cycle is mainly 
regulated by cyclins and CDKs, such that inhibiting these enzymes induces 
senescence. For example, the CDK4 and CDK6 inhibitors palbociclib, ribociclib and 
abemaciclib,91 as well as the non-selective CDK inhibitor roscovitine, can induce 
premature senescence.92 The final class of small molecules that can induce 
senescence are those that give rise to ROS. ROS production leads to oxidative 
stress and macromolecular damage in cells.93 For example, molecules such as 
H2O2, t-BuOOH, phenyl 2-pyridyl ketoxime, phenylaminonaphthoquinones and 
paraquat, through either cleavage or redox activity, can give rise to ROS and 
trigger cellular senescence. 
1.2.3 Senescence markers 
Given the important role that senescent cells have in ageing and disease, it is 
no surprising that detecting and eliminating these cells can improve the condition 
of patients suffering from some diseases.94 Most methods aim to detect common 
senescence markers that are expressed regardless of whether growth arrest arose 
from a chemical agent or replicative induction.95 However, we have yet to identify 
a single universal senescence marker such that, in general, the presence of 
senescent cells can only be confirmed by detecting multiple markers.  The most 
noticeable macroscopic sign of senescence are changes in cell morphology (Figure 
90 X. Ling, et al. “FL118 Induces p53-dependent senescence in colorectal cancer cells by promoting degradation 
of MdmX”. Cancer Res. 2014, 74, 7487–7497. 
91 O. V. Leontieva and M. V. Blagosklonny. “CDK4/6- inhibiting drug substitutes for p21 and p16 in senescence: 
duration of cell cycle arrest and MTOR activity determine geroconversion”. Cell Cycle. 2013, 12, 3063–3069. 
92 J.-Y. Park, S.-H. Park and R. H. Weiss. “Disparate effects of roscovitine on renal tubular epithelial cell apoptosis 
and senescence: implications for autosomal dominant polycystic kidney disease”. Am. J. Nephrol. 2009, 29, 509–
515. 
93 P. D. Ray, B.-W. Huang and Y. Tsuji. “Reactive oxygen species (ROS) homeostasis and redox regulation in 
cellular signaling”. Cell. Signal. 2012, 24, 981–990. 
94 Naylor, R. M., Baker, D. J. & van Deursen, J. M.Senescent cells: a novel therapeutic target for aging and age-
related diseases. Clin. Pharmacol. Ther. 2013, 93, 105–116. 
95 E. Sikora, G. Mosieniak and M. A. Sliwinska. “Morphological and functional characteristic of senescent cancer 
cells”. Curr. Drug Targets. 2016, 17, 377–387. 
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7).29 Relative to healthy cells, senescent cells in vitro have a characteristically 
flattened appearance and an irregular shape, with enlarged nuclei, increased 
nucleolar size and accumulated cytoplasmic granules. Additionally, the cells 
contain many vacuoles, as well as enlarged lysosomes and Golgi apparatus. 
Moreover, in some cell types, foci of condensed chromatin, termed senescence-
associated heterochromatin foci (SAHF), are observed.96,97 On the molecular level, 
although senescent cells are not proliferative, they are metabolically active and 
Figure 7. Senescence biomarkers. Compared with a non- senescent cell (left), a senescent cell (right) 
is larger and flatter. The nucleus of senescent cells is larger than in proliferating cells and may 
contain chromosomes with shortened telomeres and senescence- associated heterochromatin foci 
(SAHF). The levels of β- galactosidase, α- fucosidase and many other hydrolases, as well as 
lipofuscins, are higher in the lysosomes of senescent cells than they are in proliferating cells. The 
mitochondria in senescent cells produce reactive oxygen species (ROS) and have high concentrations 
of anti-apoptotic proteins of the BCL-2 family. The Golgi apparatus secretes vesicles containing 
cytokines and chemokines (senescenceassociated secretory phenotype, SASP) that cause changes in 
the tissue microenvironment and disturb surrounding cells. p16Ink4a, a tumour suppressor protein 
and cyclin- dependent kinase (CDK) inhibitor, is located in the cytoplasm. Inhibition of CDKs prevents 
the phosphorylation of the nuclear retinoblastoma protein (Rb). Note that the figure is not to scale 
and the size of each cell depends on the cell line. 
96 R. Funayama and F. Ishikawa. “Cellular senescence and chromatin structure”. Chromosoma. 2007, 116, 431–
440. 
97 R. Zhang and P. D. Adams. “Heterochromatin and its relationship to cell senescence and cancer therapy”. Cell 
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have ATP levels similar to confluent cells.98 Moreover, some types of senescent 
cells exhibit enhanced glycolysis.99,100 
Senescent cells survive by expressing anti-apoptotic B cell lymphoma (BCL) 
proteins such as BCL-XL, which makes the outer mitochondrial membrane less 
permeable and, thus, less likely to release apoptosis inducing proteins, such as 
cytochrome C.101 The absence of the proliferation marker Ki67 and lower 
phosphorylated Rb (pRb) levels in tumours are indicative of senescence.102,103 
Cells that are in the state of replicative senescence typically have short 
telomeres.104,105,106 Human primary somatic cells cannot add telomeric repeats to 
the ends of their chromosomes if their telomerase enzymes are inhibited. In this 
case, there is deprotection of chromosomes, DNA becomes damaged and there is 
limited cell proliferation.15,107,108 However, it is possible to keep chromosomes 
intact by forcing telomerase expression;15 reactivating these enzymes in mice 
prematurely aged by telomeric shortening can counter this degeneration.109 
Moreover, depending on the way in which senescence is triggered, telomere 
shortening can be present or absent, and it is important to determine whether 
98 S. Goldstein, S. R. Ballantyne, A. L. Robson and E. J. Moerman. “Energy metabolism in cultured human 
fibroblasts during aging in vitro”. J. Cell. Physiol. 1982, 112, 419–424. 
99 A. H. Bittles and N. Harper. “Increased glycolysis in ageing cultured human diploid fibroblasts”. Biosci. Rep. 
1984, 4, 751–756. 
100 A. L. Muggleton- Harris and R. Defuria. “Age-dependent metabolic changes in cultured human fibroblasts”. In 
vitro Cell. Dev. Biol. 1985, 21, 271–276. 
101 B. G. Childs, D. J Baker, J. L., Kirkland, J. Campisi and J. M. van Deursen. “Senescence and apoptosis: dueling 
or complementary cell fates?”. EMBO Rep 2014, 15, 1139–1153. 
102 D. Muñoz- Espín et al. “A versatile drug delivery system targeting senescent cells”. EMBO Mol. Med. 2018, 
10, e9355.
103 A. Takahashi, N. Ohtani and E. Hara. “Irreversibility of cellular senescence: dual roles of p16INK4a/Rb- 
pathway in cell cycle control”. Cell Div. 2007, 2, 10–15. 
104 K. A. Mather, A. F. Jorm, R. A.  Parslow and H. Christensen. “Is telomere length a biomarker of aging? A 
review”. J. Gerontol. A. 2011, 66, 202–213. 
105 A. Zietzerand P. Hillmeister. “Leucocyte telomere length as marker for cardiovascular ageing”. Acta Physiol. 
2014, 211, 251–256. 
106 S. Bekaert, T. De Meyer and P. Van Oostveldt. “Telomere attrition as ageing biomarker”. Anticancer Res. 
2005, 25, 3011–3021. 
107 M. A. Blasco et al. “Telomere shortening and tumor formation by mouse cells lacking telomerase RNA”. Cell. 
1997, 91, 25–34. 
108 E. H. Blackburn. “Structure and function of telomeres”. Nature. 1991, 350, 569–573. 
109 M. Jaskelioffet al. “Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice”. 
Nature. 2011, 469, 102–106. 
General introduction                Adapted from B. Lozano-Torres et al. 




DNA repair and/or maintenance proteins, such as γH2AX, ataxia–telangiectasia 
mutated (ATM) and MRE11, are also present at telomeres. Thus, instead of simply 
measuring telomere length, looking for telomere-dysfunction-induced foci (TIF) 
could be a less ambiguous means to identify senescence.110 The SASP includes 
secretion of different cytokines, chemokines and proteases — proteins that 
change the environment around a cell.60,111,112,113,114 These secreted proteins 
include cleaved cell-surface molecules, extracellular matrix components, 
inflammatory mediators (IL-6, GROα and CCL20) and growth factors (hepatocyte 
growth factor, HGF, and insulin-like growth factor-binding proteins, IGFBPs), 
among others. Taken together, the SASP and its associated molecules are 
powerful markers of senescence.115  
Lipofuscin is a non-degradable aggregate of oxidized proteins, lipids and 
oligosaccharides that accumulates progressively in the lysosomes of non- 
proliferative cells. This aggregate is more prominent in senescent cells and it can 
be visualized by fluorescence microscopy.116 Intracellular lipofuscin accumulation 
is correlated with senescence117 owing to its colocalization with senescence- 
associated β-galactosidase (SA-β-Gal) activity, another common biomarker of 
110 T. Brugat, F. Nguyen- Khac, A. Grelier, H. Merle- Béral and J. Delic. “Telomere dysfunction- induced foci arise 
with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic 
leukemia cells”. Blood. 2010, 116, 239–249. 
111 A. Krtolica, S. Parrinello, S. Lockett, P. Y. Desprez and  J. Campisi. “Senescent fibroblasts promote epithelial 
cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA. 2001, 98, 12072–
12077. 
112 T. Kuilman et al. Oncogene- induced senescence relayed by an interleukin- dependent inflammatory 
network. Cell 133, 1019–1031 (2008). 
113 J. C. Acosta et al. “Chemokine signaling via the CXCR2 receptor reinforces senescence”. Cell. 2008, 133, 
1006–1018. 
114 J. Campisi, J. K. Andersen, P. Kapahi and S. Melov. “Cellular senescence: a link between cancer and 
agerelated degenerative disease?” Semin. Cancer Biol. 2011, 21, 354–359. 
115 J. C. Acosta et al. “A complex secretory program orchestrated by the inflammasome controls paracrine 
senescence”. Nat. Cell Biol. 2013, 15, 978–990.
116 T. Jung, N. Bader and T. Grune. “Lipofuscin: formation, distribution, and metabolic consequences”. Ann. NY 
Acad. Sci. 2007, 1119, 97–111. 
117 M. L. Katz, W. G. Robinson, R. K. Herrmann, A. B. Groome and J. G. Bieri. Lipofuscin accumulation resulting 
from senescence and vitamin E deficiency: spectral properties and tissue distribution. Mech. Ageing Dev. 1984, 
25, 149–159. 
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senescence in lysosomes (see below).118 This activity can be detected both in vitro 
and in situ by histochemical methods, including staining with the lipophilic diazo 
dye Sudan Black B (SBB).119,120,121 
Acid β-galactosidase (β-Gal, encoded by GLB1) accumulates in the lysosomes of 
senescent cells and is the origin of SA-β-Gal activity.122,123 SA-β-Gal activity is 
conveniently measured using chromogenic or fluorogenic probes. SA-β-Gal 
hydrolyses galactosides and this activity has served as the basis of a number of 
fluorogenic probes, most of which feature a fluorophore covalently linked to the 
anomeric carbon of a β-galactose. Apart from β-Gal, there are other lysosomal 
hydrolases that are overexpressed in senescent cells.124,125 
Whereas healthy cells respond to mitogens by proliferating (growing and 
dividing), growth arrest is permanent in senescent cells; that is, they do not re-
enterthe cell cycle in response to mitogen stimulation.126 The proteins responsible 
for cell proliferation are suitable markers for identifying senescent cells. For 
example, the tumour suppressors p53, p16Ink4a and p21 are overexpressed during 
growth arrest.127,128,129,130 In particular, the cell cycle inhibitor p16Ink4a has been a 
118 E. Georgakopoulou et al. “Specific lipofuscin staining as a novel biomarker to detect replicative and stress-
induced senescence. A method applicable in cryo-preserved and archival tissues”. Aging. 2012, 5, 37–50. 
119 J. B. Gatenby and T. A. Moussa. “The sudan black B technique in cytology”. J. Microsc. Soc. 1949, 69, 72–75. 
120 G. L. Rasmussen. “A method of staining the statoacoustic nerve in bulk with Sudan black B”. Anat. Rec. 1961, 
139, 465–469. 
121 T. Jung, A. Höhn and T. Grune. “Lipofuscin: detection and quantification by microscope techniques”. 
Methods Mol. Biol. 2010, 594, 173–193. 
122 G. P. Dimri et al. “A biomarker that identifies senescent human cells in culture and in aging skin in vivo”. 
Proc. Natl Acad. Sci. USA 1995, 92, 9363–9367. 
123 A. Biran et al. “Quantitative identification of senescent cells in aging and disease”. Aging Cell 2017, 16, 661–
671. 
124 M. Knas et al. “The profile of lysosomal exoglycosidases in replicative and stress- induced senescence in early 
passage human fibroblasts”. Folia Histochem. Cytobiol. 2012, 50, 220–227. 
125 D. Hildebrand et al. “α- Fucosidase as a novel convenient biomarker for cellular senescence”. Cell Cycle. 
2013, 12, 1922–1927. 
126 C. Gey and K. Seeger. “Metabolic changes during cellular senescence investigated by proton NMR- 
spectroscopy”. Mech. Ageing Dev. 2013, 134, 130–138. 
127 J. Campisi. “Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors”. Cell. 
2005, 120, 513–522. 
128 J. Campisi and F. d’Adda di Fagagna. “Cellular senescence: when bad things happen to good cells”. Nat. Rev. 
Mol. Cell. Biol. 2007, 8, 729–740. 
129 J. Krishnamurthy et al. “Ink4a/Arf expression is a biomarker of aging”. J. Clin. Invest. 2004, 114, 1299–1307. 
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key tool used to identify senescent cells131,132 and, although it has some limitations 
as an in vivo biomarker of senescence, its use is still commonplace.133,134,135 
1.2.4 Senolytics 
The elimination of senescent cells by selectively inducing apoptosis alleviates 
several aging-related diseases, reverts long-term degenerative processes and 
extends both health span and lifespan.136 Senolysis — the selective elimination of 
senescent cells — ameliorates symptoms in mouse models of atherosclerosis, 
osteoarthritis, cataracts, cardiac hypertrophy, renal dysfunction, lipodystrophy 
and sarcopenia.62,63,137,138139 Notably, there is a lack of a senolytic drug that is 
effective in eliminating all types of senescent cells. Furthermore, as we noted 
above, the diverse causes of senescence can lead to differences in their sensitivity 
to various senolytic drugs. A selective and universal method for the elimination of 
senescent cells would be a potentially useful therapy, but no such senolytic drugs 
have been approved yet. Senolytics such as the combination of dasatinib plus 
130 B. Vandenberk, B. Brouwers, S. Hatse and H. Wildiers. “p16INK4a: a central player in cellular senescence and 
apromising aging biomarker in elderly cancer patients”. J. Geriatr. Oncol. 2011, 2, 259–269. 
131 Serrano, M., Hannon, G. J. & Beach, D. A new regulatory motif in cell- cycle control causing specific inhibition 
of cyclin D/CDK4. Nature 366, 704–707 (1993). 
132 M. Serrano, A. W. Lin, M. E. McCurrach, D. Beach and S. W. Lowe. “Oncogenic ras provokes premature cell 
senescence associated with accumulation of p53 and p16INK4a”. Cell. 1997, 88, 593–602. 
133 C. M. Beauséjour et al. “Reversal of human cellular senescence: roles of the p53 and p16 pathways”. EMBO J. 
2003, 22, 4212–4222. 
134 J. G. Rheinwald et al. “A two- stage, p16INK4A- and p53- dependent keratinocyte senescence mechanism 
that limits replicative potential independent of telomere status”. Mol. Cell. Biol. 2002, 22, 5157–5172. 
135 U. Herbig, W. A. Jobling, B. P. C. Chen, D. J. Chen and J. M. Sedivy. “Telomere shortening triggers senescence 
of human cells through a pathway involving ATM, p53, and p21CIP1, but not p16INK4a”. Mol. Cell. 2004, 14, 501–
513. 
136 A. Soto- Gamez and M. Demaria. “Therapeutic interventions for aging: the case of cellular senescence”. Drug 
Discov. Today. 2017, 22, 786–795. 
137 O. H. Jeon et al. “Local clearance of senescent cells attenuates the development of post- traumatic 
osteoarthritis and creates a pro- regenerative environment”. Nat. Med. 2017, 23, 775–781. 
138 D. J. Baker et al. “Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 
insufficiency”. Nat. Cell Biol. 2008, 10, 825–836. 
139 B. G. Childs et al. “Senescent intimal foam cells are deleterious at all stages of atherosclerosis”. Science. 
2016, 354, 472–477. 
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quercetin are in clinical trials for idiopathic pulmonary fibrosis and chronic kidney 
disease140 and, also, UBX101 for osteoarthritis in the knee is in phase I trials.141 
Because no single drug can remove all senescent cells, treatments instead 
must use several drugs, including combinations of small molecules, antibodies and 
peptides. The first hypothesis-driven approach to senolytic discovery exploited 
the resistance of senescent cells to apoptosis (recall that they release pro-
apoptotic factors to the medium as part of the SASP).142 This was thought to lead 
senescent cells to rely on pro-survival pathways to defend against their own pro-
apoptotic factors. Using bioinformatics and small interfering RNA (siRNA) 
technology, different senescent-cell antiapoptotic pathways (SCAPs) have been 
identified as senolytic targets, including the anti-apoptotic proteins BCL-2, BCL- W 
and BCL-XL, the transcription factors p53 and p21, hypoxia-inducible factor 1 
(HIF1α), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and protein kinase 
B (PKB; also known as AKT), the serine protein inhibitors (serpins) and the heat 
shock protein HSP90.142,143 With knowledge of these SCAPs, it then becomes 
possible to rationally design drugs. For example, navitoclax (ABT-263) is a specific 
inhibitor of BCL-2, BCL-XL and BCL-W (also known as BCL-2L2). Other BCL-2 family 
inhibitors, such as ABT-737 (an inhibitor of BCL-2, BCL-W and BCL-XL) or A1331852 
and A1155463 (selective inhibitors of BCL-XL), also display effectiveness in 
vitro144,145 and in vivo.146 
140 J. N. Justice et al. “Senolytics in idiopathic pulmonary fibrosis: results from a first- in-human, open- label, 
pilot study”. EBioMedicine. 2019, 40, 554–563. 
141 US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03513016, 2019. 
142 Y. Zhu et al. “The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs”. Aging Cell. 2015, 
14, 644–658. 
143 H. Fuhrmann- Stroissnigg et al. “Identification of HSP90 inhibitors as a novel class of senolytics”. Nat. 
Commun. 2017, 8, 422. 
144 R. Yosef et al. “Directed elimination of senescent cells by inhibition of BCL- W and BCL- XL”. Nat. Commun. 
2016, 7, 11190–11201 (). 
145 Y. Zhu et al. “New agents that target senescent cells: the flavone, fisetin, and the BCL- XL inhibitors, 
A1331852 and A1155463”. Aging. 2017, 9, 1–9. 
146 R. Yosef et al. “Directed elimination of senescent cells by inhibition of BCL- W and BCL- XL”. Nat. Commun. 
2016, 7, 11190–11201. 
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This section concludes by noting that senolytics need not be small molecules. 
Indeed, nanoparticles can be effective carriers that selectively kill senescent cells. 
For example, MSNs, loaded with either doxorubicin or navitoclax and capped with 
a β-1,4-galactose hexamer, can selectively release their cargo in senescent cells 
because of their characteristically high β-Gal activity.147,148 These loaded 
nanoparticles were used to treat idiopathic pulmonary fibrosis (induced with 
bleomycin) and in combination with palbociclib to reduce tumours in xenografted 
mice.102 It is not only the small-molecule drugs but also their delivery that is 
important. Thus, mice treated with bleomycin recovered their pulmonary capacity 
after treatment with doxorubicin-loaded nanoparticles but not with free 
doxorubicin. The encapsulation of the drug inside the carrier reduces 
doxorubicin’s overall toxicity by increasing its selectivity. Moreover, palbociclib 
treatment followed with doxorubicin-loaded or navitoclax-loaded nanoparticles 
leads to tumour regression in xenografted mice. 
1.2.5 Senomorphics 
Senomorphics are chemical species that inhibit the SASP without killing the 
senescent cell or reversing its proliferative arrest.143 Instead, the molecules used 
thus far for this purpose interfere with and delay the ageing process, thereby 
providing a senotherapeutic effect by a mechanism different to that of 
senolytics.149 In some cases, attenuating the SASP is accompanied by a lower 
lysosomal expansion and, thus, lower SA-β-Gal activity. The past decade has seen 
the emergence of several compounds with senomorphic activity.  
147 A. Bernardos et al. “Enzyme- responsive controlled release using mesoporous silica supports capped with 
lactose”. Angew. Chem. Int. Ed. 2009, 48, 5884–5887. 
148 A. Agostini et al. “Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles”. 
Angew. Chem. Int. Ed. 2012, 51, 10556–10560. 
149 L. J. Niedernhofer and P. D. Robbins. “Senotherapeutics for healthy ageing”. Nat. Rev. Drug Discov. 2018, 17, 
377. 
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1.2.6 The importance of targeting senescent cells 
Overcoming the gradual ageing of the world population remains a formidable 
challenge for health professionals. As life expectancy increases, the vulnerability 
to suffer from some type of chronic disease or pathology increases exponentially. 
In recent years, the scientific community has made a great effort to understand 
the molecular mechanisms that lead to ageing. A pioneering work, in which the 
mice were genetically modified to produce high levels of p53 (a tumor suppressor 
protein), revealed that the mice had almost non-existent cancer rates, but their 
half-life was significantly shorter and had aging symptoms at an early age.150 In 
contrast, “super p53” mice (carrying p53-tg alleles in addition to the two 
endogenous alleles) presented the same rate of cancer resistance but normal 
lifespan, probably because p53 is normally regulated in this model.151 It was 
concluded that there is a strong relationship between cellular senescence and 
ageing.  
As stated above, the main biological role of cellular senescence is to prevent 
the proliferation of damaged or stressed cells.29 In addition, tissue damage and 
cellular senescence provide critical signals for cellular reprogramming and it has 
been reported to be beneficial in various tissue repair settings.21,152 However, 
upon persistent damage or during ageing, the process of tissue repair becomes 
inefficient and senescent cells tend to accumulate in tissues promoting local 
inflammation, tissue ageing, dysfunction and destruction, and potentially, 
150 S. D. Tyner, S. Venkatachalam, J. Choi, S. Jones, N. Ghebraniousk,H. Igelmann,X. Lu et al. “p53 mutant mice 
that display early ageing-associated phenotypes”. Nature. 2002, 415, 45-53.  
151 I. García-Cao, M. García-Cao, J. Martín-Caballero, L. M. Criado, P. Klatt, J. M. Flores, J. C. Weill et al. “`Super 
p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally”. The EMBO J. 2002, 
21, 6225-35 
152 B. Ritschka, M. Storer, A. Mas, F. Heinzmann, M. C. Ortells, J. P. Morton et al. “The Senescence-Associated 
Secretory Phenotype induces cellular plasticity and tissue regeneration”. Genes Dev. 2017, 31, 172-83. 
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tumorigenesis and metastasis.29,153 Besides, it has been demonstrated that the 
selective elimination of senescent cells in genetic models amends a variety of 
ageing-associated symptons, ameliorate long-term degenerative processes and 
extends both healthspan and lifespan.63,154 In fact, senotherapy  has been shown 
to ameliorate and even revert certain diseases in mouse models. As we have seen 
above, a number of these pharmacologically active small compounds or senolytics 
have been reported to have remarkable therapeutic effects on multiple diseases 
in mice in association with the elimination of senescent cells.155 In fact, the 
elimination of senescent cells is considered today as a promising strategy to treat 
ageing-related diseases and delay ageing.155,156,157 
A related key issue in the senescence field is the design of methods to easily 
identify cellular senescence.158 As stated above, a first tool to detect senescent 
cells came from the discovery that senescent cells show high levels of lysosomal 
β-Gal activity.122 This is known as SA-β-Gal and it has served as the basis for the 
design of a number of chromo-fluorogenic probes (vide infra).12 Some other 
markers for senescence, related to the expression of cell cycle inhibitors and/or 
tumour suppressors, have been reported (vide ante).  
153 D. McHugh and J. Gil. “Senescence and aging: Causes, consequences, and therapeutic avenues”. J Cell Biol. 
2018,217, 65-77. 
154 D. J. Baker, T. Wijshake,T. Tchkonia,N. K. LeBrasseur, B. G. Childs, B. van de Sluis et al. “Clearance of 
p16Ink4a-positive senescent cells delays ageing-associated disorders”. Nature. 2011, 479, 232-36. 
155 M. Paez-Ribes, E. González-Gualda, G. J. Doherty and D. Muñoz-Espín. “Targeting senescent cells in 
translational medicine”. EMBO Mol Med. 2019, 11, e10234. 
156 B. G. Childs, M. Gluscevic, D. J. Baker, R. M. Laberge, D. Marquess, J. Dananberg, et al. “Senescent cells: an 
emerging target for diseases of ageing”. Nat Rev Drug Discov. 2017, 16, 718-735. 
157 M. Xu, T. Pirtskhalava, J. N. Farr, B. M. Weigand, A. K. Palmer, M. M. Weivoda, et al. “Senolytics improve 
physical function and increase lifespan in old age”. Nat Med. 2018, 24, 1246-1256. 
158 B. Lozano-Torres, A. Estepa-Fernández, M. Rovira, M. Orzáez, M. Serrano, R. Martínez-Máñez et al. “The 
Chemistry of Senescence”. Nat Rev Chem. 2019, 3, 426-441. 
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1.3  Chemical probes for the detection of senescent cells 
1.3.1 SA-β-Gal-dependent chromo-fluorogenic probes 
Proliferating cells express β-Gal encoded by the GLB1 gene that shows normal 
activity at pH 4. Since in 1995 Dimri and collaborators reported the 
overexpression of β-Gal enzyme activity at suboptimal pH (pH 6), due to the 
expansion of the lysosomal compartment of senescent cells,159 this enzymatic 
activity, known as SA-β-Gal, is one of the most commonly used  markers for the 
detection of cellular senescence.121 This marker is easy to detect and reliable both 
in vivo and in vitro.,160,161 SA-β-Gal activity is conveniently measured using 
chromogenic or fluorogenic probes taking advantage of the fact that the enzyme 
hydrolyses galactosidic bonds.148 In this context, most reported molecular probes 
able to detect SA-β-Gal are composed by two subunits, i.e. (i) a β-galactose 
residue as reactive fragment and (ii) a chromophore or fluorophore as a signalling  
moiety. In most cases both subunits are linked through O-glycosidic or N-
glycosidic covalent bonds or through self-immolative fragments containing one 
glycosidic linkage.162 In these probes, the colour or emission of the fluorophore at 
a certain wavelength is drastically reduced or shifted when galactose is linked to 
the selected signalling unit. However, in the presence of SA-β-Gal, the glycosidic 
bond is hydrolysed and the fluorophore or chromophore is released, restoring its 
emission wavelength or its colour.12
159 B. Y. Lee, J. A. Han, J. S. Im, A. Morrone, K. Johung, E. C. Goodwin, et al. “Senescence-Associated β-
Galactosidase is lysosomal β-Galactosidase”. Aging Cell. 2006, 5, 187-195. 
160 H. W. Lee, C. H. Heo, D. Sen, H. O. Byun, I. H. Kwak, G. Yoon, et al. “Ratiometric two-photon fluorescent 
probe for quantitative detection of β-Galactosidase activity in senescent cells”. Anal Chem. 2014, 86, 10001-
10005.  
161 J. Zhang, C. Li, C. Dutta, M. Fang, S. Zhang, A. Tiwari, et al. “A novel near-infrared fluorescent probe for 
sensitive detection of β-Galactosidase in living cells”. Anal Chim Acta. 2017, 97–104. 
162 B. Lozano-Torres, I. Galiana, M. Rovira, E. Garrido, S. Chaib, A. Bernardos, et al. “An OFF–ON two-photon 
fluorescent probe for tracking cell senescence in vivo”. J Am Chem Soc. 2017, 139, 8808-8811. 
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The first chromogenic probe for β-Gal, an ortho-nitrophenyl-β-galactoside 
(ONPG, Figure 8), was reported by Aizawa in 1939.163 This compound is colourless; 
however, in presence of β-Gal, the O-glycosidic bond is hydrolysed yielding 
galactose and ortho-nitrophenol, which is yellow. A further colorimetric probe for 
β-Gal detection was synthesized by Horwitz and collaborators in 1964, named X-
Gal. It consisted of a galactose linked to a substituted indole and it is a well-known 
colorimetric probe for the detection of β-Gal.164 In presence of the enzyme, the 
galactosyl moiety in X-Gal is removed giving a 5-bromo-4-chloro-3-indolyl residue, 
which dimerizes spontaneously and is oxidized into the insoluble intensely blue 
product 5,5'-dibromo-4,4'-dichloro-indigo following the mechanism shown in 
Figure 8. Since X-Gal was reported, many variants have been synthesized with 
slight modifications giving final compounds that display different colours in the 
presence of β-Gal (Figure 8). All these derivatives are usually commercialized as β-
Gal activity senescence detection kits. It is important to remark that ONPG and X-
Gal are not permeable to the cell membrane and they can only be used in lysed 
cells.  
In a pioneering work, Rotman et al described in 1961 the first fluorescent 
probe for measuring β-Gal activity, (fluorescein-di-(β-D-galactopyranoside),165,166 
(FDG in Figure 8). In this study the authors reported that PBS solutions (pH 7.2) of 
FDG were non-emissive (λexc = 400 nm) but a remarkable emission band at 490 nm 
was developed in the presence of β-Gal, due to the hydrolysis of glycosidic bonds 
and the subsequent release of fluorescein. These optical changes were also used 
163 K. Aizawa. “Studien über carbohydrasen II. die fermentative hydrolyse des p-Nitrophenol-β-Galactoside”. 
Enzymologia. 1939 , 6, 321-324. 
164 J. P. Horwitz, J. Chua, R. J. Curby, A. J. Tomson, M. A. Da Rooge, B. E. Fisher, et al. “Substrates for 
cytochemical demonstration of enzyme activity. I. Some substituted 3-Indolyl-β-D-Glycopyranosides”. J Med 
Chem. 1964, 7, 574-575.
165 B. Rotman. “Measurement of activity of single molecules of β-D-Galactosidase”. Proc Natl Acad Sci U.S.A. 
1961, 47, 1981-1991.
166 B. Rotman, J. A. Zderic and M. Edelstein. “Fluorogenic substrates for β-D-Galactosidases and phosphatases 
derived from fluorescein (3,6-dihydroxyfluoran) and its monomethylether”. PNAS U.S.A. 1963, 50, 1-6. 
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to detect β-Gal activity in droplets of silicone oil containing FDG and the enzyme. 
Following a similar approach Hirchsmann and co-workers prepared in 1962 a 
compound named MUG167 for the detection of β-Gal activity (Figure 8). Glycine 
buffer solutions of MUG (pH 7) did not show any emission (λexc = 365 nm) whereas 
in presence of the enzyme, the galactoside residue was removed yielding the 
highly fluorescent 4-methylumbelliferone fluorophore (λem = 455 nm), resulting in 
an overall OFF-ON response. Unfortunately, MUG is also impermeable to the cell 
Figure 8. Most commonly and commercially available probes for cellular senescence detection.
167 L. L. Woods and J. Sapp. “A New one-step synthesis of substituted coumarins”. J Org Chem. 1962, 27, 3703-
3705.  
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membrane. A great number of other coumarin-based fluorophores for β-Gal 
activity detection were later described.168 
A recent commercially available probe was developed by Urano and co-
workers, who described a fluorogenic hemiccyanin probe for labelling living 
senescent cells in culture and in living tissues. The prepared probe, (E)-2-[2-(6-
hydroxy-2,3-dihydro-1H-xanthen-4-yl)vinyl]-3,3-dimethyl-1-propyl-3H-indole-1 
ium, is commonly known as Spider-Gal (Figure 8).169 PBS (pH 7.4) solutions of 
Spider-Gal present an absorption band at 525 nm and are almost non-emissive. 
However, addition of β-Gal enzyme induces the appearance of a highly 
fluorescent band at 560 nm (excitation at 525 nm). The observed emission 
enhancement was ascribed to the β-Gal-induced hydrolysis of Spider-Gal that 
yielded the quinone methide derivative shown in Figure 8. In the original 
research, the response of Spider-Gal was tested in HEK cells transfected or not 
with LacZ gene and the probe was able to distinguish between different levels of 
β-Gal by confocal microscopy, flow cytometry and ex vivo fixed tissues. In the last 
years, Spider-Gal has become in a widely used tool by researchers in the field of 
cellular senescence due to its high sensitivity and its high retentivity inside cells. 
Although only a few probes based on the hydrolysis of O-glycosidic, N-
glycosidic covalent bonds by SA-β-Gal enzyme activity are marketed; many probes 
based on this same idea of β-binding a monosaccharide to a fluorophore have 
been described.12 Some of these probes for SA-β-Gal detection have been 
validated in lacZ transfection models which are not exactly realistic senescence 
models. In fact, in lacZ transfection models the transfected cells highly 
168 K. R. Gee, W. C. Sun, M. K. Bhalgat, R. H. Upson, D. H. Klaubert, K. A. Latham et al. “Fluorogenic substrates 
based on fluorinated umbelliferones for continuous assays of phosphatases and β-Galactosidases”. Anal 
Biochem. 1999, 273, 41-48. 
169 T. Doura, M. Kamiya, F. Obata, Y. Yamaguchi, T. Y. Hiyama, T. Matsuda et al. “Detection of LacZ -positive cells 
in living tissue with single-cell resolution”. Angew Chem Int Ed. 2016, 55, 9620-9624. 
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overexpress lacZ (with excessively high concomitant activity of β-Gal), and the 
bacterial enzyme is cytosolic and not localized in lysosomes (the usual subcellular 
location of SA-β-Gal activity) which could lead to failures in the detection of 
senescence.12,162 Moreover, many probes have been validated in in vivo-lacZ 
models according to two approaches: (i) transfecting tumour cells with the pCMV-
lacZ plasmid and injected them in the animal; or (ii) labelling tumours 
overexpressing with avidin-β-Gal.170,171 A more realistic approach to validate SA-β-
Gal probes used cell lines with high lysosomal β-Gal activity per se, such as cells 
from congenital dyskeratosis patients, SHIN3, SKOV3, OVK18, OVCAR3, OVCAR4, 
OVCAR5, OVCAR8 or HUVEC.164,172,173,174,175 
Certain probes have also been tested to detect replicative senescence; 
senescence induced by reactive oxygen species or chemically induced senescence. 
Kim et al. reported the ratiometric two-photon fluorescent probe (SG1) composed 
of the fluorophore 6-(benzo[d]thiazol-2′-yl)-2-(methylamino)-naphthalene, a self 
immolative carbamate as linker, a polyether as solubilizing group and galactose as 
hydrolytic moiety (Figure 9).160 The authors found that the maximum of the 
emission spectra of SG1 changed from 461 to 540 nm in the presence of β-Gal. β-
Gal enzyme induced the hydrolysis of galactose in the anomeric carbon with the 
subsequent rupture of the self immolative linker that released the polyether-
170 M. Kamiya, H. Kobayashi, Y. Hama, Y. Koyama, M. Bernardo, T. Nagano et al. “An enzymatically activated 
fluorescence probe for targeted tumor imaging”. J Am Chem Soc. 2007, 129,  3918-3929. 
171 K. Gu, Y. Xu, H. Li, Z. Guo, S. S. Zhu, S. S. Zhu et al. “Real-time tracking and in vivo visualization of  β-
Galactosidase activity in colorectal tumor with a ratiometric near-infrared fluorescent probe”. J Am Chem Soc. 
2016, 138, 5334-5340. 
172 S. Imai, Y. Kiyozuka, H. Maeda, T. Noda and H. L. Hosick. “Establishment and characterization of a human 
ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide 
antigen”. Oncology. 1990, 47, 177-184.
173 M. C. Hung, X. Zhang, D. H. Yan, H. Z. Zhang, G. P. He, T. Q. Zhang et al. “Aberrant expression of the C-ErbB-
2/Neu protooncogene in ovarian cancer”. Cancer lett. 1992, 61, 95-103. 
174 T. C. Hamilton, R. C. Young, W. M. McKoy, K. R. Grotzinger, J. A. Green, E. W. Chu et al. “Characterization of a 
human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors”. Cancer Res. 1983, 43, 
5379-5389. 
175 Y. Yuan; W. H. Kim; H. S. Han; J. H. Lee; H. S. Park; J. K. Chung; S. B. Kang and J. G. Park, “Establishment and 
characterization of human ovarian carcinoma cell lines”. Gynecol Oncol. 1997, 66, 378-387. 
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fluorophore. Probe SG1 was tested in human diploid fibroblasts (HDF) in a 
replicative model of senescence. By treating the cells with SG1, the authors 
observed that the ratio Fyellow/Fblue increased from 0.30 to 1.13 when cells 
accumulated passages and were excited at a wavelength of 750 nm. Finally, the 
authors used the probe for staining 7-month-old and 26-month-old 
Sprague−Dawley rat skin tissues, showing an enhancement of the Fyellow/Fblue ratio. 
A new senescence-specific fluorescent probe based in a rhodol core linked to 
galactose (SRP) was studied in vascular endothelial HUVEC cells, where 
senescence was induced with H2O2 (Figure 9). The SRP probe showed a high 
chemoselectivity in the presence of β-Gal versus other enzymes. Senescent 
cultured HUVEC cells exhibited high fluorescent signal after treatment with the 
probe, in sharp contrast with non-senescent HUVEC cells.176 Recently, Zhang and 
co-workers, prepared a near-infrared fluorescent probe based on hemicyanine 
skeleton ((E)-2-(2-(6-hydroxy-2,3-dihydro-1H-xanthen-4-yl)vinyl)-3,3-dimethyl-1-
propyl-3H-indol-1-ium) conjugated with a D-galactose moiety (Gal-Pro in Figure 
9). The absorption spectra of Gal-Pro in PBS presented an intense band at 596 nm 
and two weaker absorptions at 560 nm and 643 nm. Moreover, the emission 
spectra of the probe showed a weak band at 665 nm. In the presence of β-Gal, a 
new emission band at 703 nm appeared (12.8-fold enhancement). The authors 
tested the probe response in a premature senescence model of HDF cells induced 
by H2O2.164 No signal was observed for control cells, whereas in senescent cells 
clear turn-on NIR fluorescent images were captured. This molecule, (Figure 9) was 
also tested in cells with knocked-in LacZ and HeLa and MCF7 senescent cells 
where senescence was induced with camptothecin or radiation therapy. The 
176 E. J. Kim, A. Podder, M. Maiti, J. M. Lee, B. G. Chung and S. Bhuniya. “Selective monitoring of vascular cell 
senescence via β-Galactosidase detection with a fluorescent chemosensor”. Sens Actuator B-Chem. 2018, 274, 
194-00. 
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probe was validated in vivo in mice bearing LacZ(+) tumour and camptothecin 
drug treated HeLa xenograft models in order to corroborate the applicability of 
NIR-BG in genetically or drug-induced expressed β-Gal.177 
As it is apparent from the literature, only very few reports exist, in which 
senescence probes have been validated in more realistic in vivo models of 
senescence. An example is the probe AHGa (anhydride–histidine–galactose), 
which contains an N-glyosidic bond (Figure 9).162 AHGa probe was tested in SK-
MEL-103 xenografted mice in which senescence was induced by oral 
administration of palbociclib. The tumours in palbociclib-treated mice 
intravenously injected with the probe showed strong fluorescence relative to non-
senescent tumours. Moreover, confocal microscopy images of fresh sections 
obtained from different organs (such as the liver, spleen, kidneys, lungs and heart) 
showed non-significant changes in fluorescence. 
Figure 9. Some other fluorogenic probes for senescence detection. 
177 Y. Wang, J. Liu, X. Ma, C. Cui, P. R. Deenik, P. K. P. Henderson et al. “Real-time imaging of senescence in 
tumors with DNA damage”. Sci Rep. 2019, 9, 2102-2013. 
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1.3.2 Other hydrolases probes 
Apart from β-Gal, the overexpression of other lysosomal hydrolases124 such as 
α-L-fucosidase (α-Fuc), has been also employed for the detection of cellular 
senescence.125 The overexpression of α-Fuc was deduced from measurements of 
the activity of hydrolases in various cell lines using different senescence models. 
From these studies it was apparent that α-Fuc activity was higher or, at least, 
comparable with SA-β-Gal in senescent cells. Based on the above, molecular 
probes containing selected chromophores or fluorophores linked with α-fucose 
have been developed (X-Fuc178 and MUF179 in Figure 10) and used to measure α-
Fuc activity. Other enzymes, such as β-glucuronidase,180 acid phosphatase, β-
hexosaminidase,181 α-mannosidase and N-acetyl-β-glucosaminidase,182 have also 
been reported to be overexpressed in senescent cells, but in lower levels than 
those found for β-Gal and α-Fuc. In this context, p-nitrophenyl-α-D-
mannopyranoside, 4-nitrophenyl N-acetyl-ß-D-glucosaminide and 4-nitrophenyl-
ß-D-glucuronide have been employed for activity measurement of α-
mannosidase, N-acetyl-β-glucosaminidase and β-glucuronidase, respectively, in 
lysed cells (Figure 10).124 Detection of these enzymes using chromo-fluorogenic 
probes could be an alternative for effective senescence detection. 
178 J. R. Esterly, A. C. Standen and B. Pearson. “The histochemical demonstration of intestinal β-D-fucosidase 
with 5-bromo-4-chloroindole-3-yl-β-d-fucopyranoside”. J Histochem Cytochem. 1967, 15, 470-474. 
179 A. R. Rushton and G. Dawson. “Glycosphingolipid β-Galactosidases of cultured mammalian cells: 
characterization of the enzymes from mouse cell line LMTK and human Lesch-Nyhan fibroblasts”. Biochim 
Biophys Acta Lipids Lipid Metab. 1975, 388, 92-105. 
180 W. Grabowska, G. Mosieniak, N. Achtabowska, R. Czochara, G. Litwinienko, A. Bojko et al. “Curcumin induces 
multiple signaling pathways leading to vascular smooth muscle cell senescence”. Biogerontol. 2019, 20, 783-798.
181 L. Urbanell, A. Magini, L. Ercolani, K. Sagini, A. Polchi, B. Tancini et al. “Oncogenic H-Ras up-regulates acid β-
hexosaminidase by a mechanism dependent on the autophagy regulator TFEB”. PLoS ONE. 2014 , 9, e89485. 
182 M. Agirbasli, B. Radhakrishnamurthy, X. Jiang, W. Bao and G. S. Berenson. “Urinary n-acetyl-β-D-
Glucosaminidase changes in relation to age, sex, race, and diastolic and systolic blood pressure in a young adult 
biracial population: The Bogalusa heart study”. Am J Hypertens. 1996 , 9, 157-161. 
Adapted from B. Lozano-Torres et al.               General introduction 
Senolytics in Disease, Ageing and Longevity, 2020, 163 
General introduction 
71 
Figure 10. Chromo-fluorogenic probes for the detection of other lysosomal hydrolases. 
1.3.3 Lipofuscin detection 
Another proposed marker of senescence is lipofuscin. Lipofuscin is a non-
degradable aggregate of oxidized proteins, lipids and oligosaccharides that 
accumulates progressively mostly in aged post mitotic cells.116 Intracellular 
lipofuscin accumulation appears to be a universal correlate of animal 
senescence.117 Lipofuscin is an emissive aggregate that can be visualized using 
fluorescent microscopy. Moreover, histochemical methods, such as staining with 
Sudan Black B (SBB), are commonly used for lipofuscin detection. Lipofuscin 
stained with SBB is applicable for in vitro measurements.119,120,183 Studies 
demonstrated that SBB-stained lipofuscin is present in cells that expressed SA-β-
Gal activity and is absent in SA-β-Gal-negative cells.118 In a modification of this 
basic procedure, Gorgoulis, Bartek and co-workers recently developed a two-step 
staining procedure based on a biotin-antibiotin antibody-peroxidase-conjugated 
183 T. Jung, A. Höhn and T. Grune. “Lipofuscin: detection and quantification by microscopic techniques”. 
Methods Mol Biol. 2010, 594, 173-193. 
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reaction, in order to improve the in vitro and ex vivo lipofuscin detection achieved 
with commercially available SBB staining (Figure 11). In their work, the authors 
used SBB-biotin conjugate to target lipofuscin.184 After binding of lipofuscin with 
SBB-biotin the staining of senescent cells is carried out upon addition of an 
antibiotin antibody functionalized with a peroxidase-conjugated polymeric 
backbone. Finally, addition of 3,3’-diaminobenzidine (DAB) induced the 
appearance of a dark blue-black colour (due to the peroxidase-catalysed oxidation 
of DAB) which indicated the presence of lipofuscin.118 
Figure 11. Chemical structures of SBB and SBB-biotin conjugate developed by Gorgoulis, Bartek and 
co-workers to detect lipofuscin. 
1.3.4 Other approaches for the detection of senescent cells using 
chemical probes 
Based on the facts cited above, it seems clear that most of the described 
methods for the detection of cellular senescence are based on chromo-
184 K. Evangelou, N. Lougiakis, S. V. Rizou, A. Kotsinas, D. Kletsas, D. Muñoz-Espín et al. “Robust, universal 
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fluorogenic probes that evaluate SA-β-Gal activity. In spite of this fact, in recent 
years, other innovative methods for the detection of senescent cells have been 
proposed which do not rely on the presence of lysosomal β-Gal or do not display a 
final chromo-fluorogenic signal. 
The CyBC9 probe has been recently developed based on a Cy7 skeleton (Figure 
12) that was used for the detection of senescence using proliferative (young) and
senescent (old) cells.185 The probe is a nontoxic membrane-permeable fluorescent 
molecule. The probe was tested in human early mesenchymal stromal cells 
(heMSCs) (young and old) from different tissues, such as bone marrow (BM) 
Wharton’s Jelly (UC) and adipose tissue (AD). The authors demonstrated that 
CyBC9 probe is accumulated in the mitochondria of senescent cells. The selectivity 
of the probe is based in the membrane potential of mitochondria. In senescence 
cells, there is an increase in ROS species that induced the depolarization of the 
mitochondria membrane allowing the accumulation of the probe CyBC9.  
Figure 12. Probes for detection of cellular senescence, measuring SA-β-Gal activity, which are not 
functioalized with chromo-fluorophores.  
185 J. Ang, Y. Lee, D. Raghothaman, P. Jayaraman, K. L. Teo, F. J. Khan et al. “Rapid detection of senescent 
mesenchymal stromal cells by a fluorescent probe”. Biotechnol J. 2019, 14, e1800691. 
General introduction     Adapted from B. Lozano-Torres et al. 
   Senolytics in Disease, Ageing and Longevity, 2020, 163 
General introduction 
74 
Lumba et al. reported a probe for lysosomal β-Gal activity capable of detecting 
cellular senescence in cultured cells by mass cytometry.186 Mass cytometry is a 
similar technique to flow cytometry but equipped with an inductively coupled 
plasma mass spectrometry (ICP-MS) detector. The tellurophene probe contains a 
tellurene moiety as a reporter group which generates a quinone alkide when 
hydrolysed (Figure 12). The quinone alkide is a reactive alkylating agent that forms 
covalent tellurophene-bearing conjugates with protein nucleophiles, allowing the 
quantification of lysosomal β-Gal activity in individual cells by mass cytometry. 
The authors used a retinal pigment epithelial (Rpe) cell line known to undergo 
senescence upon H2O2 treatment. Upon addition of tellurophene probe, they 
authors observed a higher labelling (ca. 1.75–fold) in senescent Rpe cells 
compared to control cells by mass cytometry analysis. 
Another technique recently used in the detection of senescent cells is positron-
emission tomography (PET), for which radioactive molecules linked to β-
galactosides are used (PET-tracer in Figure 12).187 PET-tracer was tested in two 
different in vitro models: (i) HCT1-16 cells with doxorubicin-induced senescence 
and (ii) HRas driven liver progenitor cells with a doxycycline regulatable p53-
specific shRNA. For this purpose both control and senescent cells of each cell line 
were treated with the PET-tracer, washed and measured in a gamma counter. 
Senescent cells from both lines incorporated more PET-tracer than control ones 
(ca. 3-fold higher accumulation). Besides, in vivo experiments showed higher 
uptake for senescent HCT1-16 tumours (1.54-fold) compared to control ones 
whereas the observed value for HRas driven liver progenitor cells was 1.66-fold 
higher. 
186 M. A. Lumba, L. M. Willis, S. Santra, R. Rana, L. Schito, S. Rey et al. “A β-Galactosidase probe for the detection 
of cellular senescence by mass cytometry”. Org Biomol Chem. 2017, 15, 6388-6392. 
187 J. Schwenck, J. Cotton, B. Zhou, K. Wolter, A. Kuehn, K. Fuchs et al. “In vivo imaging of tumor senescence 
with a novel beta-Galactosidase specific PET tracer”. Nuklearmedizin, 2019, 58, 106. 
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1.4  Nanodevices targeting senescent cells 
Additionally to molecular-based sensors, the use of smart nanodevices is an 
active field of research and several interesting examples have been published in 
the last years applied to the detection of certain types of cells.188 These 
nanodevices are mainly constituted by inorganic or organic nanoparticles carrying 
a certain cargo and sometimes functionalized with (bio)molecules acting as 
targeting ligands.189 These complex nanoarchitectures are finding promising 
biomedical applications. Taking this into account, it is not surprising that several 
functional nanoparticles targeting senescent cells have been described recently.190 
These nanodevices are based on MSNs, carbon quantum dots (CQDs), porous 
CaCO3 nanoparticles and molecularly imprinted polymer nanoparticles 
(nanoMIPs). 
Martínez-Máñez et al. developed a nanodevice able to selectively release its 
cargo in senescent cells. The nanodevice consisted of MSNs, loaded with 
rhodamine B (Rh B), functionalised with (3-aminopropyl)triethoxysilane (APTES) 
and capped with a galacto-oligosaccharide.164 A similar system capped with 
lactose was previously reported by the same authors in 2009.191 The release 
profile of the gated nanoparticles revealed a poor cargo delivery, whereas a 
remarkable amount of Rh B was released after 24 h in presence of β-Gal enzyme 
(Figure 13a). Cargo release in the presence of β-Gal was ascribed to the enzymatic 
hydrolysis of the capping galacto-oligosaccharide. Besides, the nanoparticles were 
188 E. Aznar, M. Oroval, L. Pascual, J. R. Murguía, R. Martínez-Máñez and F. Sancenón. “Gated materials for on-
command release of guest molecules”. Chem Rev. 2016, 116, 561-518. 
189 B. Lozano-Torres, L. Pascual, A. Bernardos, M. D. Marcos, J. O. Jeppesen, Y. Salinas et al. “Pseudorotaxane 
capped mesoporous silica nanoparticles for 3,4-methylenedioxymethamphetamine (MDMA) detection in water”. 
Chem Commun. 2017, 53, 3559-3562. 
190  D. Muñoz-Espín. “Nanocarriers targeting senescent cells”. Trans Med Aging. 2019, 3, 1-5. 
191 A. Bernardos, E. Aznar, M. D. Marcos, R. Martínez-Máñez, F. Sancenón, J. Soto et al. “Enzyme-responsive 
controlled release using mesoporous silica supports capped with lactose”. Angew Chem Int Ed. 2009, 48, 5884-
5887. 
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tested in the cells lines DC1787, X-DC 1774 and X-DC4646 from patients suffering 
congenital dyskeratosis, in which lysosomal β-Gal is overexpressed. High emission 
signals were found in DC1787, X-DC 1774 and X-DC4646 cells lines, whereas poor 
cargo delivery was found in H460 control cells where endogenous β-Gal is not 
overexpressed. As stated above, Martínez-Máñez and Serrano developed 
mesoporous silica nanoparticles loaded with Rh B or Indocyanine Green (ICG) and 
capped with a β-1,4-galactose hexamer (GalNP).120 In the presence of the β-Gal 
enzyme, the capping oligosaccharide was hydrolysed and cargo was released. 
These nanoparticles were tested in a mouse model of pulmonary fibrosis and in a 
cancer mouse model of senescence induced by chemotherapy. The authors 
observed that the combination of palbociclib treatment with GalNP loaded with 
Rh B or ICG presented a more efficiently release of the fluorophore in senescent 
tumours, observing an enhancement of fluorescence. Moreover, the induction of 
pulmonary fibrosis by treating mice with bleomycin followed by intravenous 
injection with the fluorophore-loaded GalNP led to an increased fluorescent signal 
with respect to mice not treated with bleomycin, which did not present cellular 
senescence in lungs. Finally, drug-loaded nanoparticles with doxorubicin 
(GalNP(Dox)) or navitoclax (GalNP(Nav)) facilitated tumour regression in 
xenografted mice concomitantly treated with palbociclib and also the recovery in 
the pulmonary capacity in mice subjected to bleomycin-induced lung fibrosis. 
Besides, the authors found that the encapsulation of doxorubicin and navitoclax 
reduced their toxicity. 
A sensing method for cellular senescence using nanoparticles was developed 
by Feng and co-workers, who employed β-cyclodextrin-functionalized carbon 
quantum dots (β-CD-CQDs) for β-Gal activity evaluation in vitro (Figure 13b). PBS 
solutions of β-CD-CQDs showed a marked emission band at 445 nm upon 
excitation at 365 nm. The authors observed that this emission was quenched 
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upon addition of gradual amounts of p-nitrophenol due to the formation of an 
inclusion complex with the β-CDs grafted onto the external surface of the CQDs.192 
Figure 13. (a) MSNs capped with a galacto-oligosaccharide. In the presence of lysosomal β-Gal the 
galacto-oligosaccharide cap is hydrolysed and cargo is released. (b) Mechanism of detection of β-Gal 
using probe 4-nitrophenyl-β-D-galactopyranoside and β-CD-CQDs. (c) CaCO3 nanocarriers that 
selectively deliver the cargo in senescent cells. (d) Molecularly imprinted nanoparticles (nanoMIPs) 
targeting B2MG membrane protein associated to senescence. 
Taking this into account, the authors monitored β-Gal activity using a mixture 
of β-CD-CQDs and 4-nitrophenyl-β-D-galactopyranoside. β-Gal is able to 
hydrolyse the glycosidic bond in 4-nitrophenyl-β-D-galactopyranoside releasing 
p-nitrophenol which formed supramolecular inclusion complexes with the grafted 
β-CD. As a consequence, the emission of β-CD-CQDs was quenched (Figure 12b). 
β-Gal enzyme was detected in a 1.9 to 70 U L-1 range of concentrations and with a 
limit of detection as low as 0.6 U L-1. MTT viability assays showed that β-CD-CQDs 
192 C. Tang, J. Zhou, Z. Qian, Y. Ma, Y. Huang and H. A. Feng. “Universal fluorometric assay strategy for 
glycosidases based on functional carbon quantum dots: β-Galactosidase activity detection in vitro and in living 
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were non-toxic for OVCAR-3, a cell line presenting high lysosomal β-Gal activity 
per se and that is typically used to validate β-Gal probes. OVCAR-3 cells incubated 
with β-CD-CQDs showed a marked fluorescence but when exposed to both β-CD-
CQDs and the galactose derivative 4-nitrophenyl-β-D-galactopyranoside a 
marked emission quenching was observed.  
Detection and elimination of senescent cells has also been achieved with 
porous calcium carbonate nanoparticles loaded with a fluorophore (coumarin-6) 
or a drug (rapamycin).193 The authors reacted lactose with a poly(ethylene glycol) 
derivative containing amine and carboxylate moieties in opposite sides and the 
poly(ethylene glycol) derivative was adsorbed onto the external surface of the 
loaded nanoparticles. Finally, an anti-CD-9 antibody (CD-9 receptor is 
overexpressed in senescent cells) was grafted onto the external surface of the 
nanoparticles using an EDC/NHS mediated esterification reaction (Figure 13c). 
Aqueous suspensions of the coumarin-6-loaded nanoparticles at pH 7.4 showed a 
poor cargo release after 48 h. However, in the presence of β-Gal, a marked cargo 
release was observed due to lactose hydrolysis and subsequent detachment of 
the PEG chain from the surface of the nanoparticles. Confocal microscopy studies 
carried out with the coumarin-loaded-material showed that nanoparticles were 
preferentially internalized by old/senescent human dermal fibroblasts (HDF) when 
compared to the same young cells due to the overexpression of CD-9 membrane 
receptors, resulting in the subsequent release of coumarin-6 by β-Gal activity. The 
same nanoparticles loaded with rapamycin, an mTOR inhibitor that prevents 
senescence by affecting the p53/p21 pathway, displayed a senomorphic effect 
due to the rapamycin release, inducing marked reductions in β-Gal levels, 
p53/p21, CD-9 expression and also decreased senescence-associated secretory 
193 R. K. Thapa, H. T. Nguyen, J. H. Jeong, J. R. Kim, H. G. Choi, C. S. Yong et al. “Progressive 
slowdown/prevention of cellular senescence by CD9-targeted delivery of rapamycin using lactose-wrapped 
calcium carbonate nanoparticles”. Sci Rep. 2017, 7, 43299. 
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phenotypes (IL-6, IL-1 β) together with reduced senescent cells population 
numbers and prevention of cell cycle arrest.  
More recently, another method for the detection of senescent cells based on 
molecularly imprinted nanoparticles (nanoMIPs) capable of recognizing a 
membrane protein associated with senescence was proposed.194 It has been 
reported that senescent EJ bladder cancer cells (EJ), fibrosarcoma cells (HT1080) 
and human diploid fibroblasts (HDF) overexpressed the B2MG membrane 
protein.195 Bearing this idea in mind, the authors developed nanoMIPs recognising 
an extracellular epitope of B2MG. For nanoMIPs synthesis, in a first step, the 
epitope (amino acids 101-115) of β2 microglobulin (used as template) was 
covalently grafted onto the external surface of thiol-functionalised glass beads as 
a solid support by using succinimidyl-iodo acetate as linker. Then, in a second 
step, this hybrid material was suspended in a mixture of fluorescein-based acrylic 
monomers solution in order to obtain a polymer around the template (Figure 
13d). Finally, nanoMIPs were separated from the solid support washing with 
water at 65oC. The affinity of nanoMIPs for B2MG protein was tested in EJ bladder 
cancer cells after genetically-induced senescence by overexpressing p16 with a 
tetracycline(tet)-regulatable system. Flow cytometry assays and fluorescence 
microscopy images revealed the preferential accumulation of nanoMIPs in the 
external membrane of senescent cells. Moreover, the senolytic activity of 
dasatinib-loaded nanoMIPs was demonstrated in EJp16 cells. Finally, in vivo 
studies revealed that nanoMIPs tagged with the dye DyLight 800 NHS Ester were 
194 A. E. Ekpenyong-Akiba, F. Canfarotta, H. B. Abd, M. Poblocka, M. Casulleras, L. Castilla-Vallmanya et al. 
“Detecting and targeting senescent cells using molecularly imprinted nanoparticles”. Nanoscale Horiz. 2019, 4, 
757-768. 
195 M. Althubiti, L. Lezina, S. Carrera, R. Jukes-Jones, S. M. Giblett, A. Antonov et al. “Characterization of novel 
markers of senescence and their prognostic potential in cancer”. Cell Death Dis. 2014, 5, e1528.  
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able to distinguish between young (2 months) and old (11 months) C57/BL6J mice 
observing a preferential signal in the intestine, specifically in the jejunum. 
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Given the relevance of senescence in ageing related diseases and the role of 
senescent cells in cancer, the present PhD thesis aims to contribute to the field of 
cellular senescence by the design, synthesis, characterization and in vitro and in 
vivo evaluation of different molecular probes, nanodevices and prodrugs whose 
response is related with the overexpression of β-Gal in senescent cells.  
The specific objectives referred to each chapter are: 
 To develop an OFF-ON probe to target senescent cells using a new two-
photon naphtalimide-based fluorophore and its validation in vivo in mice
bearing tumor xenografts treated with senescence-inducing chemotherapy.
 To develop a new naphtalimide-styrene based two photon fluorescence
probe to target senescent cells and its validation in vivo in an orthotopic
breast cancer mouse model treated with senescence-inducing
chemotherapy, and in a renal fibrosis mouse model.
 To develop a renally clearable non-invasive Cy7-based NIR-fluorescent
molecular probe to detect cellular senescence in vivo through a simple
readable signal in urine.
 To design and validate MSNs loaded with Nile Blue (NIR-FDA-approved
fluorophore) and capped with an galactooligosaccharide as a new nanodevice
to detect cellular senescence in vitro and in vivo.
 To develop and validate in vitro and in vivo a new prodrug reducing side
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3.1 Abstract 
A naphthalimide-based two-photon probe (AHGa) for the detection of cell 
senescence has been designed. The probe contains a naphthalimide core, an L-
histidine methyl ester linker and an acetylated galactose bonded to one of the 
aromatic nitrogen atoms of the L-histidine through a hydrolysable N-glycosidic 
bond. Probe AHGa is transformed into AH in senescent cells resulting in an 
enhanced fluorescent emission intensity. Importantly, in vivo detection of 
senescence was validated in mice bearing tumor xenografts treated with 
senescence-inducing chemotherapy. Our work provides a potential technology for 
diagnostic applications in a wide variety of clinical disorders. 
3.2 Introduction 
Senescent cells show a flat and enlarged morphology with increased 
cytoplasmic and nuclear volume, and an altered phenotype. The main purpose of 
cellular senescence is to prevent the proliferation of damaged or stressed cells 
and, at the same time, to trigger tissue repair.1 However, upon persistent damage 
or during aging, the dynamic process of tissue repair becomes inefficient and 
senescent cells tend to accumulate. This accumulation in tissues is believed to 
impair tissue functions and accelerate aging.1 Several markers and phenotypic 
characteristics have been described to define senescence: (i) a complex paracrine 
response termed as senescence-associated secretory phenotype (SASP),2 (ii) the 
expression of cell cycle inhibitors and/or tumor suppressors (p16, p21 or p53)3 
and (iii) high levels of lysosomal β-galactosidase (β-Gal) activity (known as 
senescence-associated β-galactosidase, SA-β-Gal)4 and several other hydrolases.5 
It has been demonstrated that genetic ablation of senescent cells ameliorates 
a variety of ageing-associated diseases, reverts long-term degenerative processes 
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and extends longevity.6 Inspired by these findings, strategies to prevent, replace 
or remove senescent cells have become of interest both from basic research and 
application viewpoints. In fact, there is an increasing interest in the development 
of senolytics, molecules that are able to induce apoptosis preferentially in 
senescent cells.7 Such senolytics would contribute to the therapeutic treatment of 
senescence-associated diseases and may boost the long-term concept that 
rejuvenation might be possible.8 A related key issue in this field, is the design of 
tools able to accurately detect in vivo the presence of senescence. These probes 
are expected to be a fundamental instrument for the detection of senescent cells 
in aged or damaged tissues and to be a suitable tool to monitor the action of 
senolytics in multiple age-related disorders.1 However, one of the major obstacles 
limiting progress in this research area, is the nearly lack of real-time methods to 
selectively track senescence in in vivo systems. 
Detection of senescent cells usually relies on the detection of the senescence-
associated β-Gal (SA-β-Gal) activity, and several fluorescent or chromogenic 
molecular probes have been reported for the visualization of this enzymatic 
activity.9 However, these first-generation probes are usually unsuitable for in vivo 
imaging as they rely on chromogenic changes or on the use of classical one-
photon fluorescence excitation. As an alternative, the synthesis of probes using 
two-photon fluorescence has recently attracted attention.10 
Two-photon probes provide prolonged observation time, increased imaging 
depth, minimized fluorescence background, ameliorated light scattering and 
rather minimize tissue injury. 
In this context, recent stimulating studies developing fluorescent probes for 
the visualization of β-Gal activity have been described (Table S1). However, most 
of the reported probes are synthesized by using tedious multistep protocols. 
Another common drawback of these molecular sensors is the fact that are tested 
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in cultured cells or in animal models that were not directly related to senescence. 
The methodology used in these studies, is based on a lacZ gene transfection, 
which results in high levels of bacterial β-Gal expression in the cell cytoplasm 
(unlike the lysosomal β-Gal activity associated with senescent cells).11 A limited 
number of works describe the use of human cell lines overexpressing endogenous 
β-Gal per se, as it is the case of ovarian cancer cell lines.12 However, these cancer 
cell lines are obviously not senescent because senescent cells do not proliferate. 
As regards in vivo studies with mice, probes are tested in models that (i) labeled 
tumors with avidin-β-Gal13 or (ii) transfected tumor cells with pCMV-lacZ 
plasmid.14 In both cases a bacterial β-Gal overexpression is achieved. 
In this scenario, the development of more specific and reliable two-photon 
fluorescence-based probes for in vivo detection of senescence is still a challenge. 
In view of the aspects mentioned above, we report herein a novel molecular 
probe for the two-photon fluorogenic in vivo detection of senescence. The probe 
(AHGa) is based on a naphthalimide fluorophore as signaling unit containing an L-
histidine methyl ester linker and an acetylated galactose attached to one of the 
aromatic nitrogen atoms of the L-histidine through a hydrolysable N-glycosidic 
bond. Probe AHGa is transformed into AH in senescent cells (Figure 1a) resulting 
in an enhanced fluorescent emission intensity. In vivo detection of senescence 
was additionally demonstrated in mice bearing tumor xenografts treated with 
senescence-inducing chemotherapy. 
3.3 Results and discussion 
The synthesis of AHGa is shown in Scheme 1. The probe was easily prepared using 
a two-step protocol. In the first step, 4-bromo-1,8-naphtalic anhydride (A) and L-
histidine methyl ester (H) were reacted in refluxing dioxane yielding fluorophore 
AH. Then, a nucleophilic substitution reaction between AH and 2,3,4,6-tetra-O-
B. Lozano-Torres et.al, J.Am. Chem. Soc., 2017, 139, 26 
91 
acetyl-α-D-galactopyranosyl bromide (Ga) yielded the final AHGa probe. Both, AH 
and AHGa, were characterized by using 1H and 13C NMR and HRMS (Figures S1-S6). 
Figure 1b summarizes the fluorogenic behavior of AHGa and AH. Excitation at 405 
nm of AHGa in PBS (pH 4.5)-DMSO (0.01%) did not show any emission band (ɸAHGa 
= 0.002), whereas under the same experimental conditions AH displayed an 
intense fluorescence (ɸAH = 0.458, 286-fold enhancement) at 540 nm (Figure 1b 
and S7). Moreover, the emission intensity of AH remained unchanged in the 4-8 
pH range (Figure S8). 
 
Scheme 1. Synthetic route used for the preparation of AHGa probe. 
Targeting of senescent cells in vivo with AHGa was validated with the SK-Mel-
103 (human melanoma) cell line treated with palbociclib (Figure 2). Palbociclib is a 
specific CDK4/6 inhibitor, which has been displayed to induce cell cycle arrest in 
melanoma cells.15 In a common experiment, SK-Mel-103 cells were treated with 5 
µM palbociclib during two weeks in order to induce senescence. After this 
treatment, SK-Mel-103 cells presented a typical larger and flatten phenotype 
associated with senescence (Figure 2b and 2f). Cellular senescence was also 
assessed by SA-β-Gal activity assay16 (Figure 2a and 2e). Then, the cytotoxicity of 
AH and AHGa was evaluated by a luminescence-based cell viability assay. AH and 
AHGa proved to be not toxic for both control and palbociclib-treated SK-Mel-103 
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Figure 1. a) Schematic representation of AHGa activation in senescent cells. b) Emission spectra of 
PBS (pH 4.5)-DMSO (0.01%) solutions of 10-5 M AHGa (blue) and AH (orange) when excited at 405 
nm. 
Both, control and palbociclib-treated SK-Mel-103 cells were seeded in flat-
bottom-clear 96 well plates and incubated with a solution containing AHGa (10 
µM in DMEM, 0.1% DMSO) for 2 h. Cells were then analyzed by two-photon 
confocal microscopy using 750 nm as excitation wavelength. Control SK-Mel-103 
cells in the absence (Figure 2c) or presence (Figure 2d) of AHGa did not exhibit 
any noticeable fluorescence signal. Similarly, in the absence of the probe, 
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In contrast, senescent cells treated with AHGa showed a clear bright emission 
(Figure 2h). Fluorescence is related to the presence of an emission band centered 
at ca. 540 nm, and attributed to the hydrolysis of AHGa into AH that selectively 
occurred in senescent cells. The quantification of the fluorescence associated to 
AH was also determined for each treatment from confocal images (Figure 2i). A 
remarkable fluorescence emission enhancement (ca. 10-fold) for palbociclib-
treated SK-Mel-103 cells in the presence of AHGa when compared with control 
SK-Mel-103 cells was observed. The above results indicate that AHGa was cell 
membrane-permeable and that can be specifically activated in palbociclib-treated 
SK-Mel-103 cells, thereby providing an OFF-ON two-photon readout for the in situ 
quantitative tracking of senescent cells. 
Figure 2. (a,e) Conventional X-Gal chemical assay for SA-β-Gal expression of control (a) and 
palbociclib-treated (senescent) (e) SK-Mel-103 cells. (b,f) Bright channel for control SK-Mel-103 (b) 
and senescent SK-Mel-103 (f) cells. (c,d,g,h) Two-photon images of (c,d) control SK-Mel-103 and (g, 
h) senescent SK-Mel-103 cells in the absence (c,g) and in the presence (d,h) of AHGa probe. Cells
were incubated with AHGa (10 µM) with DMEM (10% FBS, 0.1% DMSO) in 20% O2 and 5% CO2 at 
37°C for 2 h, and then images were acquired by using a femtosecond pulse laser (excitation at 750 
nm) with a Leica TCS SP5 laser scanning confocal. Representative images from repeated experiments 
(n = 3) are shown. (i) Quantification of the fluorescence emission intensity of control and palbociclib-
treated SK-Mel-103 cells incubated with AHGa. Inset: Basal fluorescence is represented in white bars 

























































































Figure 3. (a,b) Tissue portions of SK-Mel-103 control tumors (a) or SK-Mel-103 senescent tumors 
after whole-mount SA-β-Gal staining. (c-f) Confocal images of representative portions of SK-Mel-103 
control tumors (c,d) and SK-Mel-103 senescent tumors (e,f) vehicle (c,e) and after intravenous tail 
injection (d,f) of AHGa probe (10 mg/ml, 200 µl). Mice were sacrificed at 3 h post-treatment. 
Quantification of the fluorescence emission intensity of SK-Mel-103 (control) and SK-Mel-103 
treated with palbociclib (senescent) in the absence or in the presence of the AHGa probe. Inset: 
Basal fluorescence is represented in white bars and AH ascribed fluorescence is represented in red. 
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Once assessed the activation of AHGa in senescent cultured cells, the probe 
was validated by the use of mice bearing tumor xenografts treated with 
senescence-inducing chemotherapy. In a typical experiment, tumor xenografts 
were generated by injecting subcutaneously SK-Mel-103 melanoma cells. Upon 
tumor formation (~200 mm3 average volume), mice were treated daily with 
palbociclib for 10 days in order to induce senescence and arrest tumor growth. 
Finally, AHGa probe was injected intravenously in the tail vein and mice were 
subsequently sacrificed at 3 h after the treatment. Next, tumors were extracted 
and cellular senescence was assessed by a SA-β-Gal staining. Tumors from 
palbociclib-treated mice showed the characteristic blue SA-β-Gal staining 
indicative of high levels of accumulated senescent cells (Figure 3b). The absence 
of the proliferative marker Ki67, and the reduction in phosphorylated Rb in 
tumors were also indicative of senescence.17 Then, fresh tumor sections were 
analyzed using confocal microscopy. The obtained results are shown in Figures 3c-
3f. As observed, control tumors showed negligible fluorescence either in the 
absence or in the presence of AHGa (Figures 3c and 3d). Tumors from mice 
treated with palbociclib in the absence of the probe were used as a control for 
tissue auto-fluorescence, and showed a weak emission (Figure 3e). In sharp 
contrast, isolated tumors from mice treated with palbociclib and intravenously 
injected with AHGa showed a strong fluorescent signal (Figure 3f). Quantification 
of the associated AH fluorescence was determined for each condition (Figure 3g). 
A marked emission enhancement (ca. 15-fold) in tumors treated with palbociclib 
compared to control tumors was observed. 
In addition, ex vivo imaging of fresh sections from different organs showed 
that emission from AH was only observed in senescent tumors, yet no significant 
emission enhancement was observed in other organs (i.e. liver, spleen, kidney, 
lung and heart) at 3 h post-injection (Figure S10). Although the probe was 
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administered by intravenous tail injection, AHGa was able to reach the senescent 
tumor, whereas no signal emission was observed in the rest of organs. These 
results pointed out the ability of AHGa probe to detect senescence in vivo. 
3.4 Conclusions 
Altogether, we describe a two-photon fluorescent probe (AHGa) for the in vivo 
detection of cell senescence. AHGa is based on a naphthalimide core with an L-
histidine methyl ester linked to an acetylated galactose through a hydrolysable N-
glycosidic bond. AHGa was not emissive upon excitation at 405 nm whereas its AH 
derivative showed a clear and intense fluorescence at 540 nm. Targeting of 
senescent cells in vivo with AHGa was validated with the SK-Mel-103 cancer cell 
line treated with palbociclib. A remarkable fluorescence emission enhancement 
(ca. 10-fold) in the presence of AHGa for palbociclib-treated SK-Mel-103 
(senescent) cells was observed when compared with control SK-Mel-103 cells, due 
to the formation of AH that selectively occurs in senescent cells. The ability of 
tracking senescence of probe AHGa was also studied in vivo by employing mice 
bearing subcutaneous tumor xenografts generated with SK-Mel-103 melanoma 
cells and treated with palbociclib. Tumors in palbociclib-untreated mice showed 
negligible fluorescence emission both in the absence or in the presence of AHGa, 
whereas tumors in mice treated with palbociclib and intravenously injected with 
AHGa showed a clear fluorescent signal. A marked emission enhancement (ca. 15-
fold) in tumors treated with palbociclib compared to non-treated tumors was 
observed. AH fluorescence was only found in senescent tumors and no significant 
emission enhancement was detected in other organs including liver, spleen, 
kidney, lung and heart. The combination of selectivity, sensitivity and 
straightforward synthesis make AHGa and efficient OFF-ON two-photon probe for 
the in vivo signaling of senescence. We believe that our study may provide an 
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efficient tool for detection of senescence in realistic in vivo models and inspire the 
design of probes with potential clinical applications.  
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3.7 Supporting Information 
3.7.1 Materials and methods 
All solvents:  dioxane, methanol (MeOH), acetonitrile (ACN), diethylether 
(Et2O), ethyl acetate (AcOEt), dimethylsulphoxide (DMSO) and phosphate-
buffered saline (PBS) were purchased from Scharlab S.L. in anhydrous or analytical 
grade and used without further purification. The chemical reagents: 4-bromo-1,8-
naphtalic anhydride (A), L-histidine methyl ester (H), triethylamine (TEA), 
acetobromo-β-D-galactose (Ga) and potassium carbonate (K2CO3) were purchased 
from Sigma-Aldrich. Palbociclib was purchased from Selleckchem. Dulbecco's 
Modified Eagle Medium (DMEM) and fetal bovine serum (FBS) were purchased 
from Gibco. Flat-bottom-clear 96 well plates were purchased from Greiner Bio-
One. CellTiter-GLO Luminescent Cell Viability Assay was purchased from Promega. 
1H and 13C NMR spectra were recorded on a Bruker FT-NMR Avance 400 
(Ettlingen, Germany) spectrometer at 300K, using TMS as an internal standard. 
High resolution mass spectrometry (HRMS) data were obtained with a TRIPLETOF 
T5600 (ABSciex, USA) spectrometer. Absorption spectra were collected in a JASCO 
V-650 spectrophotometer, and fluorescence spectra measurements were 
performed by a JASCO FP-8500 fluorescence spectrophotometer. Luminescence 
was measured in a VICTOR Multilabel Plate Reader (Pelkin Elmer). Confocal 
fluorescence images were taken on a Leica TCS SP5 laser scanning confocal 
microscope and analysed by using the LAS AF software and the HCS-A. SK-Mel-103 
(human melanoma) cancer cell line was acquired from the American Type Culture 
Collection (ATCC). Athymic nude mice (Hsd:Athymic Nude-Foxn1nu) were 
purchased from Envigo. 
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3.7.2 Synthesis of AH 
A mixture of 4-bromo-1,8-naphtalic anhydride (1.5 g, 5.41 mmol) and L-
histidine methyl ester (3.5 g, 16.24 mmol) was dissolved in anhydrous dioxane 
(150 ml) in a two-neck round bottom flask provided of condenser. Then, the 
system was purged with argon and triethylamine (8 ml) was added. The mixture 
was refluxed under argon for 10 h and stirred at room temperature for 15 h. 
Dioxane was removed under vacuum. The product was precipitated with cool 
water and filtered in vacuum. Since L-histidine was insoluble, the desired solid 
was dissolved in cool methanol, then filtered off to eliminate the unreacted L- 
histidine, then the solvent was eliminated in vacuum. AH was obtained as a yellow 
solid in 85% yield (1.98 g, 4.6 mmol). 1H-NMR (400 MHz, CDCl3):δ (ppm) = 8.59 – 
8.47 (m, 2H), 8.27 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.76 (dd, J = 8.5, 7.3 
Hz, 1H), 7.55 (s, 1H), 6.73 (s, 1H), 5.88 (dd, J = 8.1, 6.1 Hz, 1H), 3.67 (s, 3H), 3.64 – 
3.56 (m, 1H), 3.39 – 3.30 (m, 1H). 13C-NMR (400 MHz, CDCl3) δ (ppm) = 170.43, 
163.24, 163.21, 134.98, 133.82, 132.62, 131.78, 131.28, 130.91, 130.81, 129.23, 
128.25, 122.66, 121.77, 53.31, 52.68, 26.39. HRMS-EI m/z: calcd for 
C19H14BrN3O4+H+: 428.0168; measured: 428.0239. See Figures S1, S2 and S3. 
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Figure S1. 1H-NMR of AH. 
Figure S2. 13C-NMR of AH. 
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Figure S3. HRMS of AH. 
3.7.3 Synthesis of AHGa 
AH (200 mg, 0.46mmol), acetobromo-α-D-galactose (287 mg, 0.70 mmol) 
and K2CO3 (86.15 mg, 0.88 mmol) were mixed in a two-necked round-
bottomed flask and purged with argon. Then 15 ml of anhydrous acetonitrile 
were added and purged again with argon. The mixture was stirred at 70oC for 4 
h under argon atmosphere. Then the solvent was eliminated under vacuum 
and the reaction crude was precipitated with water and filtered off. The 
residue was purified by silica gel column chromatography using diethylether-
ethyl acetate as eluent (100:5 v/v) to obtain the final product AHGa as a light 
yellow solid (234.2 mg, 0.31 mmol). Yield 67%. 1H-NMR (400 MHz, CDCl3) δ 







Hz, 1H), 7.98 (d, J = 9.3 Hz, 1H), 7.77 (dd, J = 7.35, 8.39, 1H), 7.53 (s, 1H), 6.90 
(s, 1H), 6.01 (dd, J = 9.5, 5.1 Hz, 1H), 5.38 (d, J = 3.21 Hz, 1H), 5.25 (t, J = 9.85 
Hz, 1H), 5.05 – 4.95 (m, 2H), 4.09 – 3.95 (m, 3H), 3.67 (s, 3H), 3.61 (dd, J = 15.5, 
5.0 Hz, 1H), 3.42 (dd, J = 15.2, 9.49 Hz, 1H), 2.21 – 1.80 (m, 12H). 13C-NMR (400 
MHz, CDCl3) δ (ppm) = 171.29, 170.55, 170.12, 170.07, 169.85, 163.21, 163.18, 
139.22, 133.67, 132.47, 131.64, 131.29, 130.72, 128.26, 122.87, 121.99, 
113.50, 110.05, 98.13, 72.87, 71.25, 69.58, 65.98, 65.50, 61.55, 60.53, 53.69, 
52.67, 27.81, 21.18, 20.85, 20.82, 20.67. HRMS m/z: calcd for 
C33H32BrN3O13+H+: 758.1119; measured: 758.1191. See Figures S4, S5 and S6. 
Figure S4. 1H-NMR of AHGa. 
B. Lozano-Torres et.al, J.Am. Chem. Soc., 2017, 139, 26 
105 
Figure S5. 13C-NMR of AHGa. 









Table S1. Fluorogenic molecular probes for in vivo and in vivo βgal detection. 
 In vivo In vivo 
Reference Cell line βgal expression In vivo model 
βgal 
expression 
1.Tung et al., Cancer Res.,




9L  xenografts 
LacZ gene 
transfection 
2.Urano et al., J. Am. Chem. 





3.Ho et al., ChemBioChem.,
2007, 8, 560 – 566 
- - - - 
4.Kamiya et al., J. Am.








5.Egawa et al., Chem. 






6.Kamiya et al., J. Am.






7.Oushiki et al., Anal. Chem.,





8.Sakabe et al., J. Am. Chem. 





9.Han et al., Mol. BioSyst.,





10.Lee et al., Anal. Chem.
2014, 86, 10001−10005 
HDFs splitting or H2O2 - - 
11.Peng et al., J. Mater. 






12.Asanuma et al., Nat. 
Commun., 2015, 6, 6463-
6470 









13.Gu et al.,  J. Am. Chem. 
Soc., 2016, 138, 5334-5340 
293T 
LacZ gene 
transfection LoVo xenografts 
Avidin-β-
galactosidase 
OVCAR3 per se 
14.Zhang et al., Chem. 





U-87 MG xenografts pCMV-β-gal 
15.Wang et al., Chem. 
Commun., 2017, 53, 4505-
4508 
OVCAR3 per se - - 
16.Hong et al., Biomaterials, 




HepG2 xenografts pCMV-β-gal 
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3.7.4 Optical studies of AH and AHGa 
3.7.4.1 UV, excitation and fluorescence spectra of AH and AHGa 
PBS-DMSO (99:1 v/v) solutions of AH (pH=7.5) were prepared at 10-5 M and 
UV, excitation and fluorescence spectra were measured. PBS (pH 7.5)-DMSO 
(0.01%) solutions of AH and AHGa showed the typical absorption of the 
naphthalimide chromophore centred, for both compounds, at ca. 350 nm. 
Fluorescence spectra of solutions of AH and AHGa at 350 nm showed, for both 
compounds, the typical broad unstructured naphthalimide emission centred at 
ca. 430 nm. However, excitation spectra of AH and AHGa are different. At this 
respect, excitation spectra of AH showed the presence of a remarkable band 
centred at 405 nm which was absent in AHGa. Using 405 nm as excitation 
wavelength, solutions of AHGa are non-fluorescent whereas AH presented an 
intense fluorescence at 540 nm (Figure S7).  
Figure S7. UV, excitation and emission spectra of AH and probe AHGa (10-5 M) in PBS-DMSO 
(99:1 v/v) solutions at pH 7.5. 
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This could be explained by the assumption of the formation of an excimer. 
When the NH group of the indole heterocycle in the amino acid linker is free 
can stablish a strong hydrogen bond with one of the oxygen atoms of the 
naphthalimide fluorophore. This hydrogen bond confers rigidity and planarity 
to AH and, as a consequence, this compound is highly emissive.17 The presence 
of an acetylated galactose fragment in the final probe disables the formation 
of the hydrogen bond and, as a consequence, AHGa is nearly non-emissive 
(upon excitation at 405 nm).  
3.7.4.2 AH fluorescence changes with pH 
PBS-DMSO (99:1 v/v) solutions of AH at different pH were prepared at 10-5 
M and fluorescence spectra from each solution were measured (λex = 405 nm). 
Note that the emission intensity of AH did not change in the 4-8 pH range 
(Figure S8). 
Figure S8. a) Fluorescence spectra (λex = 405 nm) of AH (10-5 M) in PBS-DMSO (99:1 v/v) at pH 4, 
5, 6. 7 and 8. b) Emission intensity at 540 nm (λex = 405 nm) of AH (10-5 M) PBS-DMSO (99:1 v/v) 
solutions at pH 4, 5, 6, 7 and 8. 
3.8.7.3 AH and AHGa quantum yield measurements 
Quatum yield values were measured respect to fluorescein as standard (Φ = 
0.95) using the equation:      







































































where x and s indicate the unknown and standard solution, respectively, Φ is 
the quantum yield, S is the area under the emission curve, A is the absorbance 
at the excitation wavelength and n is the index of refraction. 
3.7.5 In vitro experiments 
3.7.5.1 Cell lines 
SK-Mel-103 (human melanoma) cancer cells were obtained from ATCC. 
Cells were maintained in DMEM, supplemented with 10% FBS, and incubated 
in 20% O2 and 5% CO2 at 37°C. Cells were routinely tested for mycoplasma 
contamination using the mycoplasma tissue culture NI (MTC-NI) Rapid 
Detection System (Gen-Probe). For senescence induction, cells were 
supplemented for 2 weeks with media containing 5 µM palbociclib. 
3.7.5.2 Cell viability assays 
SK-Mel-103 (human melanoma) cancer cells were used for cell viability 
assays. Cells were maintained in DMEM supplemented with 10% FBS, and 
incubated in 20% O2 and 5% CO2 at 37°C. For senescence induction, cells were 
supplemented with DMEM media containing 5 µM palbociclib for 2 weeks. 
Control and senescent cells were plated in flat-bottom-clear 96 well plates at a 
density of 6,000 and 4,000 cells per well, respectively. The following day, 
media was changed to DMEM supplemented with 0.1% FBS, and cells were 
treated with serial dilutions of AHGa or AH. Viability was assessed 24 h or 48 h 
later with CellTiter-GLO Luminescent Cell Viability Assay. Raw data were 
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obtained by measuring luminescence in a VICTOR Multilabel Plate Reader 
(Pelkin Elmer) (Figure S9). 
Figure S9. Relative in vivo viability of control and senescent SK-MEL-103 cells after incubation 
with AHGa or AH for 24 h or 48 h at different concentrations. Note: both AHGa and AH have 
minimal toxicity and superior biocompatibility toward cultured cells. 
3.7.6 In vivo experiments 
3.7.6.1 Mice 
Mice were maintained at the Spanish National Cancer Research Centre 
(CNIO) under specific pathogen-free conditions in accordance with the 
recommendations of the Federation of European Laboratory Animal Science 
Associations (FELASA). All animal procedures were approved by the CNIO-ISCIII 
Ethics Committee for Research and Animal Welfare (CEIyBA) and conducted in 
accordance with the recommendations of the Federation of European 




































































Concentration (mM) Concentration (mM)
B. Lozano-Torres et.al, J.Am. Chem. Soc., 2017, 139, 26 
111 
3.7.6.2 Xenograft assays 
Tumor xenografts were established by using SK-MEL-103 cells. Cells were 
routinely cultured in DMEM supplemented with 10% FBS and penicillin-
streptomycin. For tumor xenografts, cells were trypsinised, counted with a 
haemocytometer and injected subcutaneously in both dorsolateral flanks of 8- 
to 10-week-old athymic nude female mice at a concentration of 106 cells in a 
volume of 100ml per flank. Tumor volume was measured every two days with a 
calliper and calculated as V= (a x b2) / 2 where a is the longer and b is the 
shorter of two perpendicular diameters. For the induction of senescence, 
palbociclib was administered by daily oral gavage for 10 to 14 days at 100 
mg/kg dissolved in 50 mM sodium lactate. AHGa was then administered by tail 
intravenous injection at a concentration of 10 mg/ml in a volume of 200 µl. 
Mice were sacrificed 3 h later by CO2 exposure in an Euthanasia Chamber, and 
tumor xenografts were immediately removed. Tumor xenografts were 
analyzed immediately after harvesting. AH was detected using an excitation 
wavelength of 405 nm and an emission wavelength of 540 nm. Confocal 
fluorescence images were taken on a Leica TCS SP5 laser scanning confocal 
microscope and analyzed by using the LAS AF software and the HCS-A. 
Experiments were repeated 3-times and the obtained results were nearly 
coincident. 
3.7.6.3 Ex vivo imaging of different sections of fresh organsafter AHGa 
treatment  
For ex vivo imaging, mice were sacrificed by CO2 exposure in an Euthanasia 
Chamber, and organs were analyzed immediately after harvesting. Confocal 
fluorescence images were taken on a Leica TCS SP5 laser scanning confocal 
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microscope by using an excitation wavelength of 405 nm and an emission 
wavelength of 540 nm and analyzed by using the LAS AF software and the HCS-
A (Figure S10). 
Figure S10. Ex vivo imaging of sections of fresh organs of athymic nude mice at 3 h post tail 
intravenous injection of AHGa (10 mg/ml). Organs were analyzed by confocal microscopy 
immediately after removal (AH λex = 405 nm and AH λem = 540 nm). 
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Cellular senescence is a state of stable cell cycle arrest that can negatively 
affect the regenerative capacities of tissues, and can contribute to inflammation 
and to the progression of various ageing-related diseases. Advances in the in vivo 
detection of cellular senescence are still crucial to monitor the action of senolytic 
drugs and also to assess the early onset or accumulation of senescent cells. Here, 
we describe a naphthalimide-styrene-based probe (HeckGal) for the detection of 
cellular senescence both in vivo and in vivo. HeckGal is hydrolyzed by the 
increased lysosomal β-gatactosidase activity of senescent cells, resulting in 
fluorescence emission. The probe was validated in vivo using normal human 
fibroblasts and various cancer cell lines undergoing senescence induced by 
different stress stimuli. Remarkably, HeckGal was also validated in vivo in an 
orthotopic breast cancer mouse model treated with senescence-inducing 
chemotherapy, and in a renal fibrosis mouse model. In all cases, HeckGal allowed 
the unambiguous detection of senescence in vivo as well as in tissues and tumors 
in vivo. This work is expected to provide a potential technology for senescence 
detection in aged or damaged tissues.  
4.2 Introduction 
Cellular senescence is a biological process occurring in response to stress or 
damage and whose main role is to trigger tissue repair and to prevent the 
proliferation of stressed or damaged cells.1 Senescence triggered by excessive 
proliferation is known as “replicative senescence”,2 but senescence can also be 
triggered through diverse procedures such as activation of oncogenes, inhibition 
of tumor suppressor genes, accumulation of DNA damage, presence of reactive 
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oxygen species (ROS), or nucleolar stresses among others. This type of senescence 
is known as stress-induced premature senescence (SIPS).3 Senescence has a 
relevant physiological role during development and promotes tissue regeneration 
in response to circumstantial damage, but the inefficient elimination of senescent 
cells during aging or upon persistent damage can produce inflammation, fibrosis, 
tissue aging, tumorigenesis, and metastasis.1,4–6 
Evidence is accumulating that the selective elimination of senescent cells 
ameliorates a wide variety of aging-associated diseases, reverts long-term 
degenerative processes, and extends both lifespan and healthspan in mice.7,8 
Inspired by these findings, there is a growing interest in developing drugs capable 
to induce apoptosis preferentially in senescent cells. In fact, senotherapies 
(treatments with senolytic or senomorphic drugs) are a new strategy to prevent 
cell-autonomous and non-cell-autonomous effects of senescent cells.9-11 Senolytic 
drugs kill senescent cells preferentially over non-senescent cells; whereas 
senomorphic drugs reduce the secretion of pro-inflammatory and pro-fibrotic 
factors by senescent cells but without killing them.12,13 Such drugs would 
contribute to the therapeutic treatment of senescence-associated diseases and 
may stimulate the long-term idea that rejuvenation might be possible.6 A related 
important issue in the field of senotherapy is the development of new highly 
selective and sensitive tools to detect cellular senescence.14 These probes are 
expected to play an essential role in the detection of senescent cells in aged or 
damaged tissues, help in the discrimination between senolytic (selectively killing 
senescent cells) and senomorphic (selectively suppressing SASP) drugs or monitor 
the action of senotherapeutics in multiple age-related disorders.12,13 
Some of the most important markers of senescent cells are senescence-
associated heterochromatic foci (SAHF),15,16 activation of tumor suppressors and 
cell cycle inhibitors (e.g. p53, p16INK4a and p21),17-20 the overexpression of anti-





loss of important chromatin structural proteins (Lamin B1, HMGB1, and 
HGMB2),23 a senescence-associated secretory phenotype (SASP)24 and the 
presence of high levels of lysosomal β-galactosidase (β-Gal) activity, known as 
senescence-associated β-galactosidase, (SA-βGal).25 Monitoring β-Gal activity 
using chromo-fluorogenic molecular-based probes represents a simple and 
accurate manner to track senescence in most of the cases and several β-Gal 
probes are commercially available. However, most of these probes cannot be 
applied to in vivo models.12,13 For example, fluorescein-di-(β-D-galactopyranoside) 
(FDG) requires the use of chloroquine in order to increase lysosomal pH,26,27 4-
methylumbelliferyl β-D-galactopyranoside (MUG) is not permeable to cells,28 and 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal)29 is toxic and therefore 
cells need to be previously fixed. These drawbacks have boosted the interest in 
developing molecular sensors for the monitoring of β-Gal activity that could work 
on live cells and tissues. More recently, ((E)-2-(2-(6-hydroxy-2,3-dihydro-1H-
xanthen-4-yl)vinyl)-3,3-dimethyl-1-propyl-3H-indol-1-ium), known as Spider-Gal, 
has gained importance as SA-βGal kit detection, especially for flow cytometry 
since the fluorophore is covalently anchored to the cell after hydrolysis. But this 
could be a problem when applying in vivo and cause long-term toxicity.30 Most of 
the described probes are based on classical one-photon fluorophores linked to the 
anomeric carbon of β-galactose. In one-photon probes, the biological target is 
only detected by an intensity-responsive fluorescent signal, which can be 
interfered with the excitation and emission efficiency, probe concentration, and 
surrounding conditions.31,32 As an alternative, the design of molecular probes 
using two-photon fluorophores has attracted great attention in the last years due 
to their improved three-dimensional spatial localization, prolonged observation 
time, increased imaging depth, minimized fluorescence background and light 
scattering, and lower tissue injury.33 Besides, one typical inaccuracy when 
developing SA-β-Gal probes is their validation in biological models not directly 
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related to senescence. In most cases, the method used in previous in vitro studies 
are based on lacZ gene transfection and in vivo using mouse models in which 
tumors are labelled with avidin-β-Gal34,35 or transfected with the pCMV-lacZ 
plasmid,36 that results in high levels of cytosolic β-Gal expression,37-44 which is 
unrelated to the lysosomal human β-Gal, encoded by GLB1 gene, naturally 
overexpressed in senescent cells. As a consequence, there are still a very limited 
number of selective two-photon fluorescent probes for the detection of bona-fide 
cellular senescence in vivo models. Specifically, SG1 was the first two-photon 
ratiometric probe to detect senescent cells in vitro,45 and AHGa was the first two-
photon probe to detect cellular senescence in vivo.46 
Taking into account our interest in the development of fluorogenic sensors,47-51 
we report herein the synthesis and characterization of a new two-photon 
naphthalimide-styrene probe (HeckGal in Figure 1A) for in vivo detection of 
senescence. The HeckGal probe consists of a naphthalimide-styrene fluorophore 
(Heck in Figure 1A) covalently linked to an acetylated β-galactose through the 
anomeric carbon. HeckGal is poorly emissive, whereas a sudden revival of the 
emission is observed in the presence of lysosomal β-Gal activity. The probe is 
tested in vitro in human cancer cell lines, including SK-Mel-103 and A549 cells, a 
breast murine cancer line (4T1), and in a human BJ fibroblast cell line, undergoing 
senescence by different triggers. The probe is also tested in vivo in BALB/cByJ 
female mice bearing 4T1 breast cancer tumors treated with senescence-inducing 
chemotherapy, and in a model of renal fibrosis induced by treatment with folic 





4.3 Experimental section 
4.3.1 Materials. 
All chemical reagents were purchased from Sigma-Aldrich while anhydrous 
solvents and phosphate-buffered saline (PBS, 0.01M) were purchased from 
Sharlab S.L., and used without further purification. Palbociclib was purchased 
from Selleckchem and Dulbecco’s Modified Eagle Medium (DMEM) and fetal 
bovine serum (FBS) were purchased from Gibco. Flat-bottom-clear 96 well plates 
were purchased from Promega. High-resolution mass spectrometry (HRMS) and 
the data was recorded with a TRIPLETOF T5600 (ABSciex, USA) spectrometer. 1H 
and 13C NMR spectra were collected on a Bruker FT-NMR Avance 400 (Ettlingen, 
Germany) spectrometer at 300K, using TMS as an internal standard. HPLC 
measures were obtained by a Walters 1525 binary HPLC pump and spectra were 
recorded by a Walters 2998 photodiode array at 260 nm. Fluorescence spectra 
were recorded by a JASCO FP-8500 fluorescence spectrophotometer, 
Luminescence was collected in a VICTOR Multilabel Plate Reader (Perkin Elmer). 
Confocal fluorescence images were taken on a Leica TCS SP8 AOBS and two-
photon images were acquired by using a multiphoton Olympus FV1000MPE 
confocal microscope. Images were analyzed using the Image J software. SK-Mel-
103 (human melanoma) cancer cell line and 4T1 (breast cancer cells) were 
acquired from the American Type Culture Collection (ATCC). BALB/CBY female 
mice were purchased from Charles River laboratories, France. 
4.3.2 Hydrolysis reaction. 
The hydrolysis reaction of the HeckGal probe by β-Gal enzyme was analyzed by 
fluorescence spectroscopy and by HPLC-UV techniques. For this purpose, 2 µl of 
human β-Gal enzyme was added to PBS (pH 7)-DMSO (0.01%) solutions of 
HeckGal (10-5 M), and the emission spectrum at 552 nm was recorded with time 
(Figure S7a). After 15 min, HeckGal was completely hydrolyzed and the emission 
B. Lozano-Torres et.al, Anal. Chem, 2021, 93, 5, 3052 
Chapter 4 
123 
band of the product closely correlated with the emission intensity of pure Heck 
fluorophore solution. Furthermore, in the same reaction condition HPLC-UV 
studies (Figure S7b) corroborated these results. Time-conversion plots of HeckGal 
and its reaction intermediated (Heck and β-Gal) were determined by analyzing 
reaction aliquots by reversed-phase liquid chromatography using a KromasilC18 
column as the stationary phase, eluting under isocratic conditions 0.8 mL/min 
(87.4:12.5:0.1 vol% H2O/CH3CN/CH3COOH) and using photodiode array detector. 
Retention time (Rt) for Heck was 18.17 min, while Rt for HeckGal was 8.55 min 
and 4.60 min for human β-Gal enzyme. 
4.3.3 Cell lines. 
SK-Mel-103 (human melanoma) cancer cells and 4T1 (mouse breast cancer 
cells) were obtained from ATCC. Cells were maintained in DMEM, supplemented 
with 10% FBS, and incubated in 20% O2 and 5% CO2 at 37°C. Cells were routinely 
tested for mycoplasma contamination using the mycoplasma tissue culture NI 
(MTC-NI) Rapid Detection System (Gen-Probe). For senescence induction, cells 
were supplemented for 2 weeks with media containing 5 µM palbociclib. 
4.3.4 In vitro viability assays. 
SK-Mel-103 (human melanoma) cancer and 4T1 (mouse breast cancer) cells 
were used for cell viability assays. Cells were maintained in DMEM supplemented 
with 10% FBS and incubated in 20% O2 and 5% CO2 at 37°C. For senescence 
induction, cells were supplemented with DMEM media containing 5 µM 
palbociclib for 2 weeks. Control and senescent cells were placed in flat-bottom-
clear 96 well plates at a density of 6,000 and 4,000 cells per well, respectively. The 
following day cells were treated with serial dilutions of HeckGal or Heck. Viability 
was assessed 48 h later with CellTiter-GLO Luminescent Cell Viability Assay. Raw 
data were obtained by measuring luminescence in a VICTOR Multilabel Plate 





4.3.5 Mouse models. 
Balb/cByJ mice were maintained at the Spanish Research Centre Principe 
Felipe (CIPF) in accordance with the recommendations of the Federation of 
European Laboratory Animal Science Associations (FELASA). Breast 4T1 tumors 
were established by using 4T1 cells. Cells were routinely cultured in DMEM 
supplemented with 10% FBS and penicillin-streptomycin. In order to generate 
breast tumors, cells were trypsinised, counted with a LUNA™ Automated Cell 
Counter, and injected subcutaneously in the left breast of 28- to 34-week-old 
BALB/cByJ female mice at a concentration of 0.5 x 106 cells in a volume of 100 µl. 
Tumor volume was measured every two days with a caliper and calculated as V = 
(a x b2)/2 where a is the longer and b is the shorter of two perpendicular 
diameters. Palbociclib or vehicle was administered by daily oral gavage for 7 days 
at 100 mg/kg dissolved in 50 mM sodium lactate, pH 5 in order to induce 
senescence. Then, Heck-Gal was intraperitoneally (i.p.) administered at a 
concentration of 6 mg/ml in DMEM (5% DMSO) in a volume of 200 µl. Mice were 
sacrificed 2 hours later by CO2 exposure in a Euthanasia Chamber, and tumors and 
organs (lung, liver, kidney, or spleen) were immediately removed. Tumors and 
organs were analyzed immediately after harvesting. Heck was detected using an 
excitation wavelength of 500 nm and an emission wavelength of 540 nm. 
Fluorescence images were taken on an IVIS spectrum imaging system and 
analyzed by using the Living Imaging software from Caliper Life Sciences. On the 
other hand, two months-old C57BL/6J male mice were maintained at the Institut 
de Recerca Biomèdica (IRB). All animal procedures were carried out in compliance 
with the regulations of the Animal Care and Use Ethical Committee of the 
Barcelona Science Park (CEEA-PCB) and the Catalan Government under the 
recommendations of the FELASA. In order to generate renal fibrosis, mice were i.p 
injected with a single dose of either 250 mg/kg of folic acid or vehicle. 34 days 
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after treatment, the animals were administered either with a single i.p dose of 
Heck-Gal (13.33 mg/ml 200 µl) in DMSO 1%-Corn oil or with vehicle. Animals were 
euthanized 5 hours later by CO2 exposure in a Euthanasia Chamber and the 
kidneys were excised for observation with an IVIS imager (Perkin Elmer).  
4.3.6 Preparation of mouse tumour slices for imaging experiments. 
Tumours from Balb/cByJ mice ortothopically injected with 4T1 cells treated or 
not treated with palbociclib were excised and cut in half. They were pasted onto a 
petri dish exposing a tumor surface as smooth as possible. The slices were 
incubated with a 10 mM solution of HeckGal for 2 h at 37 °C in a dry incubator, 
and then washed three times with PBS, and observed under two-photon confocal 
microscope (OLYMPUS FV1000MPE). The images were acquired at different 
penetration depths (λex = 820 nm). 
4.4 Results and discussion 
4.4.1 Synthesis, Characterization, Spectroscopic Features, and 
Mechanism. 
HeckGal probe was synthesized following the synthetic procedure shown in 
Figure 1A. Naphthalimide 1 was obtained by the reaction between 4-bromo-1,8-
naphthalic anhydride and methoxylamine in refluxing dioxane. In parallel, the 
hydroxyl group of 4-hydroxybenzaldehyde was protected with t-
butylchlorodiphenylsilane (TBDPSCl) yielding compound 2, in which the aldehyde 
was converted into a double bond using a Wittig reaction resulting in compound 
3. A Heck cross-coupling reaction between 1 and 3 yielded Heck fluorophore.
Finally, Heck was consecutively reacted with NaOH, in order to remove the 
phenolic proton, and with 2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl bromide 
(Gal) yielding the HeckGal probe. The final probe and intermediate compounds 





7)-DMSO (0.01%) solutions of Heck fluorophore (10-5 M) presented an intense 
emission band centered at 550 nm (ΦHeck = 0.875) when excited at 488 nm (Figure 
1B, iii)). In contrast, excitation at 488 nm of PBS (pH 7)-DMSO (0.01%) solutions of 
HeckGal resulted in a weak broad emission (ΦHeckGal = 0.074) (Figure 1B, iii). The 
low emission intensity of HeckGal, when compared to that of Heck, is ascribed to 
a photoinduced electron transfer process from the galactose unit to the excited 
fluorophore. It was also assessed that the emission intensity of Heck remained 
unchanged in the 4-9 pH range (Figure S6). After assessing the photophysical 
properties, time-dependent fluorescent measurements in PBS (pH 7)-DMSO 
(0.01%) solutions of HeckGal in the presence of β-Gal were carried out (Figure S7, 
A). Progressive enhancement of the emission at 550 nm was observed due to the 
generation of free Heck produced by the enzyme-induced hydrolysis of the O-
glycosidic bond in HeckGal. The reaction was also analyzed by HPLC (Figure S7, B) 
which showed the progressive vanishing of the HeckGal peak (at ca. 8.5 min) with 
the subsequent appearance of Heck signal at ca. 8.2 min.  
HeckGal displays several advantages when compared with the recently 
reported AHGa probe. HeckGal presents a more extended conjugated framework 
which is reflected in a marked increase, of almost 100 nm, in the two-photon 
excitation wavelength. This increase in excitation wavelength might allow greater 
tissue penetrability, less photo-toxicity, and reduced light scattering. Moreover, 
the molecule generated after HeckGal hydrolysis with β-Gal enzyme (i.e. the Heck 
fluorophore) shows a remarkable higher quantum yield of 0.875, making the 
HeckGal probe more suitable for the differentiation between senescent from non-
senescent cells with high basal levels of the β-Gal enzyme. Besides, a comparative 
table of HeckGal and other cell senescence probes published in the last three 
years is shown in the Supporting Information (Table S1). 
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Figure 1. Synthesis of probe and mechanism of action in mice. (A) Synthetic route used for the 
preparation of the probe: a) CH3ONH2·3HCl, Et3N, dioxane; b) TBDPSCl, imidazole, DMF; c) n-BuLi, 
Ph3PCH3I, THF; d) Pd(OAc)2, (O-tolyl)3P, Et3N, DMF; e) NaOH/MeOH, acetobromo-α-D-galactose. (B) 
Schematic representation of the application of the probe in two in vivo models of senescence: i) 
kidney fibrotic C57BL/6J male mice induced by treatment with folic acid and ii) BALB/cByJ female 
mice bearing 4T1 breast cancer tumours treated with senescence-inducing chemotherapy. iii) 
Fluorescence emission spectra (λex = 488 nm) of HeckGal (yellow) and Heck fluorophore (orange) in 














































4.4.2 In Vitro Validation of HeckGal probe. 
To study the cellular toxicity after prolonged exposure to the HeckGal probe, 
human melanoma SK-Mel-103 and murine breast cancer 4T1 cells were used in 
cell viability assays and the results showed that after 48 h neither Heck nor 
HeckGal were toxic for SK-Mel-103 or 4T1 cells, in both senescence and non-
senescence states, at concentrations of up to 100 µM (Figure S8). Once proven 
the probe’s biocompatibility, the preferential activation of HeckGal in senescent 
cells in vitro was assessed in senescent SK-Mel-103, 4T1, A549 (human lung 
carcinoma), and BJ (human fibroblast) cell lines. Senescence was induced in SK-
Mel-103 and 4T1 cells by treatment with 5 µM palbociclib, a well-known specific 
CDK4/6 inhibitor,52 for two weeks. After palbociclib treatment, the cell 
morphology changed, presenting an enlarged and flattened appearance typical of 
cellular senescence. Cellular senescence was assessed by SA-β-Gal activity assay 
(Figure 2i (A and H) and 2ii (A and H). Next, control and senescent SK-Mel-103 
cells were seeded in flat-bottom-clear 96 wells plates and incubated with 10, 15, 
and 20 µM solutions of HeckGal in DMEM (0.1% DMSO) for 2 h in the case of one-
photon studies. In the case of two-photon studies, cells were seeded in p6 wells 
plates and incubated with a 10 µM solution of the probe. Cells were imaged by 
confocal microscopy using an excitation wavelength of 488 nm, and by two-
photon confocal microscopy using a 950 nm excitation wavelength. Control 
(Figure 2i (B and F)) and senescent (Figure 2i (I and M)) SK-Mel-103 cells did not 
show significant background signal before incubation with HeckGal, especially in 
two-photon studies (Compare I and M in Figure 2i). Non-senescent SK-Mel-103 
cells showed weak emission in the presence of increasing concentrations (10, 15, 
and 20 µM) of the HeckGal probe (Figure 2i (C, D, E, and G)), while palbociclib-
treated SK-Mel-103 displayed an intense fluorescent signal, increased for higher 
HeckGal concentrations (Figure 2i (J, K, L, and N)). The fluorescent signal in the 
cells is attributed to the hydrolysis of HeckGal into Heck fluorophore that 
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occurred preferably in senescent cells, which present an increased β-galactosidase 
activity. Moreover, the emission spectrum of Heck, obtained after two-photon 
excitation (Figure S9), corresponds to that obtained in a fluorimeter when using 
one-photon 488 nm excitation wavelength (Figure 1B iii). Fluorescence 
quantification from the confocal images associated with each treatment showed a 
fluorescence enhancement (ca. 2.9 fold) in palbociclib-treated SK-Mel-103 
incubated with 15 µM of the probe in one-photon confocal images  (Figure 2iii A) 
and ca. 3.1 fold for cells incubated with 10 µM of the probe in two-photon images 
(Figure 2iii B). Moreover, the ability of HeckGal to detect senescent 4T1 cells was 
also confirmed. Non-treated and palbociclib-treated (senescent) 4T1 cells were 
incubated with 15 µM solutions of HeckGal or Heck in DMEM (0.1% DMSO) for 2 
h. Figure 2ii shows that control 4T1 cells treated with HeckGal (Figure 2ii B)
showed a minimal fluorescence when compared to senescent 4T1 cells (Figure 2ii 
I) in the same conditions (3.6-fold enhancement, Figure 2iii C). This marked
difference was not observed when control and senescent 4T1 cells were treated 
with Heck (Figure 2ii C and J), demonstrating the selectivity of HeckGal to detect 
cellular senescence. The versatility of the HeckGal probe was also validated in 
other cell lines where senescence was induced with different chemotherapy. 
Thus, human lung adenocarcinoma (A549) cells were treated with cisplatin 15 μM 
for 3 weeks. Further incubation with HeckGal resulted in an enhanced 
fluorescence (ca. 6.1 fold, see Figure 2iii D for quantification of images) in 
cisplatin-treated A549 cells when compared with non-treated A549 cells (Figure 
2ii, E and L). Finally, co-staining with typical staining kits did not affect the Heck 
fluorescence signal or hydrolysis of HeckGal (Figure S10). The use of the HeckGal 
probe was also assessed by Fluorescence-Activated Cell Sorting (FACS) (Figure 2iii 
E and F) For these studies, control SK-Mel-103 cells and BJ human fibroblasts were 
exposed to 250 nM doxorubicin for 24 h to induce cellular senescence (red). On 





solutions of HeckGal for 2 h, detached from the plates, and fluorescence was 
subsequently evaluated through FACS. The studies demonstrated that HeckGal 
can distinguish between control and senescent cell populations in doxorubicin-
induced SK-Mel-103 and BJ human fibroblasts.  
Figure 2. The probe enables the detection of senescence in various cell lines regardless of the 
induction method. 
(i) Senescence induction was assessed by SAβ-Gal staining in non-treated (A) and palbociclib-treated 
cells(H). Note that senescent SK-Mel-103 cells present the typical blue staining. Confocal images of 
SK-Mel-103 and SK-Mel-103 treated with palbociclib. One photon confocal images (B-E, I-L) of 
control SK-Mel-103 (B-E) in the absence (B) or presence of 10, 15, and 20 µM of HeckGal probe (C, 
D, E respectively) and SK-Mel-103 treated with palbociclib (I-L) in the absence (I) or presence of 10, 
15 and 20 µM of HeckGal probe (J, K, L respectively). Two-photon microscopy images (F, G, M, N) of 
non-treated (F, G) and (M, N) palbociclib-treated (senescent) SK-Mel-103 cells in the absence (F, M) 
and presence (G, N) of 10 µM of HeckGal probe. Cells were incubated with HeckGal in DMEM (10% 
FBS, 0.1% DMSO) in 20% O2 and 5% CO2 at 37°C for 2 h, and then one photon images were acquired 
by using a confocal microscope (Leica TCS SP8 AOBS) and two-photon images were acquired by 
using a multiphoton confocal microscope (OLYMPUS FV1000MPE). (ii) SAβ-Gal staining of non-
treated (A) and palbociclib-treated 4T1 cells (H). Note that senescent 4T1 cells present the typical 
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probe (A) or 15 µM of Heck (B) and 4T1 treated with palbociclib (I, J) in presence of 15 µM of 
HeckGal probe (I) or 15 µM of Heck (J). SAβ-Gal staining of non-treated (D) and cisplatin-treated 
A549 cells(K). Note that senescent A549 cells present the typical blue staining. Confocal microscopy 
images of non-treated (E-F) and cisplatin-treated A549 cells (L-N), exposed to the HeckGal probe. 
Cells were incubated with HeckGal (15 μM) in DMEM + 10% FBS in 20% O2 and 5% CO2 at 37°C for 2 
h, and images were acquired by using a confocal microscope (excitation at 488 nm). (iii) 
Quantification of the fluorescence emission intensity relative to the cell surface of control and 
palbociclib-treated SK-Mel-103 cells incubated with HeckGal visualized with one photon confocal 
imaging (A) and two-photon confocal imaging (B). Quantification of the fluorescence emission 
intensity relative to the cell surface of control and palbociclib-treated 4T1 cells incubated with 
HeckGal or Heck visualized with one photon confocal imaging (C). Quantification of the fluorescence 
emission intensity relative to the cell surface of control and cisplatin-treated A549 cells incubated 
with HeckGal visualized with one photon confocal imaging (D). Error bars represent SEM (n=3) (E) 
Fluorescence-Activated Cell Sorting (FACS) analysis for control Sk-Mel-103 (grey) human melanoma 
cells and doxorubicin-treated SK-Mel-103 (red) cells after treatment with HeckGal. (F) FACS analysis 
for control BJ (grey) human fibroblast cells and doxorubicin-treated BJ (red) cells after treatment 
with HeckGal. Both cell lines were treated with 250 nM doxorubicin for 24 hours in order to induce 
cellular senescence, or with DMSO as vehicle. 14 days later, upon complete development of the 
senescent phenotype, cells were incubated with 7 µM HeckGal for 2 hours, detached from the 
plates, and washed twice with PBS. HeckGal fluorescence was subsequently evaluated by a Sony 
SA3800 Spectral Analyzer. 
4.4.3 In Vivo Validation of HeckGal probe 
Encouraged by the ability of HeckGal to detect cellular senescence in vitro, we 
took a step forward and studied the potential of the HeckGal probe to detect 
cellular senescence in vivo in two different disease models of senescence: (i) 
BALB/cByJ female mice bearing 4T1 breast cancer tumors treated with palbociclib 
and (ii) C57BL/6J male mice with renal fibrosis induced by treatment with folic 
acid (FA). BALB/cByJ female mice were orthotopically injected in the mammary fat 
pad with 4T1 cells (0.5 x 106 cell/mouse) in order to generate breast tumors. 
Seven days later, palbociclib was administered daily by oral gavage to arrest 
tumor growth and induce cellular senescence. One week after, palbociclib 
treatment was started, 100 µl of HeckGal was injected intraperitoneally (i.p.) at a 
concentration of 13.3 mg/ml, and mice were sacrificed 3 h after treatment. 
Different organs (i.e. lungs, liver, kidney, and spleen) and tumors were harvested. 





staining (Figure 3A). The reduction of Ki67, a proliferative marker, observed by 
immunohistochemistry (IHC) was also indicative of cellular senescence in 
palbociclib-treated tumors (Figure 3B). Figure 3G shows the quantification of the 
Ki67 signal. Ex vivo IVIS images demonstrated that no fluorescent signal was 
observed in control animals, neither in tumors nor in lungs, liver, kidney, or spleen 
(Figure 3C, 3D, 3E and 3F), either in the presnce or absence of HeckGal. Tumors of 
mice treated with palbociclib in the absence of HeckGal were used to monitor 
tissue auto-fluorescence and displayed a weak emission. In contrast tumors from 
mice previously treated with palbociclib and i.p. injected with HeckGal showed a 
strong emission signal in IVIS images (Figure 3F). Quantification of the average 
radiance intensity from organs and tumors was determined for each condition 
(Figure 3H). An emission enhancement of ca. 4.6 fold was observed in tumors 
treated with palbociclib when compared to control tumors. These results 
demonstrate that HeckGal is a potent tool to visualize senescence in a breast 
cancer tumor model treated with senescence-inducing therapy. Moreover, to 
evaluate Heck-Gal penetrability and their ability for two-photon imaging of 
senescent cells in the depth of tissues, fluorescence intensities of tumour slices 
from vehicle, and palbociclib-treated mice at different depths were measured by a 
Z-scan model (Fig. 3I and 3J). As could be seen in Figure 3I and 3J, a marked 
emission intensity was observed for the palbociclib-treated tumours treated with 
HeckGal probe, and senescent cells could be visualized up to a depth of 150 μm. 
These results clearly indicated the ability of HeckGal probe for tracking β-Gal 
activity at different depths using two-photon microscopy. 
To assess the versatility of the probe, HeckGal was also tested to detect 
cellular senescence in a renal fibrosis model. For this purpose, C57BL/6J male 
mice were i.p. injected with a single dose of 250 mg/kg of FA in order to generate 
renal fibrosis. 34 days post-FA injection, the presence of cellular senescence in the 
kidneys was evaluated with p21 IHC immunostaining. An increase in p21 signal 
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was observed in the kidneys of FA treated-mice, confirming cellular senescence 
(Figure 4A). Figure 4C shows the quantification of positive p21 nuclei. Once 
cellular senescence was assessed in this model, 200 µl of HeckGal were i.p. 
injected at a concentration of 6.6 mg/ml (DMSO 1%- Corn oil). 
Mice were euthanized 5 hours post-HeckGal treatment, kidneys were excised and 
analyzed by IVIS imaging. Kidneys from control mice treated with HeckGal 
presented a very weak fluorescent signal (Figure 4B left), whereas kidneys from 
FA-treated mice and injected with HeckGal (Figure 4B middle) exhibited an 
intense emission (5.8-fold higher). FA-treated mice did not present any significant 
auto-fluorescence in the absence of the HeckGal probe (Figure 4B, right). Figure 
4D showed the quantification of average radiance intensity from kidneys showed 




Figure 3. HeckGal probe enables the detection of senescence in different disease models of 
senescence.  
 (A) Representative images of tumours stained for the SA-β-Gal assay. Tumours from vehicle (left) 
and palbociclib-treated mice (right). (B) Immunohistochemical detection of the proliferation marker 
Ki67 in paraffin sections of tumors from vehicle (top) and palbociclib-treated mice (bottom). (C-F) 
IVIS images of organs and tumours from BALB/cByJ female mice bearing 4T1 breast cancer cells. 
From left to right and from top to bottom: lungs, liver, tumour, kidney, and spleen. (C) Vehicle mice. 
(D) Vehicle mice treated with  (13.33 mg/ml 100µl). (E) Mice treated with palbociclib for 1 week. (F) 
Palbociclib-treated mice injected with HeckGal (13.33 mg/ml 100µl). Mice were sacrificed two hours 
post-HeckGal treatment. (G) Quantification of Ki67 signal in paraffin sections of tumours from 
vehicle (top) and palbociclib-treated mice (bottom). Error bars represent s.d. (H) Quantification of 
average radiance intensity from organs and tumours showed in images C,D,E, and F. Error bars 
represent SEM (n=3 for each condition). (I) Two-photon fluorescence depth images of HeckGal in 
tumour tissue slices from vehicle (up) and palbociclib-treated mice (down). The slices were 
incubated with HeckGal (10 mM) for 2 h at 37oC in a dry incubator. The images were acquired at 
different penetration depths (λex = 820 nm). (J) 3D representation of images shown in Figure 3I 
demonstrating the greater penetrability of HeckGal in tumour tissue slices from palbociclib-treated 
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Figure 4. (A) Immunostaining for p21 in kidney slides. (B) IVIS images of kidneys from mice with renal 
fibrosis induced by FA treatment. From left to right: Vehicle mice + HeckGal (6 mg/ml 200 µl); FA-
treated mice (with renal fibrosis) + HeckGal (6.6 mg/ml 200 µl); and FA-treated mice (with renal 
fibrosis. Mice were sacrificed five hours post-HeckGal injection. (C) Quantification of p21 signal in 
paraffin sections of kidney from vehicle and FA-treated mice. Error bars represent SEM. (D) 
Quantification of average radiance intensity from kidneys showed in 3B image. Error bars represent 
SEM (n=3 for control mice treated with probe and FA-treated mice and n=4 for FA-treated 
mice+HeckGal).  
4.5 Conclusions 
In summary, we report herein the synthesis of a new two-photon fluorescent 
probe for the detection of cellular senescence in vivo. HeckGal is based on a 
naphthalimide core linked to an acetylated galactose which quenches the 
emission of Heck fluorophore. HeckGal is hydrolysed into the highly fluorescent 
Heck fluorophore in presence of the β-Gal enzyme. In vitro detection of cellular 


























































BJ cell lines, in which senescence was induced by treatment with different 
therapies. The probe was validated to detect cellular senescence by one-photon 
and by two-photon confocal images and by FACS. The use of HeckGal to detect 
cellular senescence was also validated in vivo in BALB/C mice bearing 4T1 breast 
tumours, where senescence was induced with palbociclib. Ex vivo IVIS images 
showed that fluorescence ascribed to the hydrolyzed HeckGal probe (Heck 
fluorophore) was only observed in senescent tumours, whereas a negligible 
emission was found in other organs. Besides, HeckGal probe was also tested in a 
renal fibrosis model induced with FA. In this model, emission was only observed in 
fibrotic senescent kidneys from FA-treated mice. We hope that the studies 
presented here will help in the field of cellular senescence diagnosis in more 
translatable in vivo models. We also envisage that HeckGal or similar probes can 
be essential tools in the detection of senescent cells in aged or damaged tissues, 
and to assess treatment response of senolytics in aging-related diseases. 
4.6 Associated content 
Supplemental Information includes chemical characterization of the probe and 
reaction intermediates, experimental procedures, studies of the mechanism of 
hydrolysis, studies of fluorescence emission vs. pH, and calculations of quantum 
yields. Toxicity of HeckGal and Heck in SK-Mel-103 and 4T1 cells is also shown in 
the supplementary information, as well as some confocal images of SK-Mel-103 
with different confocal objectives. The immunohistochemical detection of Ki67 is 
provided in the supplemental material.  
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4.10 Supporting information 
4.10.1 Table S1. Recently published fluorogenic molecular probes for cellular 
senescence detection. 
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4.10.2 Synthesis of Heck and HeckGal. 
6-Bromo-2-methoxy-1H-benzo[de]isoquinoléine-1,3(2H)-dione (1): A mixture of 4-
bromo-1,8-naphthalic anhydride (2.7 g, 10 mmol) and methoxylamine 
hydrochloride (1.25 g, 15 mmol) were dissolved in anhydrous dioxane (150 mL). 
Then the system was purged with argon and trimethylamine was added (15 mL), 
maintaining the mixture overnight. The product was precipitated with cool water, 
filtered in vacuum and washed with cold water. The product was obtained as a 
yellow-brown solid 2.97 g. Yield 98%.1H NMR (400 MHz, CDCl3) δ 8.71 (dd, J = 7.3, 
1.1 Hz, 1H), 8.62 (dd, J = 8.5, 1.1 Hz, 1H), 8.46 (d, J = 7.9 Hz, 1H), 8.07 (d, J = 7.9 Hz, 
1H), 7.88 (dd, J = 8.5, 7.3 Hz, 1H), 4.12 (d, J = 4.8 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 160.39 (2C), 134.18 (1C), 132.71 (1C), 131.80 (1C), 131.47 (1C), 131.31 
(2C), 131.03 (1C), 128.41 (1C), 123.40 (1C), 122.51 (1C), 64.51 (1C).  
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4-{[(2-Methyl-2-propanyl)(diphenyl)silyl]oxy}benzaldehyde (2): A mixture of 4-
hydroxybenzaldehyde (3 g, 24.6 mmol) and imidazole (1.68 g, 28.56 mmol) was 
added in a round bottom flask and purged with argon. The mixture was dissolved 
in anhydrous DMF (40 mL) and stirred at room temperature until the complete 
dissolution of the reagents. Then, tert-butylchlorodiphenylsilane was added 
dropwise (5.12 mL, 19.64 mmol) and the reaction was stirred for 4 h at room 
temperature. After complete reaction, the DMF was partially removed under 
vacuum. The reaction mixture was poured into water (50 mL) and the product was 
extracted with petroleum ether (2 x 50 mL). The organic layer was washed with 
brine (3 x 20 mL) and dried over MgSO4. The petroleum ether was removed under 
vacuum and the product was obtained as a white solid, 6.75 g. Yield 76%. 1H NMR 
(400 MHz, CDCl3) δ 9.81 (s, 1H), 7.73 – 7.68 (m, 4H), 7.65 (d, J = 8.7 Hz, 2H), 7.48 – 
7.43 (m, 2H), 7.42 – 7.35 (m, 4H), 6.86 (d, J = 8.6 Hz, 2H), 1.12 (s, 9H). 13C NMR 
(101 MHz, CDCl3) δ 191.00 (1C), 161.35 (1C), 135.53 (6C), 132.09 (1C), 131.84 (4C), 
130.40 (2C), 128.12 (2C), 120.43 (2C), 26.52 (3C), 19.61 (1C).  
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Figure S2. 1H-NMR and 13C-NMR of compound 2. 
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4-{[(2-Methyl-2-propanyl)(diphenyl)silyl]oxy}styrene (3): Ph3PCH3I (6.4 g, 15.8 
mmol) was added in a two-neck round bottom flash and then was purged with 
argon. Afterward, the solid was dissolved in anhydrous THF (40 mL) and a solution 
of n-BuLi was added dropwise (6.0 mL, 2.5 M in hexane, 15.8 mmol) at 0oC. After 
stirring 15 min, a solution of compound 2 (3.67 g, 10.2 mmol) in anhydrous THF 
(20 mL) purged with argon was added dropwise. The mixture was stirred for 5 h 
and quenched with cold brine (50 mL). The product was extracted in diethyl ether 
(3 x 25 mL). The combined organic layers were dried over MgSO4, filtered off and 
concentrated in vacuum. The crude product was purified in a silica flash column 
using diethyl ether as eluent. The product was obtained as a white solid, 3.06 g. 
Yield: 84 %. 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.56 (m, 4H), 7.37 – 7.21 (m, 6H), 
7.08 – 7.01 (m, 2H), 6.67 – 6.59 (m, 1H), 6.48 (dd, J = 17.6, 10.9 Hz, 1H), 5.43 (dd, J 
= 17.6, 1.0 Hz, 1H), 4.96 (dd, J = 10.9, 0.9 Hz, 1H), 1.01 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 155.58 (1C), 136.44 (1C), 135.64 (2C), 133.01 (4C), 130.83 (1C), 130.06 
(4C), 127.93 (2C), 127.30 (2C), 119.86 (2C), 111.71 (1C), 26.66 (3C), 19.61 (1C). 
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Figure S3. 1H-NMR and 13C-NMR of compound 3. 
E-2-(methoxyamine)-6-(4-hydroxystyryl)-1H-benzo[d]isoquinoleine-1,3(2H)-dione  
(Heck): A mixture of compound 2 (1.1 g, 3.1 mmol), 3 (1.1 g, 3.6 mmol), Pd(AcO)2 
(0.035 g, 0.15 mmol) and P(o-tolyl)3 (0.095 g, 0.312 mmol) were added into a two-
neck round bottom flask. The system was purged with argon and the solids were 
dissolved in DMF (10 mL). After complete dissolution of the mixture, 
trimethylamine was added (2.17 g, 21.5 mmol). The mixture was heated at 90oC 
for 24 h. After this time, the reaction was poured into cold water (20 mL) and the 
solid was washed with water and dried under vacuum. The solid was dissolved in 
THF and tetra-n-butylammonium fluoride was added (1.30 g, 5 mmol) to the 
solution. The mixture was stirred overnight at room temperature. The solvent was 
removed under vacuum and a brown solid was obtained. The crude product was 
purified by column chromatography using silica gel (eluent: 
dichloromethane/methanol 50:1) to obtain a red solid, 0.63 g. Yield 62 %. 1H NMR 
(400 MHz, DMSO) δ 9.02 (dd, J = 8.6, 0,8 Hz, 1H), 8,56 (dd, J=7.3, 0.8 Hz, 1H), 8.49 
(d, J = 7.9 Hz, 1H), 8.23 (d, J = 7.9 Hz, 1H), 8.01 (d, J = 16.1 Hz, 1H), 7.91 (dd, J = 
8.6, 7.3 Hz, 1H), 7.71 (d, J = 8.6 Hz, 2H), 7.55 (d, J = 16.0 Hz, 1H), 6.85 (d, J = 8.6 Hz, 
2H), 3.97 (s, 3H). 13C NMR (101 MHz, DMSO) δ 160.23 (1C), 159.99 (1C), 158.49 
(1C), 142.24 (1C), 135.69 (1C), 131.35 (1C), 131.01 (1C), 130.82 (1C), 129.29 (2C), 
129.08 (1C), 127.73 (1C), 127.48 (1C), 126.88 (1C), 122.87 (1C), 122.82 (1C), 
120.34(1C), 119.46 (1C), 115.67 (1C), 63.53 (1C). HRMS: Calculated for 
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Figure S4. 1H-NMR, 13C-NMR and HRMS of Heck fluorophore. 
E-2-(methoxyamine)-6-[4-(acetogalactoxy)styryl)]-1H-benzo[de]isoquinoleine-
1,3(2H)-dione (HeckGal): A round bottom flask was charged with compound Heck 
(0.345 g, 1 mmol) and dissolved in methanol (10 mL). Then, NaOH (120 mg, 3 
mmol) was added. The red color of the mixture changed to dark-red. The mixture 
was stirred for 1 h at room temperature. After complete reaction, the solvent was 
removed under vacuum pressure. Then, in a round bottom flask, acetobromo-α-D-
galactose (822 mg, 2 mmol) and the solid obtained were mixed and the crude was 
purged with argon atmosphere. The mixture was dissolved in anhydrous 
acetonitrile. The reaction was stirred for 4 h at 70oC and then the solvent was 
removed under vacuum pressure. The crude product was purified by column 
chromatography using silica gel (eluent: hexane/ethyl acetate 2:1) to obtain a red-
orange solid 0.405 g. Yield 60 %. 1H NMR (400 MHz, DMSO) δ 9.02 (dd, J = 8.6, 0.8 
Hz, 1H), 8.57 (dd, J = 7.3, 0.8 Hz, 1H), 8.49 (d, J = 8.0 Hz, 1H), 8.23 (d, J = 8.0 Hz, 
1H), 8.01 (d, J = 16.1 Hz, 1H), 7.91 (dd, J = 8.6, 7.3 Hz, 1H), 7.71 (d, J = 8.6 Hz, 2H), 
7.55 (d, J = 16.1 Hz, 1H), 7.17 (d, J = 3.5 Hz, 1H), 6.85 (d, J = 8.6 Hz, 2H), 5.33 (dd, J 
= 1.1, 3.4 Hz, 1H), 5.28 – 5.19 (m, 2H), 4.90 (dd, J = 10.7, 3.5 Hz, 1H), 4.38 (t, J = 5.9 
Hz, 2H), 3.97 (s, 3H), 2.14 – 1.90 (m, 12H). 13C NMR (101 MHz, DMSO) δ 169.86 
(1C), 169.80 (1C), 169.75 (1C), 169.09 (1C), 160.31 (1C), 160.09 (1C), 158.47 (1C), 
142.55 (1C), 131.09 (1C), 129.20 (1C), 128.79 (1C), 128.62 (1C), 127.51 (1C), 
126.54 (1C), 123.42 (1C), 122.95 (1C), 122.57 (1C), 121.76 (1C), 121.26 (1C), 




(1C), 68.06(1C), 67.35 (1C), 64.32 (1C), 63.61 (1C), 61.08 (1C), 20.51 (1C), 20.42 
(1C), 20.35 (1C), 20.29 (1C). HRMS: Calculated for C35H34NO13 (M+H+) 676.2030 
m/z; measured 676.2013 m/z (M+H+). Calculated for (M+K+) 714.1589; measured 
714.1573 m/z (M+K+). 





Figure S5. 1H-NMR, 13C-NMR and HRMS of HeckGal fluorophore.
4.10.3 Heck fluorescence emission not depends on pH 
Figure S6. (A) Fluorescence spectra (λex = 488 nm) of Heck (10-5 M) H2O-DMSO (0.01%) at pH 4, 5, 6. 
7, 8 and 9. (B) Emission intensity at 552 nm (λex = 488 nm) of Heck (10-5 M) H2O-DMSO (0.01%) 
solutions at pH 4, 5, 6, 7, 8 and 9. Error bars represent SD (n=3) 
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4.10.4 Hydrolysis reaction of Heck-Gal into Heck fluorophore 
Figure S7. (A) Time dependence of fluorescence emission of HeckGal (yellow) aqueous solutions (pH 
7)-DMSO (0.01%) in the presence of human β-Gal (λex = 488 nm). The enhancement of emission 
band is ascribed to the conversion of HeckGal into Heck fluorophore (orange). (B) HPLC-UV studies 
of HeckGal aqueous solutions (pH 7)-DMSO (0.01%) hydrolysis in presence of human β-Gal. 
4.10.5 Heck and HeckGal quantum yield measurements 
Quantum yield values were measured with respect to rhodamine 6G as standard 














where x and s indicate the unknown and standard solution, respectively, Φ is the 
quantum yield, S is the area under the emission curve, A is the absorbance at the 
excitation wavelength and n is the index of refraction. 
A









































4.10.6 In vitro viability assays 
Figure S8. Relative in vitro viability in cultured cells. (A) Control (black) and senescent (red) SK-Mel-
103 cells after incubation with Heck for 48 h at different concentrations. (B) Control (black) and 
senescent (red) SK-Mel-103 cells after incubation with HeckGal for 48 h at different concentrations. 
(C) Control (black) and senescent (red) 4T1 cells after incubation with Heck for 48 h at different 
concentrations. (D) Control (black) and senescent (red) 4T1 cells after incubation with HeckGal for 
48 h at different concentrations. Note: both HeckGal and Heck have minimal toxicity and superior 
biocompatibility toward cultured cell line until 25 µM. 
en
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4.10.7 Emission spectrum of Heck after two-photon excitation 
Fluorescence spectrum obtained from bright images of SK-Mel-103 cells treated 
with Palbociclib incubated with 10µM of HeckGal was measured with confocal 
microscope (OLYMPUS FV1000MPE) after two-photon confocal excitation. The 
obtained fluorescence spectrum corresponds to fluorescence spectrum of Heck 
fluorophore obtained in a two-photon fluorescence spectrophotometer.  
Figure S9. Fluorescence spectrum of Heck after confocal two-photon excitation. 



























4.10.8 Co-staining does not affect to Heck signal  
In order to demonstrate that other typical staining kits do not affect to Heck 
fluorescence signal and the hydrolysis of HeckGal, confocal images from co-
stained SK-Mel-103 with HeckGal (10µM) and Wheat Germ Agglutinin (WGA) stain 
(1 µg/ml). 
Figure S10. One photon confocal images of control SK-Mel-103 (A,C) in presence of 10 µM of 
HeckGal probe and Wheat Germ Agglutinin (WGA) stain (1 µg/ml) (Objectives: 20x a, 63x c) and SK-
Mel-103 treated with palbociclib (B,D) in presence of 10 µM of HeckGal probe (Objectives: 20x b, 
63x d).  
A B
C D
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There is a growing need for non-invasive, cheap, and versatile diagnostic methods 
and the development of low-cost point-of-care assays constitutes a potential 
solution. Here, we describe the design of a renal clearable fluorogenic probe 
(Cy7Gal) which produces a fluorogenic signal readable in the urine. The Cy7Gal 
probe is applied to the detection of the burden of senescence in several in vivo 
models. The probe is composed of a dye (Cy7) conjugated with a galactose 
derivative. Upon administration of the probe in vivo, the up-regulated β-
galactosidase enzyme in senescent cells cleaves the O-glycosidic bond in Cy7Gal, 
releasing the highly emissive Cy7 dye that is renally cleared and measured in 
unmodified urine by an IVIS imaging system or by a fluorimeter. A good 
correlation between the burden of senescence and emission in urine is observed. 
Cy7Gal probe is the first example for the fluorogenic in vivo detection of 
senescence in urine and may serve as a basis for the development of generalized 
fluorogenic diagnostic platforms for the easy diagnosis in the urine of different 
diseases as well as for monitoring therapeutic treatments without the use of 
expensive equipment or trained personnel. 
5.2 Introduction 
The design and development of new cost-effective and of easy implementation 
diagnostic tools is an important goal in health.1-4 However, diagnosis of many 
diseases in remote or less developed countries or resource-limited settings is 
difficult as in many cases it is necessary the use of costly imaging techniques, well-
equipped laboratories, and trained personnel.5-7 The design of low-cost easy-to-
use diagnostic systems, able to detect target biomarkers from readily accessible 
bio-fluids, constitutes a potential solution.8 An approach that fulfils these 
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characteristics is the design of probes able to be transformed by the action of 
certain biomarkers in cells and tissues and have a rapid renal clearance thus 
allowing detection in the urine. Based on this concept of renal clearable probes, 
some very few reports describe the use of multiplexed protease-responsive 
nanoparticles that release small reporter probes into the urine in response to 
proteolytic cleavage in disease environments.5,9,10 In such systems, the reporters 
are finally detected in urine by mass spectrometry or immunoassays. This 
approach has also recently been elegantly exploited to detect acute kidney injury 
(AKI) with fluorescent and chemiluminescent derivatives equipped with the (2-
hydroxypropyl)-β-cyclodextrin (HPβCD) moiety that allowed a renal clearance of 
the probes.11,12 A more recent example describes a nanosensor based on ultra-
small renally removable nanoparticles able to recognize deregulated protease in 
cells. In this case, a colorimetric signal is indirectly detected by measuring the 
ability of excreted nanoparticles in urine to oxidize a chromogenic peroxidase 
substrate in the presence of hydrogen peroxide.13 However, some of these 
systems still rely on the use of complex techniques, expensive analytical assays, or 
use nanoparticles which could result in undesired accumulation or side effects.14 
In this scenario, the design of probes able to be transformed by the action of 
certain biomarkers in tissues and have a rapid renal clearance allowing its 
detection is appealing. In this approach, the dye or fluorophore, in an OFF state, is 
for instance hydrolysed in the presence of a certain deregulated enzyme at the 
site of the disease, turning ON the fluorescence of the dye that is renally cleared 
allowing its detection in the urine. The rapid optical readout of diseases through a 
simple urine measurement after injection of the probe in the patient can 
revolutionize the field of biosensors and it represents an attractive new diagnostic 
alternative to other procedures. However, such a simple idea has not been widely 
developed. Exploring this paradigm, and as a proof of concept, we report herein 




cellular senescence in the urine. Cellular senescence is a stress response 
mechanism characterized by cell cycle/proliferation arrest and complex changes 
in morphology, chromatin organization, secretome, and overexpression of 
lysosomal β-galactosidase, also referred to as senescence-associated β-
galactosidase (SA-β-Gal).15-17 Cellular senescence is one hallmark of aging and it 
has been reported that quantification of the global burden of senescence across 
tissues can be informative toward assessing biological aging.18 Moreover, there is 
clear evidence that the accumulation of senescent cells is involved in the 
pathophysiology of many aging related diseases.19-22 However, although the 
quantification of senescence in biopsies from different human tissues is an active 
area of research, there are not simple non-invasive procedures to monitor cellular 
senescence in vivo.15,23 The probe we develop here (Cy7Gal) is used to detect SA-
β-Gal activity in senescent cells. SA-β-Gal hydrolyses in cells the poorly-emissive 
Cy7Gal into the highly fluorescent dye Cy7.24 Moreover, Cy7 is quickly renally 
cleared allowing its detection and measurement in urine (Figure 1b). We validate 
the procedure in vivo by monitoring chemotherapy-induced cellular senescence in 
breast tumour syngeneic model in BALB/cByJ mice and physiological senescence 
in aged mice. 
5.3 Results and discussion 
5.3.1 Synthesis, spectroscopic characterization, and mechanism studies. 
The Cy7Gal probe was prepared following a two-step synthetic procedure shown 
in Figure 1a. First, 2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl bromide was 
reacted with 4-hydroxyisophthalaldehyde in anhydrous acetonitrile yielding 
compound 1. Then, a Knoevenagel condensation between 1 and 2,3,3-trimethyl-1-
(4-sulfobutyl)indolium (2) yielded the Cy7Gal probe. Besides, the Cy7 fluorophore 
was synthesized by protecting the hydroxyl group of 4-hydroxyisophthalaldehyde 
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with t-butyldimethylsilyl chloride followed by a Knoevenagel condensation with 2 
and the subsequent deprotection of the hydroxyl group (Supplementary 
Information, Scheme S1). Cy7Gal and Cy7 were fully characterized by 1H-NMR, 
13C-NMR, and HRMS (see Supplementary Information). PBS (pH 7) solutions of Cy7 
(1.0 x 10-5 M) show an intense broad emission band centered at ca. 660 nm (ΦCy7 
= 0.43) when excited at 580 nm (Figure 1c), whereas as a clear contrast, PBS (pH 
7) solutions of Cy7Gal are poorly fluorescent at the same excitation wavelength
(ΦCy7Gal = 0.0062) (Figure 1c). Besides, the emission intensity of Cy7 fluorophore 
and Cy7Gal remains unchanged in the 5-10 pH range (Supplementary Information, 
Figure S1). The hydrolysis of Cy7Gal in PBS (pH 7) solutions in the presence of the 
β-galactosidase enzyme was studied by HPLC (Supplementary Information, Figure 
S2a). The obtained chromatograms show the progressive disappearance of the 
Cy7Gal peak with the subsequent appearance of Cy7 signal in the presence of the 
enzyme, whereas Cy7Gal remains stable in PBS in the absence of β-galactosidase. 
Moreover, specificity and selectivity of the probe to β-galactosidase was 
demonstrated after incubation of Cy7Gal with different interfering species such as 
cations, anions, small peptides and enzymes (Supplementary Information, Figure 
S2b) for 0.5 h. Of all the species tested, only β-galactosidase induced a marked 
emission enhancement at ca. 660 nm due to the hydrolysis of Cy7Gal which 
generates the Cy7 fluorophore. Besides, a more marked emission enhancement 
was observed when Cy7Gal was incubated in the presence of both esterase and β-
galactosidase enzymes. This greater enhancement, when compared to that 
observed when only β-galactosidase was present, is ascribed to the hydrolysis of 
the acetate moieties in Cy7Gal by esterase and then to the rupture of the O-




Figure 1. Design and synthesis of the diuretic probe, mechanism of action in mice, and optical 
features. (a) Synthetic route used for the preparation of Cy7Gal probe. (b) Schematic representation 
of the application of Cy7Gal in an in vivo model of senescence. Cy7Gal probe is administered to 
mice, hydrolysed into Cy7 fluorophore by SA-β-Gal, and excreted through urine. Fluorescence of 
urine is directly measured in a fluorimeter. (c) Fluorescence emission spectra (λexc = 580 nm) of 
Cy7Gal (left) and Cy7 fluorophore (right) in aqueous solutions at pH 7. 
5.3.2 Cy7Gal monitors senescence induction in mouse mammary tumour 
cells in vitro. 
In order to validate the ability of Cy7Gal to monitor senescence induction in cells, 
we used the 4T1 mouse mammary tumour cell line, which is considered a murine 
model of triple negative-breast cancer cells.25,26 Cells were treated with palbociclib 
(5 µM) for two weeks. Palbociclib is a CDK4/6 inhibitor which has been reported 
to induce cell cycle arrest and senescence in 4T1 cells.27 Cellular senescence 
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induction was corroborated by the increase in SA-β-Gal activity assay using the X-
Gal test (Figure 2a and 2d). Besides, western blot experiments demonstrated the 
overexpression of β-galactosidase in 4T1 senescent cells (Supplementary 
Information, Figure S3a). Treatment with palbociclib was also accompanied by an 
increase in cell size and in the number of intracellular vesicles, in agreement to 
morphological features described for senescent phenotypes.28 Subsequently, 4T1 
control and senescent cells were treated with Cy7Gal (20 µM) and analyzed by 
confocal microscopy 2 h post-treatment. Both control (Figure 2b) and palbociclib 
treated 4T1 cells (Figure 2e) did not exhibit any noticeable fluorescence signal in 
the absence of the probe when excited at 580 nm. Similarly, control non-
senescent 4T1 cells displayed poor fluorescence emission after exposure to 20 µM 
of Cy7Gal (Figure 2c). In contrast, senescent 4T1 cells treated with Cy7Gal showed 
intense red emission (Figure 2f) which is attributed to the hydrolysis of Cy7Gal 
into Cy7 by increased SA-β-Gal activity in senescent cells. Quantification of the 
fluorescence signal associated with Cy7 from confocal images was determined for 
all treatments. A significant increase in the fluorescence signal (ca. 3.2 fold) was 
observed in palbociclib-treated 4T1 cells treated with Cy7Gal when compared 
with control 4T1 cells (Figure 2m). 
To further confirm the β-galactosidase-catalysed cleavage of Cy7Gal, we found 
(Figure 2g-2l) that a marked reduction in the emission intensity (ca. 60%) was 
obtained after pre-incubation of senescent 4T1 cells with D-galactose (a specific 
inhibitor of β-galactosidase, 5 mM) for 0.5 h and then treated with Cy7Gal, when 
compared to senescent cells administered only with the probe. Besides, the 
response of Cy7Gal probe was demonstrated to be dependent on the increased 
lysosomal β-galactosidase activity in senescent cells. For this purpose, two siRNAs 
were used to knock-down the expression of GLB1,19 the gene that encodes 
lysosomal β-galactosidase in 4T1 cells. As shown in the Supplementary 





100µM100µM 20µM 20µM 20µM
g h i
d e f







































































 Figure 2. Cy7Gal monitors senescence induction in breast cancer cells. (a,d) Typical X-Gal assay for 
SA-β-Gal activity in control 4T1 (a) and 4T1 cells treated with palbociclib (d). Senescent 4T1 cells 
present the typical blue staining. (b-f) Confocal images of control 4T1 (b,c) and 4T1 treated with 
palbociclib (e,f) in the absence (b,e) or in presence of 20 µM of Cy7Gal probe (c,f). Cells were seeded 
in a clear flat bottom 96-well plate and after 24 h incubated with Cy7Gal in DMEM (10% FBS, 0.1% 
DMSO) in 20% O2 and 5% CO2 at 37 °C for 2 h; next, cellular nuclei were stained with Hoechst 33342 
and then fluorescence images were acquired by using a confocal microscope (Leica TCS SP8 AOBS). 
Representative images from repeated experiments (n = 3) are shown. (g-l) Confocal images of 
control 4T1 (g-i) and 4T1 cells treated with palbociclib (j-l) in the absence (g,j), in the presence of 20 
µM of Cy7Gal probe (h,k), and pre-treated with D-galactose (a specific inhibitor of β-galactosidase) 
and then with 20 µM of Cy7Gal probe (i,l). Cells were seeded in a clear glass 6-well plate and, after 
24 h, cells were pre-incubated or not with D-galactose for 30 min and treated with Cy7Gal in DMEM 
(10% FBS, 0.1% DMSO) in 20% O2 and 5% CO2 at 37 °C for 2 h, next, cellular nucleus were stained 
with Hoechst 33342, finally confocal images were acquired by using a confocal microscope (Leica 
TCS SP8 AOBS). Representative images from repeated experiments (n = 3) are shown. (m) 
Quantification of the fluorescence emission intensity from (b-f) confocal images. Error bars 
represent SEM. (n) Quantification of the fluorescence emission intensity from (g-l) confocal images. 
Error bars represent SEM. (o) Relative in vitro viability in cultured cells treated with serial 
concentrations of Cy7Gal probe after 48 h. Note that the red dotted box corresponds to 25 µM. 
transcription of GLB1 at 48 h post-transfection and resulted in a significantly 
decreased number of SA-β-Gal-positive cells, when compared to a scrambled 
siRNA. Confocal microscopy images of control and senescent 4T1 treated with 
Cy7Gal showed a marked decrease in the emission in the red channel (ca. 54 %, 
Supplementary Information, Figure S3d) for cells transfected with hs.Ri.GLB1.13.3 
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siRNA, when compared to non-transfected cells or cells transfected with 
scrambled siRNA (Supplementary Information, Figure S3c). Finally, viability assays 
indicated that the probe was innocuous for both normal and senescent cells 
(Figure 2o). Thus, Cy7Gal is an appropriate probe to monitor senescence 
induction in cell cultures. 
5.3.3 Renal clearance of Cy7 fluorophore allows cell senescence burden 
evaluation in vivo in a 4T1 breast cancer model treated with senescence-
inducing chemotherapy 
Once assessed the activation of Cy7Gal in 4T1 senescent cells, the probe was 
validated in a chemotherapy-induced senescence triple-negative breast cancer 
mouse model. For tumour generation, 4T1 cells were injected subcutaneously into 
the left mammary fat pad of young female BALB/cByJ mice. Mice were 
subsequently treated for 7 days with palbociclib at concentrations of 10 mg/Kg, 50 
mg/Kg or 100 mg/Kg by daily oral gavage in order to induce different degrees of 
senescence burden in the tumours. Tumour volume was measured every two days 
with a calliper. Figure 3a shows that tumours from mice treated with 10 mg/Kg of 
palbociclib grew similarly to the untreated ones, while tumours from mice treated 
with 50 and 100 mg/Kg of palbociclib displayed a reduction in their size. 
Immunohistochemical staining of the proliferation biomarker Ki67 in autopsy 
samples revealed that samples from mice treated with 50 or 100 mg/Kg of 
palbociclib exhibited a significantly lower proportion of Ki67 positive nuclei than 
those from untreated mice or mice treated with the lowest palbociclib dose 
(Figures 3b and 3c). Moreover, X-Gal staining in cryosections of mice treated or 
not with palbociclib revealed the specific induction of senescence (SA-β-Gal 
activity) in the tumours but not in organs, such as liver or kidney (Supplementary 
Information, Figure S4). This is indicative of an enhancement in cellular 




In order to test the ability of probe Cy7Gal for cellular senescence detection in 
vivo, BALB/cByJ mice bearing 4T1 tumours and treated with palbociclib at 
different concentrations (i.e. 10 to 50 and 100 mg/Kg) were anesthetized and the 
Cy7Gal probe was intraperitoneally (i.p.) administered (2.5 µmol). Ex vivo studies 
demonstrated that the Cy7Gal probe allows to detect cellular senescence in 
palbociclib treated tumours. In fact, ex vivo IVIS images from mice treated with 
Cy7Gal revealed a strong fluorescence signal in tumours from mice administered 
with 100 mg/Kg of palbociclib, while the fluorescent signal decreases as a function 
of the reduction in palbociclib dose (Figure 3f). In addition, no significant 
fluorescent signal in the liver, lungs, heart, spleen, or kidney from mice injected 
with Cy7Gal was found and no auto-fluorescence was observed for palbociclib 
treated mice at 100 mg/Kg dose in any organ (Figure 3g). 
Interestingly, fluorescence analysis in vivo using an IVIS® spectrum 15 min after 
Cy7Gal administration, clearly showed fluorescence accumulation in the bladder 
suggesting a rapid renal clearance of the Cy7 fluorophore (Supplementary 
Information, Figure S5). Urine was, therefore, collected after mice recovered from 
anesthesia and analyzed by IVIS. The emission in urine was higher in mice treated 
with increasing amounts of palbociclib (Figure 3d). The emission of Cy7 in the 
urine was also measured in a fluorimeter and the amount of the fluorophore 
determined from a calibration curve indicating a correlation between palbociclib 
doses and µmoles of Cy7 in urine (Figure 3e). 
To further study the renal clearance of the Cy7Gal probe, we synthesized and 
characterize (Supplementary Information, Scheme 2) an analogous molecule 
lacking the sulfonic groups (WOS-Cy7Gal) that make the Cy7Gal a more 
hydrophobic dye disfavouring its accumulation in bladder.30
In a comparative experiment Cy7Gal or WOS-Cy7Gal were i.p. administered 
(2.5 µmol) to BALB/cByJ mice bearing 4T1 tumours induced by palbociclib (100 
mg/Kg). Both probes gave a strong positive signal in the tumours and, 
B. Lozano-Torres et.al, Submitted 
Chapter 5 
169 
interestingly, we detected signal accumulated in the bladder, but not the kidney 
of animals injected with the Cy7Gal, but not the WOS-Cy7Gal probe 
(Supplementary Information, Figures S6a and S6b). The concentrations of Cy7 and 
WOS-Cy7 fluorophores were measured in plasma and in the excreted urine. In 
agreement with a renal clearance of the Cy7 fluorophore, we found a detectable 
concentration in the urine (2.34 µmol) while the plasma concentration was 
significantly lower (0.33 µmol) (Supplementary Information, Figure S6c). In 
contrast, concentrations of WOS-Cy7 fluorophore were basically undetectable in 
plasma (0.02 µmol) and urine (0.01 µmol). These results were also corroborated 
by measuring the average radiance intensity of Cy7 and WOS-Cy7 in urine 
(Supplementary Information, Figure S6d) and indicate the crucial role of the 
sulfonic acid moieties in the renal clearance of the Cy7 fluorophore. 
170 
Figure 3.. Renal clearance of Cy7 fluorophore correlates with chemotherapy-induced senescence in 
vivo in a 4T1 breast cancer model. (A) BALB/cByJ female mice carrying orthotopic 4T1 mammary 
tumours were treated daily with different doses of palbociclib (oral gavage, 10, 50 or 100 mg/Kg). 
For each tumour, the relative volume change was calculated as V = (a x b2)/2 where a is the longest 
and b is the shortest of two perpendicular diameters. Values are expressed as mean ± SEM. (B) 
Quantification of immunohistochemical detection of Ki67 in paraffin sections of tumours as a 
measurement of the burden of cellular senescence. The number of Ki67 positive cells decreases as 
the dose of palbociclib increases. (C) Images of immunohistochemical detection of Ki67 in paraffin 
sections of tumours. From left to right and from top to bottom: (i) Control, (ii) palbociclib 10 mg/Kg, 
(iii) palbociclib 50 mg/Kg, (iv) palbociclib 100 mg/Kg. Ki67, which is indicative of proliferation of the 
cells, decreases as a function of the appearance of senescent cells in tumours. (D) Average radiance 
intensity from urine ascribed to the renal clearance of Cy7 fluorophore in mice treated with different 
doses of palbociclib (oral gavage, 10, 50 or 100 mg/Kg) and intraperitoneally administered with 
Cy7Gal (23.3 mg/ml, 100 µl). Values are expressed as mean ± SEM. (E) Amount (µmoles) of Cy7 
excreted through urine in mice treated with different doses of palbociclib (oral gavage, 10, 50 or 100 
mg/Kg). Values are expressed as mean ± SEM. (F) IVIS images of organs (From left to right and from 
up to bottom: liver, lungs, heart, spleen, left kidney right kidney) and tumours from BALB/cByJ 
female mice bearing 4T1 breast cancer cells (i) control,(ii) palbociclib 10 mg/Kg, (iii) palbociclib 50 
mg/Kg, (iv) palbociclib 100 mg/Kg injected with Cy7Gal probe (23.3 mg/ml, 100 µl (2.5 µmol) per 
mouse). Mice were sacrificed 20 min post-treatment. (G) Quantification of average radiance intensity 
from organs and tumours showed in f images. Values are expressed as mean ± SEM. 
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5.3.4 In vivo cell senescence burden evaluation in naturally aged 
BALB/cByJ mice 
Aging is a universal physiological state with a progressive functional decline, which 
is accompanied by the development of age-related diseases.31 Senescence has 
been associated with age-dependent organismal changes, and the progressive 
increase of senescent cells with time is known to contribute to the functional 
impairment of different organs.32 In fact, strong correlations have been reported 
between aging and certain phenotypes such as mitochondria dysfunction,33 
epigenetic changes,34 and an increase in cellular senescence.35 In this scenario, 
tools to measuring easily the pace of aging are of interest.36 Regarding this matter, 
we tested the ability of probe Cy7Gal to evaluate the burden of senescence in 
healthy old and young individuals. For this purpose, 2 and 14 months old 
BALB/cJyB mice were i.p. injected with the Cy7Gal probe. IVIS images of the 
anesthetized mice 15 min post Cy7Gal injection revealed fluorescence 
accumulation in the bladder of 14 months old mice (Supplementary Information, 
Figure S7). Urine collected in an Eppendorf tube after recovery from anesthesia 
was analyzed by IVIS (Figure 4a). A stronger fluorescent signal (ca. 5.4 fold) in 
urine from old mice treated with Cy7Gal was observed when compared with the 
fluorescence in the urine of young mice also administered with the probe. The 
amount in µmol of Cy7 in the urine was also calculated and a significantly large 
amount of Cy7 in urine (8.1 fold) from old animals was found compared with 
young individuals (Figure 4b). Moreover, 2 and 14 months old control mice not 
treated with Cy7Gal showed negligible fluorescence in urine (Figure 4a and 4b). A 
simple mass balance of the amount of Cy7Gal injected and that of Cy7 in urine 
allows calculating that, on average, 49% of injected Cy7Gal was excreted in urine 
as Cy7 in old mice whereas for young mice this was only 6.1% (Figure 4b). These 
differences are in agreement with a larger burden of cellular senescence in old 




Figure 4. In vivo cell senescence burden evaluation by Cy7Gal in naturally aged BALB/cByJ mice. (a) 
Average radiance intensity from urine ascribed to the renal clearance of Cy7 fluorophore in young (2 
months) and aged (14 months) BALB/cByJ mice. Values are expressed as mean ± SEM. (b) Amount 
(µmols) of Cy7 excreted through urine from young (2 months) and aged (14 months) BALB/cByJ 
mice. Values are expressed as mean ± SEM. (c) IVIS images of (i) bladders, (ii) brains and (iii) lungs; 
from left to right in each image 2 months old mice (1st column), 2 months old mice intraperitoneally 
injected with Cy7Gal (23.3 mg/ml, 100 µl) (2nd column), 14 months old mice intraperitoneally 
injected with Cy7Gal (23.3 mg/ml, 100 µl) (3rd column) and 14 months old mice (from left to right) 
(4th column). (d) Average radiance intensity from organs showed in c images. Values are expressed 
as mean ± SEM. 
studied by IVIS imaging (Figure 4c (i), (ii) and (iii) respectively). Control mice not 
treated with Cy7Gal showed negligible fluorescence in these organs at any age. In 
contrast, quantification of the emission intensity in IVIS images revealed an 
increase of 5.2 in the bladder of aged mice. We also observed increases of 2.3 and 
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3-fold for brain and lungs respectively in aged mice when compared to young 
animals (Figure 4d (i), (ii) and (iii) respectively). This observation is in agreement 
with increases in cell senescence incidence in lungs reported with aging.38,39 In the 
brain, SA-β-gal activity is not a specific marker of neuronal senescence, as many  
healthy neurons have large lysosomal compartments with increased levels of β-
galactosidase.40 Interestingly, however, the results suggest the capacity of the 
probe to permeate the blood-brain barrier. 
5.3.5 In vivo senescence burden evaluation in a senescence-accelerated 
mouse model 
In addition to natural aging, we next decided to test the probe in a strain of 
accelerated senescence mice (SAM). Inbreeding of AKR/J mice and selection for 
the early appearance of features such as hair loss, skin coarseness, and short life 
span, led to the isolation of senescence-prone (P) and senescence-resistant (R) 
series of mice which were crossed separately to establish the inbred SAMP and 
SAMR strains. Relative to their genetic background-controls (SAMR1 mice), 
SAMP8 mice exhibit several traits that are known to occur during aging at earlier 
physiological ages and, therefore, constitute a suitable model to test aging 
phenotypes.41 
The SAMP8 model has been widely used in aging research to study immune 
dysfunction,42 osteoporosis43 or brain atrophy.44 Because the phenotypic age-
related differences between SAMP8 and SAMR1 mice begin to be evident after 
approximately 6 months of age,45-47 2 and 14 months old SAMR1 and SAMP8 mice 
were i.p. injected with the Cy7Gal probe. As in the models above, urine was 
collected after mouse recovery from anesthesia and analyzed by IVIS (Figure 5a). 
The amount of Cy7 in the urine was also determined from a calibration curve 
(Figure 5b). Even though urine collection from SAMP8 and SAMR1 was more 




Figure 5. In vivo senescence burden evaluation by Cy7Gal in a senescence-accelerated mice model. 
(a) Average radiance intensity in urine in young (2 months) and aged (14 months) SAMP8 and 
SAMR1 mice treated or not with Cy7Gal. Values are expressed as mean ± SEM. (b) Amount of Cy7 
excreted (expressed in µmols) through urine from young (2 months) and aged (14 months) SAMP8 
and SAMR1 mice treated or not with Cy7Gal. Values are expressed as mean ± SEM. (c) 
Representation of the amount of urine-excreted Cy7 fluorophore in mice with low senescence (LS) 
burden treated with Cy7Gal (  BALB/cJyB female mice carrying orthotopic 4T1 breast tumours, 2 
months old BALB/cJyB mice,  2 months old SAMR1 mice and   2 months old SAMP8 mice) and in 
mice with high senescence (HS) burden treated with Cy7Gal (  BALB/cJyB female mice carrying 
orthotopic 4T1 breast tumours treated with 50 mg/Kg of Palbociclib,  BALB/cJyB female mice 
carrying orthotopic 4T1 breast tumours treated with 100 mg/Kg of Palbociclib,  14 months old 
BALB/cJyB mice,  14 months old SAMR1 mice and   14 months old SAMP8 mice). Values are 
expressed as mean ± SEM. (d) Receiver operating characteristic curve by moles of excreted 
fluorophore discriminated healthy from diseased mice with an area under the curve of 0.95 (N = 3 
independent experiments, n = 3 or 5 mice per group as in Fig. 3, 4 and 5, P < 0.0001 from a random 
classifier shown by the dashed line). 
 lower amount of urine collected, the results still clearly show a stronger 
fluorescent signal in the urine (due to a larger amount of Cy7) in old mice treated 
with the probe when compared with the emission in urine from young mice. Thus, 
14-month-old SAMR1 mice excreted approximately 2.0-fold µmols of Cy7 
fluorophore (after Cy7Gal hydrolysis) compared to young SAMR1 mice, while a 
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3.1-fold Cy7 amount increase in urine is observed for SAMP8 mice aged 14 
months with respect to young animals. Moreover, a larger Cy7 quantity (1.7 fold) 
in urine is found for 14 months old SAMP8 when compared with 14 months old 
SAMR1 mice in agreement with the reported large burden of cell senescence in 
SAMP8 animals. 
5.3.6 Cy7Gal is a sensitive and specific probe for senescence burden 
evaluation regardless of the murine model 
Finally, to determine the accuracy of the Cy7Gal probe as a tool for evaluation of 
senescence we divided mice in those with a low (LS) and high (HS) burden of 
senescence regardless of the murine models used. Mice in the first group include 
2 months old BALB/cJyB, SAMR1 and SAMP8 mice, and BALB/cByJ mice bearing 
4T1 tumours (not treated with palbociclib), whereas the second group includes 14 
months old BALB/cJyB, SAMR1 and SAMP8 mice, and BALB/cByJ mice bearing 4T1 
tumours treated with 50 and 100 mg/Kg of palbociclib (Figure 5c). The plot 
revealed a mean urinary signal increase of ca. 4.8 fold in the HS group relative to 
LS mice. Besides the rate of true positives and false positives (one-specificity) by 
receiver operating characteristic (ROC) curve shows that the probe discriminated 
well HS and LS groups with an area under the curve of 0.95 (Figure 5d, P < 
0.0001). 
5.4 Conclusions 
Precision medicine aims to guide health care decisions toward the most effective 
treatment for a certain patient to improve care quality.48 Regarding this, the 
development of new cost-effective and easy implementation diagnostic tools is an 
important goal.49 One attractive approach in this area is to detect biomarkers 
from readily accessible biofluids using detection systems as simple as possible that 




can detect the activity of a certain enzyme in vivo with a simple readout can be of 
importance for the diagnosis of certain diseases.53 An approach that fulfills these 
characteristics is the design of fluorogenic probes (in an OFF state) able to be 
transformed by the action of certain biomarkers (i.e an overexpressed enzyme) in 
cells and tissues to give a final product (in an ON highly emissive state) that has a 
rapid renal clearance thus allowing its ready detection in the urine using a simple 
fluorimeter. As an example towards the development of renal clearable 
fluorogenic probes we report herein the case of detection of cellular senescence, 
based on the detection of overexpression of lysosomal β-galactosidase, using the 
fluorogenic probe Cy7Gal. This enzyme hydrolyses in vivo the poorly-emissive 
Cy7Gal into the highly fluorescent dye Cy7, which is renally cleared and detected 
in urine. We provide evidence of the ability of the probe to monitor the burden of 
cellular senescence in vivo BALB/cByJ mice bearing breast cancer tumour treated 
with senescence-inducing chemotherapy and in aged mice models. Cy7Gal probe 
is the first diagnostic tool for the in vivo detection of senescence in the urine. Our 
findings demonstrate that renal clearable fluorogenic probes are a versatile 
modular tool that opens new opportunities to develop simple diagnoses in urine 
for a variety of diseases where the abnormal enzymatic activity is a biomarker. We 
anticipate that this technology can also be applied in the monitoring of 
therapeutic treatments. Such adaptive detection platform could be applicable in 
low-resource environments and might democratize access to advanced and 
sensitive diagnoses. 
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5.10 Supporting information 
5.10.1 Materials. 5-Formylsalicylaldehyde was purchased from Tokyo Chemical 
Industry Co., Ltd. (TCI) while α-acetobromogalactose, potassium carbonate and 1-
(4-sulfobutyl)-2,3,3-trimethylindolium) inert salt, sodium acetate and acetic 
anhydride were obtained from Sigma-Aldrich and used without further 
purification. Anhydrous acetonitrile was purchased from Acros Organics. 
5.10.2 Synthesis and characterization of Cy7Gal. 5-formylsalicylaldehyde (75 
mg, 0.5 mmol), α-acetobromogalactose (607 mg, 1.5 mmol) and potassium 
carbonate (400 mg, 4 mmol) were mixed in a round bottom flask under argon 
atmosphere and dissolved in 30 mL of anhydrous acetonitrile. The reaction 
mixture was heated to 70oC, and stirred for 4 hours under argon atmosphere and 
the solvent was removed under vacuum. The residue was purified by column 
chromatography on silica gel (hexane-ethyl acetate 2:1 v/v as eluent) to obtain 
product 1 as pale green oil (230 mg, 0.46 mmol, 92.6% yield). Then, compound 1 
(90 mg, 0.17 mmol), 1-(4-sulfobutyl)-2,3,3-trimethylindolium inner salt (2) (100 
mg, 0.35 mmol) and sodium acetate (47.80 mg, 0.35 mmol) were dissolved in 2 
mL of acetic anhydride in a Schlenk flask under an argon atmosphere. The 
reaction mixture was heated to 70 oC and stirred for 4 hours under argon 
atmosphere and solvent was eliminated under vacuum. The crude was purified by 
reverse phase column chromatography (dicholoromethane-methanol 10:1 v/v as 
eluent) to obtain Cy7Gal as a red-brown solid. (120 mg, 0.116 mmol, 68.1% yield).  
1H NMR (400 MHz, CDCl3) δ = 7,72 – 7,62 (m, 1H), 7,53 (dd, J = 7,5; 1,6 Hz, 1H), 
7,49 – 7,43 (m, 2H), 7,42 – 7,32 (m, 2H), 7,00 (d, J = 7,3 Hz, 2H), 6,79 (t, J = 7,2 Hz, 
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1H), 6,69 (t, J = 7,3 Hz, 1H), 6,37 (d, J = 1,7 Hz, 1H), 5,69 (d, J = 8,3 Hz, 1H), 5,49 (d, 
J = 1,3 Hz, 1H), 5,42 (dd, J = 3,4; 0,9 Hz, 1H), 5,34 – 5,32 (m, 2H), 5,24 (s, 1H), 5,07 
(dd, J = 10,4; 3,4 Hz, 1H), 4,17 – 4,04 (m, 4H), 3,48 (s, 4H), 2,91 (s, 4H), 2,03 (s, 
12H), 1,93 (s, 4H), 1,82 (s, 4H), 1,58 (s, 12H) ppm. 
13C NMR (400 MHz, CDCl3) δ = 193.63 (2C), 170.52 (1C), 170.28 (1C), 170.15 (1C), 
169.80 (1C), 169.07 (1C), 144.10 (1C), 143.12 (1C), 140.70 (2C), 140.11 (2C), 
139.11 (1C), 130.30 (1C), 130.21 (1C), 129.96 (1C), 129.88 (1C), 127.64 (1C), 
124.61 (1C), 124.50 (1C), 121.86 (1C), 121.61 (1C), 115.77 (1C), 114.70 (1C), 
114.19 (1C), 112.51 (1C), 108.17 (1C), 92.29 (1C), 70.97 (1C), 68.89 (1C), 67.55 
(1C), 66.57 (1C), 61.15 (1C), 53.56 (2C), 52.87 (2C), 48.15 (2C), 32.27 (1C), 31.56 
(1C), 29.82 (4C), 23.34 (2C), 21.02 (1C), 20.94 (1C), 20.78 (1C), 20.67 (1C) ppm. 
HRMS: Calculated for C52H63N2O16S2 (M+H+) 1035.3619 m/z; measured 1035.3606 
m/z (M+H+), 1051.3546 (M+H2O-2H+). 
5.10.3 Synthesis and characterization of Cy7. 4-hydroxyisophthalaldehyde 
(1.5 g, 9.9 mmol) and imidazole (1.7 g, 25 mmol) were dissolved in 100 mL of 
anhydrous dichloromethane. Tert-butyldimethylsilyl chloride (1.8 g, 12 mmol) was 
then added dropwise to the solution. The reaction was stirred at room 
temperature overnight. Afterwards, the mixture was washed with brine (2x100 
mL) and the organic phase was dried with MgSO4. The solvent was removed under 
vacuum and the crude was purified by silica column using a mixture hexane:ethyl 
acetate (10:1) as eluent. Product 3 (2.48 g, 9.39 mmol, 94.8% yield) was obtained 
as colorless oil. Subsequently, 3 (79.24 mg, 0.3 mmol) was added in a Schlenk tube 
with sodium acetate (83.9 mg, 1.02 mmol) and 2,3,3-trimethyl-1-(4-sulfobutyl)-
indolium. The mixture was dissolved in acetic anhydride under argon atmosphere. 




under vacuum and treated with dichloromethame and the solvent was eliminated 
again under vacuum. Finally, deprotection of hydroxyl group was assessed by 
stirring the obtained product in a solution of KF·2H2O (47 mg, 0.5 mmol) in 
acetonitrile (2 mL) for 2 h at room temperature. Then, the mixture was treated 
with saturated NaHCO3 water solution (1 mL) and extracted with CH2Cl2 (3x20 mL). 
The organic layer was washed with brine and dried with MgSO4. The crude was 
purified by reverse phase column chromatography (dicholoromethane-methanol 
8:1 v/v as eluent). Cy7 was obtained as brown-green solid (85 mg, 0.120 mmol, 40 
% yield). 
1H NMR (400 MHz, CDCl3) δ = 7.60 – 7.45 (m, 4H), 7.35 (d, J = 2.5 Hz, 2H), 7.28 (d, J 
= 2.0 Hz, 1H), 7.15 – 6.96 (m, 3H), 6.84 – 6.69 (m, 1H), 5.81 (ddt, J = 16.9, 10.2, 6.7 
Hz, 1H), 5.37 (dt, J = 9.1, 4.1 Hz, 1H), 5.02 – 4.90 (m, 2H), 2.04 (dd, J = 14.9, 7.3 Hz, 
4H), 1.77 (d, J = 4.7 Hz, 4H), 1.67 (dt, J = 15.4, 7.6 Hz, 4H), 1.45 (dd, J = 14.8, 7.5 
Hz, 4H), 1.37 (s, 12H) ppm. 
13C NMR (101 MHz, CDCl3) δ = 174.97 (2C), 160.73 (1C), 154.00 (1C), 149.87 (1C), 
140.72 (2C), 140.08 (2C), 130.71(1C), 130.12 (1C), 128.89 (1C), 128.44 (2C), 125.20 
(2C), 124.39 (1C), 123.17 (2C), 117.05 (1C), 114.61 (2C), 109.08 (1C), 107.48 (1C), 
53.97 (2C), 48.90 (2C), 42.15 (2C), 28.67 (2C), 26.23 (2C), 19.29 (2C) ppm. 
HRMS Calculated for C38H44N2O7S2 (M+H+) 705,269 m/z; measured 705,2673 m/z 
(M+H+). 
Scheme S1. Synthetic route of fluorophore Cy7. 
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5.10.4 Synthesis and characterization of WOS-Cy7Gal. Product 1 (90 mg, 
0.17 mmol) 1-butyl-2,3,3-trimethyl-3H-indol-1-ium iodide (120 mg, 0.35 mmol) 
and sodium acetate (47.80 mg, 0.35 mmol) were mixed in a Schlenk flask under 
argon atmosphere and dissolved in 2 mL of acetic anhydride. The reaction mixture 
was heated to 70 oC and stirred under argon atmosphere. After 4 hours, the 
solvent was removed under vacuum and the crude product was purified in a silica 
flash column using diethyl ether as eluent. WOS-Cy7Gal was obtained as red-
brown oil (50 mg, 0.05 mmol, 33% yield). 
1H NMR (400 MHz, CDCl3) δ = 7.60 – 7.51 (m, 2H), 7.20 – 7.14 (m, 4H), 7.08 (dd, J = 
21.5, 6.2 Hz, 2H), 6.97 (t, J = 7.4 Hz, 2H), 6.71 (d, J = 7.7 Hz, 2H), 6.38 (bs, 1H), 5.70 
(d, J = 8.3 Hz, 1H), 5.50 (d, J = 1.3 Hz, 1H), 5.43 (d, J = 2.5 Hz, 1H), 5.08 (dd, J = 
10.4, 3.4 Hz, 1H), 4.34 (t, J = 6.4 Hz, 1H), 4.14 (t, J = 6.6 Hz, 2H), 4.10 (dd, J = 6.7, 
4.0 Hz, 1H), 4.08 – 4.03 (m, 1H), 3.61 (t, J = 7.6 Hz, 4H), 2.04 (s, 3H), 2.02 (s, 3H), 
2.01 (s, 3H), 2.00 (s, 3H), 1.72 (s, 12H), 1.66 (dd, J = 13.9, 6.1 Hz, 4H), 1.62 – 1.55 
(m, 4H), 0.99 (t, J = 7.3 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ = 193.44 (2C), 170.49 (1C), 170.26 (1C), 170.00 (1C), 
169.50 (1C), 169.05 (1C), 147.19 (1C), 143.36 (1C), 142.18 (1C), 140.38 (1C), 
139.41 (1C), 136.17 (1C), 135.60 (1C), 127.66 (1C), 127.46 (1C), 124.58 (1C), 
124.10 (1C), 122.50 (1C), 122.29 (1C), 122.01 (1C), 121.95 (1C), 119.23 (1C), 
119.21 (1C), 114.19 (1C), 108.44 (1C), 107.75 (2C), 93.69 (1C), 71.83 (1C), 68.89 
(1C), 67.94 (1C), 67.54 (1C), 61.37 (1C), 48.31 (2C), 42.61 (2C), 31.56 (1C), 30.31 
(1C), 29.82 (4C), 24.58 (1C), 22.81 (1C), 21.01 (1C), 20.93 (1C), 20.77 (1C), 20.73 




HRMS Calculated for C52H64N2O10 (M +H+) 876.459 m/z; measured 876.7992 m/z 
(M +H+). 
Scheme S2. Synthetic route of probe WOS-Cy7Gal. 
5.10.5 Characterization. All obtained products were characterized by 1H and 13C 
NMR spectra on a Bruker FT-NMR Avance 400 (Ettlingen, Germany) spectrometer 
at 300 K, using TMS as internal standard and by high resolution mass 
spectrometry (HRMS) with a TRIPLETOF T5600 (ABSciex, USA) spectrometer. 
Fluorescence was characterized in a JASCO FP-8500 fluorescence 
spectrophotometer. 
5.10.6 Hydrolysis of Cy7Gal by human-βGal. 2 µl of human β-Gal enzyme 
(Biotechne) were added to PBS (pH 7) solutions of Cy7Gal (10-5 M). 
Chromatograms of Cy7Gal, Cy7 and Cy7Gal+β-Gal after 30 min were obtained by 
reversed-phase liquid chromatography using a KromasilC18 column as the 
stationary phase, a mixture water-acetonitrile under gradient conditions (flow: 0.8 
mL/min, initial condition 90:10 vol. %, final condition 10:90 vol. %) as mobile 
phase and a photodiode array detector. 
5.10.7 Interferents. To study the specificity and selectivity of the probe to β-
galactosidase, fluorescence intensity of solutions of Cy7Gal (20 µM, PBS, pH 7.4) 
was measured in the presence of cations (150 µM), anions (150 µM), small 
peptides (150 µM), proteins (150 µg/mL) and enzymes (150 µg/mL) (Figure S2b) at 
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37 °C after 30 min in a JASCO FP-8500 fluorescence spectrophotometer (λex = 580 
nm; λem = 665 nm). 
5.10.8 Cell culture. The 4T1 mouse mammary tumour cell line was obtained 
from the American Type Culture Collection (ATCC), cultured in DMEM 
supplemented with 10% FBS (Sigma) and maintained in 20% O2 and 5% CO2 at 37 
°C. Cells were routinely tested for Mycoplasma using the universal mycoplasma 
detection kit (ATCC). For senescence induction, 4T1 cells were treated with 5 µM 
palbociclib (Eurodiagnostico) for 14 days. Cellular senescence was assessed by 
senescence β-galactosidase KIT acquired from Cell Signaling. 
5.10.9 Confocal in vitro experiments. 4T1 control and senescent cells were 
seeded in a clear flat bottom 96-well plate at a density of 3,000 and 4,000 cells 
per well respectively. After 24 h cells were treated with Cy7Gal (20 µM) and 
confocal images were acquired 2 h post-treatment in a Leica TCS SP8 AOBS 
confocal microscope (λexc= 552 nm; λem= 574-765 nm). Images were analyzed by 
using the Image J software. 
5.10.10 Competition experiments with D-Galactose. A total of 200,000 
control or 500,000 senescent 4T1 cells were seeded per well in a clear glass 6-well 
plate. The following day, cells were pre-incubated or not with D-galactose (5 mM) 
for 30 min and then treated with Cy7Gal (20 µM) in DMEM (10% FBS, 0.1% DMSO) 
in 20% O2 and 5% CO2 at 37 °C for 2 h. Finally, confocal images were acquired by 
using a confocal microscope (Leica TCS SP8 AOBS) (λexc= 552 nm; λem= 574-765 




5.10.11 Downregulation experiments. . For transient downregulation of GLB1, 
a total of 20,000 control or 50,000 senescent 4T1 cells were seeded per well in a 
24-well plate. After 24 h, cells were transfected with TriFECTa® Kit DsiRNA Duplex 
siRNAs (Integrated DNA Technologies) hs.Ri.GLB1.13.3 or scrambled siRNA, using 
lipofectamine RNAiMAX reagent (Thermo Fisher Scientific) as per manufacturer's 
instructions. 48 h after transfection, cells were washed once with PBS and fixed 
for 10 min with SA-β-Gal staining kit fixative. Then, cells were stained overnight 
using the SA-β-Gal staining kit (Cell Signaling) following manufacturer’s 
instructions. The following day, cells were thoroughly washed with PBS and 
imaged using a colored bright field microscope. On the other hand, 48 h after 
transfection, cells were treated with Cy7Gal solutions (20 µM) and imaged in a 
Leica TCS SP8 AOBS confocal microscope (λexc= 552 nm; λem= 574-765 nm). Images 
were analyzed by using the Image J software. 
5.10.12 Western blot analysis of β-galactosidase expression. To determine 
the levels of β-galactosidase protein in 4T1 cells (control and senescent), whole-
cell extracts were obtained by using lysis buffer (25 mM Tris-HCl pH 7.4, 1 mM 
EDTA, 1% SDS, plus protease and phosphatase inhibitors). Cell lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, blocked with 5% 
nonfat milk and incubated overnight with the primary antibody for β-
galactosidase detection (β-galactosidase (E2U2I) rabbit mAb #27198 from Cell 
Signaling). Besides, GAPDH (#14C10 from Cell Signaling) was used as reference. 
Then, membranes were washed and probed with the secondary antibody 
conjugated to horseradish peroxidase, anti-rabbit IgG peroxidase antibody 
(#A6154, Sigma) for enhanced chemiluminescence detection (Amersham 
Pharmacia Biotech). 
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5.10.13 In vitro cytotoxicity studies. For the in vitro cytotoxicity studies, 4T1 
cells were plated in a 96-well plate (6,000 control and 4,000 senescent cells per 
well) and allowed to adhere to the wells. At 24 h post-seeding, the cells were 
incubated with varying concentrations of the Cy7Gal probe (diluted in DMEM) for 
24 h. The cell viability was evaluated using the cellTiter-Glo® Luminnescent Cells 
assay (Promega). Luminescence was collected in a VICTOR Multilabel Plate Reader 
(Pelkin Elmer). 
5.10.14 Animals. BALB/cByJ mice were acquired from Charles River laboratories, 
France, and maintained at the Spanish Centro de Investigación Príncipe Felipe 
(CIPF). SAMR1 and SAMP8 mice were housed and bred at the Universitat de 
València (UV). All animal procedures were approved by the CIPF and UV Ethics 
Committees for Research and Animal Welfare (CEBA) and conducted in 
accordance with the recommendations of the Federation of European Laboratory 
Animal Science Associations (FELASA). 
5.10.15 In vivo 4T1 breast cancer model treated with senescence-inducing 
chemotherapy. Breast 4T1 tumours were established by using 4T1 cells in 
Balb/cByJ mice. Cells were routinely cultured in DMEM supplemented with 10% 
FBS and penicillin-streptomycin. In order to generate mammary tumours, cells 
were trypsinised, counted with a LUNA™ Automated Cell Counter and 0.5 x 106 
cells in a volume of 100 µl were injected subcutaneously in the left mammary fat 
pad of 28- to 34-week-old Balb/cByJ female mice. Palbociclib dissolved in 50 mM 
sodium lactate, pH 4, at different doses was administered by daily oral gavage for 
7 days. Tumour volume was measured every two days with a caliper and was 
calculated as V = (a x b2)/2 where a is the longest and b is the shortest of two 
perpendicular diameters. 
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5.10.16 Renal clearance of Cy7Gal. Mice were anesthetized intraperitoneally 
(i.p.) injected with Cy7Gal at a concentration of 23.3 mg/ml (100 µl, 2.5 µmol per 
mice) and maintained in an IVIS spectrum (Perkin Elmer) for 15 min tacking 
photographs every 2 minutes (λexc= 535 nm; λem= 640 nm; Time exposure: 10 s). 
Urine was collected after mice recovered from anesthesia in an Eppendorf tube 
and analyzed directly by IVIS (λexc= 535 nm; λem= 640 nm; Time exposure: 1s). 
Radiance quantification of images was performed using the software of live image 
from Caliper Life Sciences. Besides, fluorescence of urine from all mice was 
analyzed with a fluorescence spectrophotometer (JASCO FP-8500). For this 
purpose, 5 µl of urine was diluted in 95 µl of distilled water and fluorescence 
spectra was recorded at λem= 560 nm (λexc= 535 nm). The amount of Cy7 
fluorophore excreted in urine was calculated through a calibration curve. For the 
calibration curve, a stock solution of Cy7 in blank urine from mouse was prepared. 
Serial dilutions were prepared in the same urine and 5 µl of each Cy7 urine 
solution was added to 95 µl of distilled water and measured in the fluorimeter 
under the same condition.  
5.10.17 Experiments with WOS-Cy7Gal. To demonstrate that sulfonic groups 
are responsible of the renal clearance of Cy7, a similar molecule to Cy7Gal 
without sulfonic acid moieties (WOS-Cy7Gal) was i.p. injected in chemotherapy-
induced 4T1 breast cancer BALB/cByJ mice at the same dose expressed in moles 
(2.5 µmol per mice, 19.7 mg/ml, 100 µl). Urine was collected following the same 
protocol as above and compared with urine from mice injected with Cy7Gal probe 
(λexc= 535 nm; λem= 640 nm; Time exposure: 1 s). Furthermore, in order to assess 
the biodistribution of the fluorophores from the Cy7Gal and WOS-Cy7Gal probes, 
fluorescence was measured in both urine and plasma. Plasma samples were 
obtained 10 minutes after the probe or vehicle injection by submandibular 
puncture of mice with a 25G needle. Blood was collected in heparinised tubes 
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and, subsequently, these samples were centrifuged at 350 g for 4 minutes and the 
supernatant (plasma) was collected. 10 µl of each plasma sample was diluted in 
90 µl of distilled water and fluorescence reading was performed in a fluorimeter 
(λexc= 535 nm; λem= 566 nm). For the calibration curve, a stock solution of Cy7 in 
blank plasma from mouse was prepared. Serial dilutions were prepared in the 
same plasma and 10 µl of each Cy7 urine solution was added to 90 µl of distilled 
water and measured in the fluorimeter under the same condition. 
5.10.18 Ex vivo IVIS studies. Mice were immediately sacrificed after collecting 
the urine by CO2 exposure in a euthanasia chamber, and tumours and organs 
(lungs, liver, kidney, spleen, brain or bladder) were immediately harvested and 
freshly analyzed by IVIS. Cy7 fluorophore was detected using an excitation 
wavelength of 535 nm and an emission wavelength of 640 nm, time exposure 1 s. 
Fluorescence Images were taken on an IVIS spectrum imaging system and 
analyzed and quantified by using the Living Imaging software from Caliper Life 
Sciences.  
5.10.19 Ki67 inmunohistochemistry. Tumours were fixed with 4% 
paraformaldehyde (PFA) in PBS for 4 h, embedded in paraffin, sectioned at 5 μm 
and mounted onto pre-coated slides. Sections were dewaxed, incubated with the 
primary antibody Ki67 (Cell Signaling, at 1:800) and then with the corresponding 
peroxidase-conjugated secondary antibody in an automated immunostaining 
platform (Leica Microsistems Bond RXm). After the peroxidase detection, the 
sections were counterstained with hematoxylin, dehydrated, and coverslipped. 
5.10.20 Statistical analyses. All the statistical analyses were conducted in 
GraphPad 5.0 (Prism). All the sample sizes and statistical tests are specified in the 





ANOVA at 95% confidence. For each animal experiment, groups were established 
before tumourigenesis or treatment with Cy7Gal or WOS-Cy7Gal, and therefore 
no randomization was used in the allocation of groups. Investigators were not 
blinded to the groups and treatments during the experiments. 
5.10.21 Cy7 and Cy7Gal quantum yield measurements 
Quantum yields values were measured employed rhodamine 6G as standard (Φ = 














where x and s indicate the unknown and standard solution, respectively, Φ is the 
quantum yield, S is the area under the emission curve, A is the absorbance at the 
excitation wavelength and n is the refraction index. 
5.10.22 Cy7 fluorescence emission at different pH. 
Figure S1. . (a) Fluorescence spectra (λex = 580 nm) of Cy7 (10-5 M) H2O at pH 5, 6, 7, 8, 9 and 10. (b) 
Emission intensity at 665 nm (λex = 580 nm) of Cy7 (10-5 M) H2O solutions at pH 5, 6, 7 8, 9 and 10. 
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Figure S2. (a) Chromatograms of Cy7, Cy7 + β-Gal and Cy7Gal. For hydrolysis studies, aqueous 
solutions of Cy7 and Cy7Gal at a concentration of 10-5 M (pH 7) were prepared. Human β-
galactosidase was then added (5 µl) to Cy7Gal solutions and chromatograms were acquired after 30 
min (λabs = 358 nm for Cy7Gal and λabs = 254 nm for Cy7) with a Waters 1525 binary HPLC pump 
equipped with a Waters 2990 diode array detector. Chromatograms were obtained using Empower 
3 software. Conditions: Kromasil-C18 column, 0.8 mL/min, H2O:MeOH gradient elution: 90:10 to 
10:90. Data analysis was performed using OriginPro8 software. (b) Fluorescence intensity changes of 
Cy7Gal solutions (20 μM) treated with β-galactosidase and with interfering species. From left to 
right: Blank (only Cy7Gal, 20 µM), Ca2+, Na+, SO4-, Cl-, ClO-, DTT (DL-dithiothreitol), GSH (γ-L-glutamyl-
L-cysteinyl-glycine), Glu (glutamate), Albu (albumin from human serum), Lys (lysozyme from chicken 
egg white), Cat (catalase from bovine liver), Phos (phosphatase Alkaline from porcine kidney), Amy 
(alfa-amylase from porcine pancreas), Ribo (ribonuclease A from bovine pancreas), Per (peroxidase 
from horseradish), Plp (Pphosphorylase a from rabbit muscle), Ure (urease from Canavalia 
ensiformis (Jack bean) Type III), Gox (glucose oxidase from Aspergillus niger), OHd (alcohol 
dehydrogenase from Saccharomyces cerevisiae), Est (esterase from porcine liver), β-Gal (human β-
galactosidase). Cations (150 µM), anions (150 µM), amino acids (150 µM), proteins (150 µg/mL) and 
enzymes (150 µg/mL). All measurements were acquired at 37 °C for 0.5 h. The data are the mean ± 
s.d. n = 3 independent experiments. λex = 580 nm, λem = 665 nm. 
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5.10.24 Silencing and western blotting experiments of β-galactosidase 
Figure S3. GLB1 transient downregulation inhibits Cy7Gal fluorescence in senescent cells and 
western blotting support the overexpression of β-Galactosidase in senescent 4T1 cells. (a) Western 
blot analysis of β-galactosidase expression in the control or senescent 4T1 cells. (b)Representative 
images of SA-β-Gal staining of control and palbociclib-treated 4T1 cells 48 h after transfection with 
hs.Ri.GLB1.13.3 siRNA and scrambled siRNA. (c) Confocal images of control 4T1 and 4T1 treated with 
palbociclib before and after transfection with hs.Ri.GLB1.13.3 siRNA and scrambled siRNA in 
presence of 20 µM of Cy7Gal probe. Cellular nucleus was stained with Hoechst 33342. (d) 
Quantification of the fluorescence emission intensity from obtained confocal images of control 4T1 
and 4T1 cells treated with palbociclib before and after transfection with hs.Ri.GLB1.13.3 siRNA and 
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5.10.25 X-Gal staining of kidney, liver and tumors from BALB/cByJ female 
mice carrying orthotopic 4T1 mammary tumors with or without 
palbociclib treatment 
Figure S4. Representative images of kidney, liver and tumors from BALB/cByJ mice treated with 
vehicle or with palbociclib after X-Gal assay for SA-β-Gal activity. Note that tumours from 
palbociclib-treated mice show a prominent blue staining after X-Gal assay, indicating a higher SA-β-




5.10.26 Images of BALB/cByJ female mice bearing 4T1 mammary tumors
treated with palbociclib and i.p. injected with Cy7Gal 
Figure S5. Top: IVIS images of BALB/cByJ female mice bearing 4T1 breast tumor treated by oral 
gavage with palbociclib (10, 50 and 100 mg/Kg) i.p. injected with Cy7Gal (left) and BALB/cByJ female 
mice bearing 4T1 orthotopic tumors treated by oral gavage with 100 mg/Kg palbociclib (right). 
Bottom: IVIS images of BALB/cByJ female mice bearing 4T1 breast tumor i.p. injected with WOS-
Cy7Gal (left) and BALB/cByJ female mice bearing 4T1 orthotopic tumors treated by oral gavage with 
100 mg/Kg palbociclib and i.p. injected with WOS-Cy7Gal (right). 
Vehicle
10mg/Kg 50mg/Kg 100mg/Kg 100mg/Kg 
Palbociclib
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5.10.27 Fluorophore biodistribution in BALB/cByJ mice bearing 4T1
mammary tumours treated with palbociclib and in the animal model of 
accelerated aging SAMP8 and its control SAMR1, after i.p. injection with 
Cy7Gal or WOS-Cy7Gal. 
Figure S6. In vivo biodistribution study of Cy7Gal and WOS-Cy7Gal using two different animal 
models. (a) IVIS images of tumours, bladder and kidney. From left to right: vehicle mice, mice 
treated with 100 mg/Kg of palbociclib, vehicle mice i.p. injected with WOS-Cy7Gal probe, mice 
treated with 100 mg/Kg of palbociclib and i.p. injected with WOS-Cy7Gal probe, vehicle mice i.p. 
injected with Cy7Gal probe, mice treated with 100 mg/Kg of palbociclib and i.p. injected with Cy7Gal 
probe. (b) Quantification of average radiance intensity from organs and tumors showed in (a) 
images. (c) µmoles of Cy7 excreted through urine or present in plasma of vehicle mice or mice 
treated with 100 mg/Kg of palbociclib. Values are expressed as mean ± SEM. (d) Average radiance 
intensity from urine ascribed to the renal clearance of Cy7 or WOS-Cy7 fluorophores in vehicle mice 
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5.10.28 Images of 2 and 14 months old BALB/cByJ female mice i.p. 
injected with Cy7Gal 
Figure S7. IVIS images of 2 and 14 months old BALB/cByJ female mice (left) and images of 2 and 14 
months old BALB/cByJ female mice i.p. injected with Cy7Gal (right).
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In vivo optical detection of cellular senescence is accomplished by using 
mesoporous silica nanoparticles loaded with the NIR-FDA approved Nile Blue (NB) 
dye and capped with a galactohexasaccharide (S3). Emission at 672 nm of NB is 
highly quenched inside S3, yet a remarkable emission enhancement is observed 
upon cap hydrolysis in the presence of β-galactosidase and dye release. The 
efficacy of the probe to optically detect cellular senescence is tested in vitro in 
melanoma SK-Mel-103 and breast cancer 4T1 cells and in vivo in palbociclib-
treated BALB/cByJ mice bearing breast cancer tumor.  
6.2 Introduction 
Cellular senescence is a stable state of cell cycle arrest necessary for 
maintaining the organism homeostasis.[1] However, the improper elimination of 
senescent cells, provokes local inflammation, tissue degeneration and contributes 
to aging.[2] Today scientific evidence supports that accumulation of senescent cells 
is involved in the pathophysiology of many age-related diseases[3] and has 
boosted the concept that senescent cells is an attractive therapeutic target.[4,5] 
Recent reports, using in vivo models, evidence that a wide variety of diseases can 
be ameliorated by the elimination of senescent cells.[6,7] 
Characteristic signs of cellular senescence include changes in cell morphology,[8] 
the appareance of condensed nuclear chromatin foci, known as senescence-
associated heterochromatic foci (SAHF).[9] and the overexpression or activation of 
tumor supressor proteins  such as p53, p16INK4a and p21 that contribute to cell 
cycle arrest.[10] Moreover, one of the most widely used markers to detect celular 
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senescence is the overexpression of lysosomal β-galactosidase, also referred to as 
senescence-associated β-galactosidase (SA-β-Gal).[11] 
Measurement of SA-β-Gal activity using chromo-fluorogenic probes has 
become popular as an easy and simple procedure to detect senescence.[12,13] The 
use of molecularly imprinted nanopartilces has also been described recently for 
senescence detection.[14,15] However, most of the actual probes are suitable for in 
vitro studies, whereas probes to detect cellular senescence in vivo in realistic 
senescence models are scarce. One general drawback of most of these probes is 
that, even in realistic senescence models, detection is only posible after the 
animal sacrifice. Consequently, the development of  suitable methods for in vivo 
senescence detection remains an unresolved problem.[2]
Based on the above, we report herein the use of nanoparticles[16] for in vivo 
detection of cellular senescence using a NIR fluorophore. The probe consists of 
galactohexasaccharide-capped mesoporous silica nanoparticles (MSNs) which are 
able to release their cargo in senescent cells due to the hydrolysis of the capping 
oligosaccharide by SA-β-Gal.[17] We tested a number of fluorophores as cargo and 
finally selected Nile Blue (NB) due to its remarkable features as in vivo imaging 
agent. NB is an organic dye approved by the Food and Drug Administration (FDA) 
for human use[18] and it exhibits near infrared (NIR) emission at 672 nm.[19,20] Most 
importantly, NB is an aromatic planar fluorophore, which is highly quenched at 
high concentrations or in confined spaces as it forms non-emissive π-stacked 
aggregates.[21]  
MSNs have been widely used as drug delivery systems due to their properties, 
such as biocompability and easy functionalization.[22] In addition to MSNs, other 
carriers for cargo delivery such as liposomes, micelles, polymers, etc have also 
been used in recent years.[23] In our case, MSNs were chosen as nanocarriers, due 
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Figure 1. Representation of S3 activation in BALB/cByJ female mice orthotopically injected with 4T1 
cells to generate breast tumors. After tumor formation, mice were administered with palbociclib to 
generate senescence and treated with S3 achieving in vivo detection of cellular senescence. 
to their high loading capacity, allowing the NB dye to be entrapped at high 
concentration resulting in effective dye-dye π-stacking interactions and 
quenching. This compact packaging together with the gating capability exerted by 
the capping galactohexasaccharide (vide infra) would hardly be obtained using 
other nanocarriers. In fact, MSNs are well suited for the preparation of on-
command delivery carriers by the functionalization of the outer surface with 
(bio)molecules that prevent payload release unless exposed to specific stimuli.[23] 
Besides, in MSN the cargo is simply encapsulated, while in some other 
nanoparticles cargo molecules need to be covalently linked. 
In vivo and real time 
detection of senescence 
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The prepared nanoparticles (i.e. S3 in Figure 1) are therefore poorly emissive, yet 
SA-β-Gal-induced hydrolysis of the capping hexagalacto-saccharide to give 
galactose residues, is expected to result in NB release, selectively inducing a 
marked NIR emission enhancement in senescent cells. Targeting of senescent cells 
in vitro with S3 is validated in SK-Mel-103 (human melanoma) and 4T1 (murine 
breast cancer) cell lines treated with palbociclib. Moreover, in vivo detection of 
cellular senescence is demonstrated in BALB/cByJ mice bearing breast cancer 
tumor treated with senescence-inducing chemotherapy. 
6.3 Results and discussion 
6.3.1 Synthesis, Characterization, Spectroscopic Features and Mechanism 
S3 is easily prepared from mesoporous silica nanoparticles,[24] which are 
loaded with NB, externally functionalized with APTES and finally capped with 
β(1,4)-hexagalacto-saccharide (Scheme S1).The mesoporous structure in S3 and 
the starting mesoporous silica material (S0) was clearly observed by HR-TEM 
(Figure 2a, b and S1a) and by powder X-ray diffraction (Figure S1b). S3 was also 
characterized by porosimetry (Figure S2a, b and Table S1), ATR (Figure S3) and DLS 
(Figure S4). Moreover, from dye delivery experiments and thermogravimetric 
studies, the content of NB in S3 was determined to be 0.45 mmol g-1 of solid 
(Figure S5). 
Quenching of NB inside the pores of S3, was assessed. Free NB solutions 
presented much higher fluorescence than suspensions of S3, which showed 
negligible emission at equivalent NB concentrations (Figure 2c). Moreover, 




Figure 2. (a) HR-TEM images of S3, (b) TEM-EDX of S3. (c) Fluorescence of a NB solution (1.81 x 10-4 
M) and of S3 suspensions at equivalent concentrations of the dye. (d) Emission intensity of NB
solutions vs fluorophore concentration. (e) Release profile of S3 in the absence (grey line) and in the 
presence of β-Gal (black line). Experiments were carried out in water-DMSO 99:1 v/v mixtures at pH 
4.5. Error bars are expressed as 3σ 
emissive (Figure S6). Quenching of NB at high concentrations was also studied in 
solution by monitoring the emission of the fluorophore at 666 nm (λexc = 635 nm) 
at different NB concentrations in water (pH = 4.5)-DMSO 99:1 v/v mixtures. 
Emission of NB solutions increased until a concentration of ca. 1.0 x 10-4 M, 
whereas at higher concentrations the fluorescence decreased. In fact, NB 
concentrations higher than 10-3 M are poorly emissive (Figure 2d). From the 
amount of NB loaded and the specific pore volume in S3 a molar concentration of 
the dye in the pores of ca. 0.49 M was calculated which is in agreement with the 
low emission observed for S3 in Figure 2c.  
Delivery of NB from S3 was studied in the presence and in the absence of β-Gal 
enzyme (Figure 2e). S3 show a marked NB delivery in the presence of β-Gal of ca. 
90% of the maximum dye released after 24 h, which corresponded to 31.4 % (5.69 
x 10-5 M) of the dye entrapped (Figure S7). In contrast a low NB release in the 
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absence of β-Gal was found. Release in the presence of β-Gal is due to the 
hydrolysis of glycosidic bonds in the capping galacto-saccharide which reduced 
steric crowding around the pores allowing NB delivery. 
6.3.2 In vitro validation 
Specific targeting of senescent cells in vitro with S3 was demonstrated in SK-
Mel-103 (human melanoma) and 4T1 (murine breast cancer) cells treated with 5 
µM palbociclib (a CDK4/6 inhibitor which suppresses DNA replication inducing cell 
cycle arrest) for two weeks to induce senescence. Senescence was confirmed by 
X-Gal staining (Figures 3a,3e, 3i and 3m). 
Confocal microscopy studies of palbociclib-treated SK-Mel-103 and 4T1 cells, 
incubated with S3,  revealed an intense fluorescent signal (Figure 3g and 3o), 
whereas non-senescent SK-Mel-103 and 4T1 cells treated with S3 presented weak 
fluorescence (Figure 3c and 3k). Both control and senescent SK-Mel-103 and 4T1 
cells showed also negligible background (Figures 3b, 3f, 3j and 3n respectively). In 
addition, it was found that control and senescent cells treated with equivalent 
doses of free NB presented nearly the same fluorescence (Figures 3d, 3h, 3l and 
3p, see also Figure S8). Quantification of fluorescence showed 7-fold emission 
enhancement in senescent SK-Mel-103 cells treated with S3 compared to controls 
(Figure 3q). For the 4T1 cell line, the emission enhancement of senescent cells 
tretaed with S3 when compared to control 4T1 cells was 10-fold. Results are 
indicative of S3 uptake and galacto-oligosacchadride hydrolysis by SA-β-Gal in 
senescent cells, resulting in NB release. Moreover it was found that S3 




Figure 3. (a,e,i,m) X-Gal assay for detection of SA-β-Gal expression in (a) control and (e) senescent 
SK-Mel-103 cells and in (i) control 4T1 and (m) senescent 4T1 cells. (b,c) Confocal images of control 
SK-Mel-103 cells (b) in the absence or (c) in the presence of S3. (f,g) SK-Mel-103 cells treated with 
palbociclib (f) in the absence (g) or in the presence of S3. (d,h) Confocal images of (d) control SK-Mel-
103 cells or (h) SK-Mel-103 cells treated with palbociclib in the presence of equivalent doses of free 
NB. (j,k) Confocal images of control 4T1 cells (j) in the absence or (k) in the presence of S3. (n,o) 4T1 
cells treated with palbociclib (n) in the absence (o) or in the presence of S3. (l,p) Confocal images of 
(l) control 4T1 cells or (p) 4T1 treated with palbociclib in the presence of equivalent doses of free NB. 
Cells were incubated with S3 (7.8 µg/ml) for 4.5 h in DMEM (10% FBS) in 20% O2 and 5% CO2 at 37°C, 
washed three times and stained with Hoechst (1.5 ng/ml) for 15 min. Confocal images were acquired 
by using confocal microscope (Leica TCS SP8 AOBS). Representative images from repeated 
experiments (n=3) are shown. (q) Quantification of fluorescence emission ascribed to released NB in 
control and palbociclib-treated SK-Mel-103 cells incubated with S3 and quantification of 
fluorescence emission upon treatment with equivalent doses of free NB. Autofluorescence is the 
emission observed in SK-Mel-103 cells without treatment with S3 or free NB. (r) Quantification of 
fluorescence emission ascribed to released NB in control and palbociclib-treated 4T1 cells incubated 
with S3 and quantification of fluorescence emission upon treatment with equivalent doses of free 
NB. Autofluorescence is the emission observed in 4T1 cells without treatment with S3 or free NB. 
Error bars represent s.d. 
6.3.3 In vivo validation 
In vivo detection of celular senescence with S3 was validated in mice bearing 
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BALB/cByJ female mice were orthotopically injected with 4T1 (mouse mammary 
carcinoma) cells (0.5 x 106 cell/mouse) to generate breast tumors.  
Mice were divided into four groups: (A) control individuals with 4T1 tumors; 
(B) control individuals with 4T1 tumors administered with S3; (C) mice only 
administered with palbociclib; and (D) individuals with 4T1 tumors treated with 
palbociclib and S3. Groups C and D were daily treated by oral gavage with 
palbociclib after tumor development to induce sensecence and arrest of tumor 
growth. Once completed 7 days of palbociclib treatment, S3 nanoparticles were 
intravenously administered to groups B and D, and mice were monitored by an in 
vivo imaging system (IVIS) at different time points for 48 h. No autofluorescence 
was observed from control (A) and palbociclib (C) treated mice (Figure S10). Mice 
from groups A, B and C showed negligible fluorescence in the tumor area, while a 
strong fluorescent signal was observed for group D, which was administered both 
with palbociclib and S3 (Figure 4a). The peak of maximum fluorescence in mice 
treated with palbociclib and S3 (group D) was observed 24-36 h post-injection of 
the nanoparticles (Figure 4a), whereas a clear decrease in the fluorescence signal 
was found at 48 h. Quantification of the relative values of radiance (p/s/cm2/sr x 
1010) showed and enhancement of 4.3 fold at 24 h and 7.3 fold at 36 h in 
palbociclib+S3 treated mice when compared to vehicle ones (Figure 4b). 
Mice were euthanized and blood, lungs, liver, kidney, spleen and tumors were 
ex vivo analyzed. Senescence in tumors from mice treated with palbociclib was 
confirmed by X-Gal staining (Figure 4c) and reduced immunostaining of the Ki67 
proliferation marker indicative of cell cycle arrest (Figure S11). IVIS images o 
excised organs and tumors from vehicle (A) or palbociclib-treated mice (C) did not 
show any fluorescence (Figures 4c, i) and iii)). Similarly, tumors from vehicle mice 
injected with S3 (B) did not show any noticeable fluorescent signal (Figure 4c, ii)). 
In contrast, strong emission (ca. 17.6 fold) was observed in tumors from mice 




Figure 4d). Biodistribution of nanoparticles was studied by determining silicon 
levels in various organs by inductively coupled plasma mass spectroscopy (ICP-
MS) (Figure S12). Nanoparticles reach both senescent and non-senescent tumors 
at 24 h whereas levels of Si are significantly reduced 48 h post-injection, which is 
consistent with the patterns of fluorescence signal (vide ante). S3 also acumulated 
in spleen, lungs and kidney at 24 h, whereas maxiumum silicon acumulation was 
found in spleen at 48 h. Note that even though some mesoporous silica 
nanoparticles accumulate in liver, spleen or kidney, negligible fluorescence was 
detected in these organs 24 h post injection. This is due to the very low emission 
from the capped S3 (due to π-stacking NB interactions in the pores) and also 
indicates that nanoparticles remain capped in these organs which did not 
overexpress SA-β-Gal enzyme. Blood biochemistry and hematology analysis of 
different paremeters, such as albumin (ALB), bilirubin (BIL), alkaline phosphatase 
(AKP), glutamic pyruvic transaminase (GPT) and aspartate transaminase (GOT), 
showed no noticeable signs of organ damage and systemic inflammatory response 
after nanoparticles administration (B and D) when compared to S3 untreated (A 
and C) groups (Figure S13).  
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Figure 4. (a) IVIS images at different time points of BALB/cByJ female mice bearing 4T1 breast 
tumor. From left to right control mice treated with S3 (two mice from group B) and BALB/cByJ mice 
treated by oral gavage with palbociclib (senescent tumors) for 1 week and intravenously injected 
with S3 (two mice from group D). (b) Quantification of fluorescence emission intensity from tumor 
signals with time. Error bars represent s.d. (c) X-Gal assay for SA-β-Gal expression in tumors from 
control group A (up) and palbociclib-treated group C (bottom). (i,ii, iii,iv) IVIS images of organs and 
tumors from BALB/cByJ female mice bearing 4T1 breast tumor. From left to right and from top to 
bottom: lungs, liver, tumor, kidney and spleen. (i) Control mice (group A). (ii) Control mice treated 
with S3 (group B, 4 mg/ml 200 µl). (iii) BALB/cByJ female mice bearing 4T1 breast tumor treated oral 
gavage with palbociclib for 1 week (group C). (iv) Palbociclib-treated mice intravenously injected 
with S3 (group D, 4 mg/ml 200 µl). Mice were sacrificed 24 h post-treatment for these images. (d) 
Quantification of fluorescence emission from organs and tumors in i,ii,iii and iv images. Error bars 
represent s.d. 
6.4 Conclusions 
As summary, we describe here MSN loaded with NB dye and capped with a 
galacto-oligosaccharide for the in vivo detection of cellular senescence. S3 
nanoparticles are poorly emissive due to π-stacking interactions of NB molecules 

















































































































cells resulting in a marked emission enhancement. In vitro targeting of senescent 
cells with S3 was validated in SK-Mel-103 and 4T1 cells treated with palbociclib. A 
remarkable enhanced emission in palbociclib-treated SK-Mel-103 and 4T1 
senescent cells was observed when incubated with S3 in comparison with control 
cells. S3 was validated in vivo in BALB/cByJ female mice orthotopically injected 
with 4T1 cells to generate breast tumors and treated with palbociclib. In vivo IVIS 
images showed a remarkable emission enhancement (4.3 fold at 24 h and 7.3 fold 
at 36 h) in tumors from mice treated with palbociclib and intravenously injected 
with S3, whereas negligible signal was found in mice only treated with S3 and in 
palbociclib-treated mice without S3 administration. In good accordance, ex vivo 
IVIS images showed that fluorescence ascribed to NB was only observed in 
senescent tumors (17.6-fold enhancement) but not in control tumors or other 
organs. The performance in terms of selectivity and sensitivity makes S3 and 
efficient OFF-ON probe for the in vivo detection of senescence. We anticipate that 
this or similar probes able to detect cellular senescence in vivo will become 
essential tools to follow treatment response and efficacy of senotherapies in a 
wide range of aged-related diseases. 
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6.7 Supporting information 
6.7.1 Materials and methods. 
Chemical reagents were purchased from Sigma-Aldrich and were used without 
further purification. Anhydrous solvent and phosphate-buffered saline (PBS) were 
acquired from Sharlab S.L. Dulbecco’s Modified Eagle Medium (DMEM) and fetal 
bovine serum (FBS) were purchased from Gibco. Palbociclib was acquired from 
Selleckchem. Flat-bottom-clear 96 well and cellTiter-Glo(R) Luminescent Cell 
viability were obtained from Promega. Senescence β-Galactosidase Staining KIT 
was purchased from Werfrem. Anti-Ki67 antibody was acquired from Cell 
Signaling. Recombinant Human β-Galactosidase-1/GLB1 Protein (Human β-Gal) 
was purchased from R&D systems a biotechne brand. SK-MEL-103 human 
melanoma cancer cells and 4T1 breast cancer cells lines were purchased from the 
American Type Culture Collection (ATCC). BALB/CBY female mice were acquired 
from Charles River laboratories, France. 
High resolution transmission electron microscopy (HR-TEM) images were 
recorded with a 200 KV in a JEOL JEM 2100F microscope equipped with a X ray 
detector (XRD) and Powder X-ray diffraction (PXRD) measurements were obtained 
on a Philips D8 Advance Diffractometer using CuKα radiation. Thermogravimetric 
analyses were carried out a TGA/SDTA 851e Mettler Toledo balance, using an 
oxidant atmosphere (air, 80 mL/min) with a heating program consisting of a 
heating ramp of 10°C per min from 25oC to 100oC, then temperature was kept at 
100oC for 60 min and finally a new heating ramp of 10oC per min from 100oC to 
1000oC was applied and an isothermal heating step at the final temperature for 30 
min. Porosity of materials was determined by N2 adsorption-desorption isotherms 
recorded with a Micromeritics ASAP2010 automated sorption analyzer. Fourier-
transform infrared (FTIR) spectra were recorded using a Nicolet 6700 instrument 
(Thermo scientific, USA) in the 4000–400 cm-1 range. Dynamic light scattering 
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(DLS) measurements were carried out in a Malvern Zetasizer Nano ZS. Absorption 
spectra were recorded in a JASCO V-650 spectrophotometer and fluorescence 
spectroscopy was carried out with a JASCO spectrofluorometer FP-8500. Confocal 
fluorescence images were recorded on a Leica TCS SP8 AOBS. Luminescence was 
collected in a Wallac VICTOR2TM Multilabel Plate Reader (Pelkin Elmer Sciences) 
spectrophotometer. Confocal images were analyzed using ImageJ software. IVIS 
images were analyzed by using the Living Image software. Ki67 immunostainings 
were performed by an automated immunostaining platform (Leica Microsistems 
Bond RXm). Silicon determination was performed in an Inductively Coupled 
Plasma Mass Spectrometer System (ICP-MS) Agilent 7900 in H2 mode, using 
germanium as internal standard. 
6.7.2 Synthesis of materials. 
Scheme S1. Synthetic procedure of solid S3. NB was loaded into calcined MSNs (S1). Then, the 
external surface of the NB-loaded nanoparticles was functionalized with aminopropyl moieties (S2). 
Finally, β(1,4)-hexagalacto-saccharide (GALACTAN) was covalently grafted onto the external surface 






Nile Blue (NB) APTES
GALACTAN
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Synthesis of mesoporous silica nanoparticles (S0). Cetyltrimethyl ammonium 
bromide (CTAB, 1.00 g, 2.74 mol) was first dissolved in 480 mL of deionized water 
at 40 oC. Upon total dissolution, aqueous NaOH (2.00 M, 3.5 mL) was added to the 
CTAB solution, followed by increasing solution temperature to 80 oC. TEOS (5.00 
mL, 2.25 x 10-2 mol) was then added dropwise to the surfactant solution. The 
mixture was allowed to stir for 2 h at 80 oC to obtain a white precipitate. The solid 
product was obtained by filtration and washed with deionized water until neutral 
pH and dried at 60 oC for 12 h (mesoporous silica nanoparticles as-made). To 
prepare the final porous material S0 the as-synthesized solid was calcined at 550
oC using an oxidant atmosphere for 5 h in order to remove the template phase. 
Synthesis of S2. In a typical synthesis, 200 mg of S0 and Nile Blue (NB, 70 mg, 0.16 
mmol) were suspended in 5 mL of anhydrous acetonitrile in a round-bottomed 
flask under inert atmosphere. The mixture was stirred for 24 h at room 
temperature to obtain S1. Then, without the isolation of S1 nanoparticles, (3-
aminopropyl) triethoxysilane, (APTES, 1.4 mg, 6.32 mmol) was added. The final 
reaction mixture was stirred for 5 h at room temperature. S2 was recovered by 
filtration and washed with water (see Scheme S1). 
Synthesis of S3. To obtain final S3, β(1,4)-hexagalacto-saccharide (447 mg) was 
dissolved in 31 mL of distilled water. After complete dissolution, S2 (250 mg) and 
NB (7 mg, 0.016 mmol) were added. The suspension was stirred for 20 h at room 
temperature and the final solid (S3) was recovered by centrifugation and washed 
with distilled water (see Scheme S1).  
Chapter 6 
218 
6.7.3 Materials characterization. 
All the prepared solids were characterized using standard techniques. At this 
respect, Figure S1 shows HR-TEM images of calcined nanoparticles (S0) and the 
PXRD patterns of as made MCM-41 nanoparticles, S0 and S3 solids. HR-TEM 
images show the spherical shape of the nanoparticles (with diameters in the 80-
100 nm interval) and the mesoporous structure. Moreover, the PXRD pattern of 
the as-made mesoporous silica nanoparticles shows the typical low-angle 
reflections. For the calcined solid (S0), a slight displacement of the peaks related 
to the condensation of silanol groups during the calcination process is found. 
Besides, the presence of the (100) peak in the PXRD pattern of S3 indicated that 
cargo loading and the different surface chemical modifications had not damaged 
the mesoporous structure. 
Figure S1. (a) HR-TEM images of S0. (b) Powder X-ray diffraction patterns of mesoporous silica 
nanoparticles as synthesized, calcined (S0) and the final material S3. 
The N2 adsorption-desorption isotherm of S0 nanoparticles shows an 
adsorption step at intermediate P/P0 value 0.3, which is characteristic for 
mesoporous solids with empty pores (Figure S2). This step is related to the 
nitrogen condensation inside the mesopores by capillarity. The absence of a 
hysteresis loop in this interval and the narrow BJH pore distribution suggest the 
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existence of uniform cylindrical mesopores. Application of the BET model results 
in a value for the total specific surface of 1081.2 m2·g-1 for S0 nanoparticles. N2 
adsorption-desorption isotherms for the functionalized and loaded solid S3 show 
a significant decrease in N2 volume adsorbed and are flat when compared (at the 
same scale) to those of S0. Total specific surface area for S3 significantly 
decreased to 78.3 m2·g-1 due to cargo loading inside the mesopores and external 
surface functionalization with the oligosaccharide. In order to calculate pore size 
and total pore volume, the BJH model was applied on the adsorption band of the 
isotherm for P/P0 < 0.6 (associated to adsorption inside the pores). BET specific 
values, pore volumes and pore sizes calculated from N2 adsorption-desorption 
isotherms for S0 and S3 nanoparticles are listed in Table S1. 
Figure S2. N2 adsorption-desorption isotherms of (a) S0 and (b) S3. The inset figures show pore sizes. 
Loading and functionalization of the calcined S0 nanoparticles was assessed 
also by ATR (Figure S3). As could be seen, all the prepared nanoparticles (S0, S1, 
S2 and S3) present the typical band of the Si-O-Si vibration at 1095 cm-1. Dealing 
with NB, the most representative bands were located at ca. 2900 and 2500 cm-1 
(ascribed to the stretching vibrations of C-H bonds) and at ca. 1600 cm-1 (due to 
the N-H bending vibration). These vibrations are also observed, but with lower 
intensity, in S1 solid in which NB was encapsulated inside the pores of the 
siliceous support. The most remarkable feature of the final S3 nanoparticles was 
































































































the appearance of a broad band in the 3600-2800 cm-1 interval which could be 
ascribed to the O-H bond stretching vibration of the grafted hexa-galacto 
oligosaccharide. 
Table S1. BET specific surface values, pore volumes and pore sizes calculated from N2 adsorption-
desorption isotherms for selected materials.  
a Pore size cannot be observed with N2 adsorption-desorption isotherms method due to the 
presence of the galacto-oligosaccharide covering the external surface, however, direct measures 
obtained by HR-TEM showed similar values in pore size for S0 and S3. 















S0 1081.2 0.92 2.69 
S3 78.3 0.04 --a 
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The hydrodynamic size of S0 and S3 nanoparticles was measured by dynamic 
light scattering (DLS) and the obtained results are shown in Figure S4. DLS studies 
were carried out at 25 oC on previously sonicated suspensions of S0 and S3 
nanoparticles in water at a concentration of 0.5 mg/mL. DLS measurements 
showed an increase in the hydrodynamic nanoparticle diameter, from 144 nm for 
S0 to 282 nm for S3 ascribed to the functionalization of the surface with the bulky 
oligosaccharide. 
















Figure S4. Particle size distribution by intensity obtained by DLS measurements for calcined 
nanoparticles S0 (black line) and final solid S3 (red line).  
Thermogravimetric measurements carried out with S0, S1, S2 and S3 (Figure 
S5) nanoparticles allowed us to calculate the organic matter in the loaded and 
functionalized solids. At this respect, these curves indicated an organic matter 
content of 19% for S1 (loaded with NB), 21% for S2 (loaded with NB and 
functionalized with APTES) and 30% for S3 (loaded with NB and capped with the 
galacto-oligosaccharide). Besides, from dye delivery experiments and the 
thermogravimetric studies, the content of NB in S3 was determined to be 0.45 
























Figure S5. Thermogravimetric curves of S0, S1, S2 and S3 nanoparticles. 
Finally, the quenching of NB, when inside the pores of S3, was assessed. At this 
respect, Figure S6 shows confocal microscopy images of S3 nanoparticles in the 
bright field and in the red channel. As could be seen in the bright field image, S3 
nanoparticles are well dispersed and non-aggregated. On the other hand, in the 
image of the red channel negligible fluorescence form the nanoparticles was 
observed. This fact supports that NB form non-emissive -stacking aggregates 
when confined in the inner of the pores of the mesoporous support. 
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Figure S6. Confocal images of S3 nanoparticles. (a) Bright field and (b) red channel (λexc = 638 nm and 
λem = 648-749 nm). 
6.7.4 Calculations of loaded and released NB. 
We can calculate the molar concentration of NB inside the pores of 




= 4.55 · 10−4𝑚𝑜𝑙𝑜𝑓𝑁𝐵 ∈ 1𝑔𝑜𝑓𝑆3 
From the specific pore volume (0.92 cm3g-1) of the mesoporous nanoparticles it 





4.55 · 10−4 𝑚𝑜𝑙𝑁𝐵 𝑔𝑆3⁄
9.2 · 10−4 𝐿 𝑔𝑆3⁄
= 0.49𝑀 
Moreover, from the release experiments (using 2 mg of S3) it was calculated 
that after 24 h a 31.4 % of the total loaded NB (i.e. 2.85𝑥10−6𝑚𝑜𝑙𝑁𝐵) was
delivered. The amount of NB released was calculated using the calibration curve 






















Figure S7. Absorbance of aqueous solutions of NB at 608 nm vs dye concentration. 
6.7.5 Cargo release experiments. 
In a typical experiment, 2 mg of S3 were suspended in 5 mL of water-DMSO 
99:1 v/v mixture at pH 4.5, in the presence or absence of 5 mg of enzyme human 
β-Gal. The suspension was stirred using a magnetic bar. Sample aliquots of 0.4 mL 
were taken at scheduled times and were centrifuged to remove S3. Free NB was 
monitored via the absorption band of the dye centered at 608 nm. 
6.7.6 In vitro studies. 
SK-MEL-103 (human melanoma) cancer cells were obtained from ATCC. Cells 
were maintained in DMEM, supplemented with 10% FBS, and incubated in 20% O2 
and 5% CO2 at 37°C. In a first step, cells were incubated with 5µM palbociclib in 
DMEM for one week to induce senescence. Then, cells were seeded in flat- 
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Figure S8. Confocal images of control and palbociclib-treated SK-Mel-103 cells (a) in the presence of 
different concentrations of S3 and (b) in the presence of different concentrations of free NB. 
Representative images from repeated experiments (n=3) are shown. 
Figure S9. Relative in vitro viability of control and senescent SK-Mel-103 cells after incubation with 
S3 nanoparticles for 48 h at different concentrations. SK-Mel-103 were maintained in DMEM 
supplemented with 10% FBS, and incubated in 20% O2 and 5% CO2 at 37 °C. For senescence 
induction, cells were supplemented with DMEM media containing 5 µM palbociclib for 2 weeks. 
Control and palbociclib-treated cells were plated in flat-bottom-clear 96 well plate at a density of 
3,500 and 4,000 cells per well, respectively. The following day, cells were treated with serial 
suspensions of S3. Viability was assessed 48 h later with CellTiter-GLO Luminescent Cell Viability 
Assay by measuring luminescence in a VICTOR Multilabel Plate Reader. 
bottom-clear 96 well plate. After 24 h cells were treated with S3 (7.8 µg/ml) for 
4.5 h in DMEM (10% FBS) in 20% O2 and 5% CO2 at 37°C, and washed 3 times with 
PBS to remove the non-endocytosed nanoparticles. Afterward, cells were treated 















































































by using confocal microscope (Leica TCS SP8 AOBS). The obtained results are 
shown in Figures 3 and S8. Besides, it was found that S3 nanoparticles were not 
toxic for both control and senescent SK-Mel-103 cells (Figure S9).  
6.7.7 In vivo studies. 
Mice were maintained at the Spanish Research Centre Principe Felipe (CIPF) in 
accordance with the recommendations of the Federation of European Laboratory 
Animal Science Associations (FELASA). All animal procedures were approved by 
the CIPF Ethics Committee for Research and Animal Welfare (CEIyBA). Breast 4T1 
tumors were established by using 4T1 cells. Cells were routinely cultured in 
DMEM supplemented with 10% FBS and penicillin-streptomycin. In order to 
generate breast tumor, cells were trypsinised, counted with a LUNA™ Automated 
Cell Counter and injected subcutaneously in the left breast of 28- to 34-week-old 
BALB/CBY female mice at a concentration of 0.5 x 106 cells in a volume of 100 µl. 
Tumor volume was measured every two days with a calliper and calculated as V= 
(a x b2) / 2 where a is the longer and b is the shorter of two perpendicular 
diameters. Palbociclib was administered by daily oral gavage for 7 days at 100 
mg/kg dissolved in 50 mM sodium lactate, pH 5 in order to induce senescence. 
Then, S3 was intravenously (i.v.) administered at a concentration of 4 mg/ml in a 
volume of 200 µl. 24 h post-injection emission of NB was monitored on an IVIS 
spectrum imaging system and analyzed by using the Living Imaging software from 
Caliper Life Sciences (Figure S10). Then, mice were sacrificed by CO2 exposure in a 
Euthanasia Chamber, and tumors and organs (lung, liver, kidney or spleen) were 
immediately removed. Tumors and organs were analyzed after harvesting and 
fluorescence images were taken on an IVIS spectrum imaging system and 
analyzed by using the Living Imaging software from Caliper Life Sciences. 
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Figure S10. IVIS images 24 h post injection of S3 of BALB/cByJ female mice bearing 4T1 breast cancer 
tumors. From left to right vehicle mice (group A), BALB/cByJ mice treated by oral gavage with 
palbociclib (senescent tumors) for 1 week (group C), vehicle mice intravenously injected with S3 
(group B) and BALB/cByJ mice treated by oral gavage with palbociclib (senescent tumors) for 1 week 
and i.v. injected with S3 (group D). 
6.7.8 Inmunohistochemistry protocol. 
Tumors were fixed with 4% PFA for 4h, embedded in paraffin, cut into thin 
slices and mounted onto slides for analysis. Then, samples were stained by 
indirect immunoperoxidase immunostaining. For this purpose, slides were 
incubated with the primary antibody Ki67 and then with the corresponding 
secondary antibody. Finally, sections were stained with hematoxylin, dehydrated, 
and coverslipped. The obtained results are shown in Figure S11. 
Figure S11. Immunohistochemical detection of Ki67 in paraffin sections of (a) tumors from control 





cycle arrest which is indicative of intratumoral senescence. (c) Quantification of Ki67 
immunohistochemical staining with ImageJ software.  
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6.7.9 Biodistribution experimental protocol. 
For silicon (Si) biodistribution studies, lungs, liver, spleen, kidneys, tail, bladder 
and tumor were harvested and conserved at -80 oC. Organs were first weighted 
and then individually introduced in polytetrafluoroethylene (PTFE) bottles. 1mL of 
tetramethylammonium hydroxide solution (TMAH) was added to each recipient, 
bottles were firmly closed and digestion was carried out for 2 h at 80 oC using a 
digestion unit Bloc digest 20. After cooling, digested samples were diluted with 
milliQ water to 10 mL in polypropylene Erlenmeyer flasks, then filtered with 0.45 
μm Nylon filters and kept in polystyrene tubes. Silicon determination was 
performed in an Inductively Coupled Plasma Mass Spectrometer System (ICP-MS) 
Agilent 7900 in H2 mode, using germanium as internal standard. Data are 
expressed as μg Si/g sample. The obtained results are shown in Figure S12. As 
could be seen Si levels decrease over time in most organs probably due to the 
degradation and elimination of S3 through urine and feces.1 
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Figure S12. Biodistribution of S3 nanoparticles. Silicon levels analyzed by Inductively Coupled Plasma 
1 J. Lu, M. Lion, Z. Li, J. I. Zink and F. Tamanoi, Small. 2010, 16, 6, 1794–1805 
B. Lozano-Torres et al. Angew. Chem. Int. Ed., 2020, 59, 15152 
Mass Spectroscopy (ICP-MS). Data expressed as mean ± SEM (n=4) and represented as μg Si per g of 
sample.  
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6.7.10 Toxicity and pro-inflammatory factors in vivo evaluation of S3. 
To study the safety of S3 in in vivo applications, blood samples were collected 
and albumin (ALB), bilirubin (BIL), alkaline phosphatase (AKP), glutamic pyruvic 
transaminase (GPT) and aspartate transaminase (GOT) were analysed to evaluate 
the function of liver. Additionally, to discard non-desired pro-inflammatory effect 
of S3 nanoparticles, the levels of neutrophils, lymphocytes and monocytes were 
analysed in blood samples. As shown in Figure S13 no significant differences 
between animals treated with S3 nanoparticles or untreated were observed in 
measured parameters, thus discarding toxicity or side effects derived of 
nanoparticles administration.  
Figure S13. Evaluation of systemic toxicity and pro-inflammatory factors effects derived from S3 
nanoparticles administration. (a) Albumin, (b) Bilirubin, (c) Alkaline phosphatase enzymes (AKP), 
aspartate transaminase (GOT) and glutamic pyruvic transaminase (GPT).  Note that mice groups 
treated with S3 present no significant differences in the function of liver compared to non treated 
ones. (d) Number of neutrophils, lymphocytes and monocytes as systemic inflammation indicators. 





























































































































Chapter 7 | Galacto-conjugation of 
Navitoclax as an efficient strategy to 
increase senolytic specificity and 







Galacto-conjugation of Navitoclax as an 
efficient strategy to increase senolytic 
specificity and reduce platelet toxicity  
Estela González-Gualda,1 Marta Pàez-Ribes,1 Beatriz Lozano-Torres,2,3,4,5 
David Macias,1 Joseph R. Wilson III,1 Cristina González-López,1 Hui-Ling Ou,1  
Sofía Mirón-Barroso,1 Zhenguang Zhang,1 Araceli Lérida-Viso,5 Juan F. 
Blandez,2 Andrea Bernardos,2,3,4,6 Félix Sancenón,2,3,4,5 Miguel Rovira,7 
Ljiljana Fruk,8 Carla P. Martins,9 Manuel Serrano,7 Gary J. Doherty,10 Ramón 
Martínez-Máñez,2,3,4,5,6 Daniel Muñoz-Espín1 
1CRUK Cambridge Centre Early Detection Programme, Department of Oncology, Hutchison/MRC 
Research Centre, University of Cambridge, Cambridge, UK  
2Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico 
(IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain 
3Unidad Mixta UPV-CIPF de Investigación en Mecanismos de Enfermedades y Nanomedicina, Centro 
de Investigación Príncipe Felipe, Universitat Politècnica de València, Valencia, Spain 
4CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain 5Unidad Mixta 
de Investigación en Nanomedicina y Sensores, IIS La Fe, Universitat Politècnica de València, Valencia, 
Spain 
6Senolytic Therapeutics S.L., Parc Científic de Barcelona, Barcelona, Spain 
7Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and 
Technology (BIST), Barcelona, Spain 
8Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK 
9Bioscience, Oncology R&D Unit, AstraZeneca, Cambridge, UK 
10Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's 
Hospital, Cambridge, UK 
Estela González-Gualda, Marta Pàez-Ribes, and Beatriz Lozano-Torres contributed equally in this 
work. 
(Reprinted with permission from Aging Cell. 2020;00:e13142.  
Copyright © 2020, The Authors. Aging Cell published by the Anatomical Society 
and John Wiley & Sons Ltd. All rights reserved.) 
234 
7.1 Abstract 
Pharmacologically active compounds with preferential cytotoxic activity for 
senescent cells, known as senolytics, can ameliorate or even revert pathological 
manifestations of senescence in numerous preclinical mouse disease models, 
including cancer models. However, translation of senolytic therapies to human 
disease is hampered by their suboptimal specificity for senescent cells and 
important toxicities that narrow their therapeutic windows. We have previously 
shown that the high levels of senescence associated lysosomal β-galactosidase 
(SA-β-Gal) found within senescent cells can be exploited to specifically release 
tracers and cytotoxic cargoes from galactose-encapsulated nanoparticles within 
these cells. Here, we show that galacto-conjugation of the BCL-2 family inhibitor 
Navitoclax results in a potent senolytic prodrug (Nav-gal), that can be 
preferentially activated by SA-β-Gal activity in a wide range of cell types. Nav-gal 
selectively induces senescent cell apoptosis and has a higher senolytic index than 
Navitoclax (through reduced activation in nonsenescent cells). Nav-gal enhances 
the cytotoxicity of standard senescence-inducing chemotherapy (cisplatin) in 
human A549 lung cancer cells. Concomitant treatment with cisplatin (CDDP) and 
Nav-gal in vivo results in the eradication of senescent lung cancer cells and 
significantly reduces tumour growth. Importantly, galacto-conjugation reduces 
Navitoclax-induced platelet apoptosis in human and murine blood samples 
treated ex vivo, and thrombocytopenia at therapeutically effective concentrations 
in murine lung cancer models. Taken together, we provide a potentially versatile 
strategy for generating effective senolytic prodrugs with reduced toxicities. 
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7.2 Introduction 
Senescence is an evolutionarily conserved cellular response to severe stress and 
damage characterized by stable cell cycle arrest, upregulation of pro-survival 
signalling pathways and the induction of a complex secretory phenotype, termed 
the senescence-associated secretory phenotype (SASP).1 Physiological roles of 
cellular senescence include prevention of the propagation of damaged or 
dysfunctional cells and promotion of tissue repair; these processes are facilitated 
by immune system cells driving the clearance of senescent cells.2 Senescence 
plays an active role in tumour suppression, reprogramming, tissue regeneration, 
wound healing and embryogenesis. However, the processes of senescence and 
immune clearance are dysregulated during aging, where senescent cells 
accumulate in tissues contributing to the onset and progression of multiple age-
related disorders through a variety of cell autonomous and paracrine effects that 
disrupt tissue homeostasis.2 Among other pathologies, senescence is associated 
with fibrotic disorders, cardiovascular diseases, obesity, diabetes, osteoarthritis, 
neurological disorders, inflammatory diseases and cancer.3,4 Conclusive evidence 
is accumulating that therapy-induced senescent cells (both with a cancerous and 
stromal origin) can drive tumorigenesis, either by releasing complex pro-
inflammatory and tumour-promoting SASP cocktails,5,6 or by the reversion of the 
cell cycle arrest and the acquisition of stemness and aggressive clonogenic growth 
potentials.7 Genotoxic stress, which is induced by many chemotherapies, 
promotes cellular senescence. Remarkably, it has been shown that 
chemotherapy-induced senescent breast cancer cells can promote tumour relapse 
in the lung,8 and senescent stromal cells form the niche that promotes metastasis 
in the bone.9 In the case of non-small cell lung cancer (NSCLC), neoadjuvant 
platinum-based chemotherapy results in the accumulation of senescent cancer 
cells in patients and evidence has been found of the escape of replicative arrest in 
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humans (therapy-induced) senescent lung cancer cells.10 Therefore, treatment 
modalities that eliminate therapy-induced senescent cells may be critical for 
tumour eradication. Recent research has identified targetable vulnerabilities of 
senescent cells that can be exploited by a novel group of drugs called senolytics. 
These compounds preferentially kill senescent cells by different mechanisms.11,12 
Senolytics include the BCL-2 family inhibitors Navitoclax (ABT-263)13 and ABT-
737;14 the flavonoid fisetin;15 combinations of tyrosine kinase inhibitors and 
flavonoids (e.g. dasatinib and quercetin);16 FOXO4-p53 interfering peptides;17 
HSP90 chaperone inhibitors;18 and other compounds such as piperlongumine19 
and cardiac glycosides.20,21 Senolytics have emerged as promising agents for 
treatment of pulmonary fibrosis, atherosclerosis, osteoarthritis, type 1 and 2 
diabetes mellitus, and neurocognitive decline. They can also rejuvenate aged 
hematopoietic and muscle stem cells and extend the lifespan of naturally aged 
mice.12 Despite successful preclinical proofs-of-concept for senolytics, their 
potential translatability is hampered by their associated toxicities, necessitating 
the development of more specific, and less toxic, second-generation senolytics. 
Navitoclax has been validated in a variety of preclinical models showing high 
potency in killing senescent cells—however, it also has significant on-target 
haematological toxicity, including thrombocytopenia.22 This narrows its 
therapeutic window and can preclude concomitant treatment with other agents 
with haematological toxicities. While targetable vulnerabilities of senescence have 
been discovered, these are often also present in nonsenescent tissues leading to 
problems with specifically targeting senescent cells. One consistent feature of 
senescent cells is their enrichment in lysosomes and lysosomal proteins, including 
senescence-associated β-galactosidase (SA-β-Gal) which is widely used as a 
marker of senescence23 and can be readily detected.24 We previously showed that 
the encapsulation of nanoparticles with galacto-oligosaccharides (GalNPs) is an 
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efficient method to preferentially deliver cytotoxic drugs and tracers to the 
lysosomes of senescent cells where SA-β-Gal activity hydrolyzed the galacto-
oligosaccharides, thereby releasing the cargo.25,26 We demonstrated that galacto-
encapsulated doxorubicin is preferentially released into fibrotic tissues and 
tumours accumulating senescent cells, and its concomitant administration with 
the senescence-inducing anti-cancer treatment palbociclib effectively halts 
tumour growth in xenograft models of melanoma and NSCLC.26 We have also 
shown that a fluorescent probe covalently linked to multi-acetylated galactose is 
preferentially hydrolyzed by senescent cells, releasing the free fluorophore.27 The 
presence of multiple acetyl moieties in the galactose residue is thought to render 
it membrane- permeable and therefore accessible to the lysosomal 
compartment.28 
Here, we have modified Navitoclax with an acetylated galactose to exploit the 
enriched SA-β-Gal activity of senescent cells (Figure 1a). Using a variety of model 
systems, we show that galacto-conjugation of Navitoclax, which we name Nav- 
Gal, results in a prodrug with selective, pro-apoptotic senolytic activity released in 
senescent cells that is dependent on GLB1 activity. Concomitant treatment of 
Nav-gal with the senescence-inducing chemotherapy (CDDP) efficiently arrests 
tumour progression in models of orthotopically transplanted murine lung 
adenocarcinoma cells, and in a tumour xenograft model of human NSCLC. 
Importantly, galacto-conjugation of Navitoclax reduces thrombocytopenia in 
treated mice at therapeutically effective doses, as well as apoptosis of platelets in 
human blood samples treated ex vivo. Overall, we propose galacto-conjugation of 
cytotoxic drugs as a versatile methodology for developing second-generation 
prodrugs with high senolytic activity and reduced toxicity. We provide evidence 
ofthe efficacy of combining senescence-inducing chemotherapies with 
senotherapies in cancer, with potential for clinical application. 
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Figure 1. Galacto-conjugation of the senolytic Navitoclax into a new generation senolytic prodrug, 
namely Nav-gal, as an efficient strategy for selective senolysis. (a) Schematic representation of the 
mechanism of action of Nav-gal prodrug. Nav-gal is passively taken up by both nonsenescent and 
senescent cells. In nonsenescent cells, its conjugation with a cleavable galactose renders it inactive 
and unable to inhibit anti-apoptotic proteins, such as BCL-2, preventing the induction of apoptosis. 
In senescent cells, the increased lysosomal and galactosidase activity, a hallmark of cellular 
senescence, allows the hydrolysis of the cleavable galactose, resulting in the release of active 
Navitoclax into the cytoplasm of senescent cells. Free Navitoclax will inhibit anti-apoptotic BCL-2 
proteins, which are overexpressed in senescent cells, driving specific apoptosis of these cells. (b) 
Chemical structures of Nav-gal prodrug and Navitoclax. The presence of galactopyranoside, 
covalently linked to the N of bis(sulfonyl)aniline as synthesized in this prodrug, hinders two key 
interactions: (i) π-π interaction between the phenylthioether moiety and the bis(sulfonyl)aniline 
ring; and (ii) the hydrogen bond between morpholine with Tyr-199,29 thereby preventing the 
inhibitory effect of the molecule. This moiety, the galactopyranoside, can be hydrolysed in the 
presence of β-Gal (cleavable galactose). (c) Chromatograms depicting hydrolysis reaction of Nav-gal 
aqueous solutions in the presence of human β-Gal followed by HPLC-UV as described in the text.  
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7.3 Results 
7.3.1 Synthesis, characterisation and hydrolysis reaction studies 
RNA interference and drug screening approaches led to the identification of the 
anti-apoptotic BCL-2 protein family as potential therapeutic targets in senescent 
cells, and Navitoclax (ABT-263) as a drug with a potent senolytic activity.13,30 Here, 
we have engineered a novel prodrug, namely Nav-gal, by modifying the molecular 
structure of Navitoclax following the synthetic procedure shown in Figure S1A. To 
do so, Navitoclax was reacted with 2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl 
bromide (Gal) through bimolecular nucleophilic substitution (SN2) in the presence 
of potassium carbonate yielding the Nav-gal prodrug (Figure 1b), which was 
comprehensively characterized by several nuclear magnetic resonance techniques 
(NMR), including 1H-NMR, 13C-NMR and correlated spectroscopy (COSY) NMR, as 
well as by attenuated total reflectance (ATR) and high-resolution mass 
spectrometry (HRMS) (Figures S1B–F). The 1H-NMR signal centred at 5.6 ppm 
(Figure S1B) corresponds to the anomeric proton of the attached galactose and 
indicates the successful covalent linkage of the monosaccharide to Navitoclax. In 
addition, the appearance of a signal centred at 1,749 cm−1 in the ATR spectra 
(Figure S1E) indicates that galactose remains acetylated after purification. Correct 
functionalization to the nitrogen atom of bis(sulfonyl)aniline is further 
corroborated through the fragmentation peaks observed in the mass spectrum 
(Figure S1F). After extensive structural characterization, we examined the ability 
of Nav-gal to be enzymatically hydrolysed to Navitoclax. GLB1 is the human 
lysosomal β-Gal responsible for the SA-β-Gal activity.24 We used high performance 
liquid chromatography (HPLC) to examine the time-dependent hydrolysis reaction 
of PBS (pH 7)-DMSO (0.01%) solutions containing Nav-gal in the presence of 
recombinant GLB1 and compared the peaks with those of Navitoclax (Figure 1c). 
The obtained chromatograms showed the Nav-gal peak with the subsequent 
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appearance of free Navitoclax signal in the presence of the β-Gal activity of the 
lysosomal enzyme and confirmed that Nav-gal was completely hydrolysed. No 
significant spontaneous Nav-gal hydrolysis was observed (data not shown).  
7.3.2 Nav-gal is a prodrug with effective wide-ranging senolytic activity 
that depends on GLB1 activity 
Since senescent cells are commonly characterized by high lysosomal SA-β-Gal 
activity, we hypothesized that galacto-conjugated Navitoclax would be 
preferentially processed and activated senescent cells and hence could function 
as a prodrug with more selective senolytic activity. To investigate this, we 
performed cell viability assays using a model of therapy-induced senescence. The 
lung carcinoma cell line A549 was treated with cisplatin (CDDP) for 10 days, 
resulting in elevated SA-β-Gal activity and expression of markers of senescence 
(Figure S2A–C). Cisplatin-treated A549 cells were then subjected to increasing 
doses of either Navitoclax or Nav-gal for 72 h. As shown in Figure 2a, the 
concentration of Navitoclax required to induce death in 50% of the cells, termed 
half maximal inhibitory concentration (IC50), after 72 h of treatment was 1.93 μM 
for nonsenescent and 0.12 μM for cisplatin-induced senescent A549 cells, while 
the IC50 for Nav-gal was 9.76 μM for nonsenescent and 0.28 μM for senescent 
A549 cells (Figure 2b). A similar approach was performed in a model of 
palbociclib-induced senescence with a human melanoma cell line (SK-Mel-103) 
(Figure 2c,d and Figure S2A-C). These results show (in two different models of 
chemotherapy-induced senescence) that Nav-gal has an improved senolytic index 
over Navitoclax and indicates that this effect is mainly mediated by a higher 
degree of protection of nonsenescent cells from cytotoxic activity. In an attempt 
to determine whether senolytic activity and nonsenescent cell protection by Nav-
gal were more widely observed, we then performed cell viability assays using a 
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variety of cell lines and diverse triggers of cellular senescence. Figure 2e-i show 
the effects on cell viability of both Navitoclax and Nav-gal at different 
concentrations in cisplatin-induced senescent mouse lung adenocarcinoma 
(KrasG12D/+;p53−/− (KP) L1475(luc) cells),31 palbociclib-induced senescent mouse 
breast cancer 4T1 cells, doxorubicin- induced senescent human colorectal 
carcinoma HCT116 cells, irradiation-induced senescent mouse lung fibroblasts 
(MLg) and oncogene-induced senescent human lung fibroblasts (IMR90), versus 
their nonsenescent counterparts. Efficient implementation of cellular senescence 
using these triggers was confirmed by SA-β-Gal staining and Western blotting for 
senescence markers (Figure S2D,E). In all the human/murine cell types tested, and 
independently of the senescence-inducing trigger used, Nav-gal showed effective 
senolytic activity and a significantly higher degree of protection of nonsenescent 
cells when compared to Navitoclax.To determine whether the senolytic effect of 
the prodrug Nav-gal depends on the increased lysosomal β-Gal active of 
senescent cells, siRNAs were used to knock-down the expression of GLB1 in A549 
and SK-Mel-103 cells. As shown in Figure 3af, siRNA2 efficiently downregulated 
the transcription of GLB1 at 48 h post-transfection and resulted in a significantly 
decreased number of SA-β-Gal-positive cells in both cell lines, when compared to 
scrambled siRNA and siRNA 1. While the killing efficiency of Navitoclax was 
maintained in the senescent cells in both cell lines (Figure 3g), transient 
downregulation of GLB1 significantly prevented the senolytic activity of Nav-gal 
(Figure 3h) in A549 and SK-Mel-103 cells, indicating that the selective senolysis of 




Figure 2. The prodrug Nav-gal shows efficient, broad range, senolytic activity and an increased 
senolytic index, conferring a protective effect on nonsenescent cells. (a, b) Quantification of viability 
and half maximal inhibitory concentration (IC50) of (a) Navitoclax and (b) Nav-gal on control and 
cisplatin-induced senescent A549 cells. Senolytic indices for each drug are shown in the tables 
below. Viability assay on A549 cells was performed as n = 5, and graphs depict one representative 
repeat. (c, d) Quantification of viability and maximal inhibitory concentration (IC50) of (c) Navitoclax 
and (d) Nav-gal on control and palbociclib-induced senescent SK-Mel-103 cells. Senolytic indices of 
each drug are shown in the tables below. Viability assay on SK-Mel-103 cells was performed as n = 3, 
and graphs depict one representative repeat. (e–i) Quantification of cell viability upon Navitoclax 
and Nav-gal treatment of control and  
E. González-Gualda, M. Páez-RivesB. Lozano-Torres et al. 
Aging Cell, 2020, 19, e1314 
243 
Figure 2. (e) cisplatin-induced senescent KRasG12D/WT;p53−/− lung adenocarcinoma tumour cells 
L1475(luc) (n = 4), (f) palbociclib-induced senescent 4T1 cells (n = 3), (g) doxorubicin-induced 
senescent HCT116 cells (n = 2), (h) irradiation-induced senescent MLg cells (n = 3) and (i) oncogene-
induced senescent IMR90 cells (previously treated for 72 h with 200 nM 4-hydroxytamoxifen (4-
OHT)). Data in (c-g) represent mean ± SD of replicates, and statistical significance was calculated 
using a two-tailed Student's t test; *p < .05, **p < .01, ***p < .001  
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Figure 3. GLB1 transient downregulation prevents the senolytic activity of Nav-gal. (a) 
representative images of SA-β-Gal staining of control and cisplatin-induced senescent A549 cells 48 
h after transfection with scrambled siRNA, siRNA 1 and siRNA 2. Scale bar = 200 μm. (b) Percentage 
of SA-β-Gal-positive cells in conditions presented in (a). (c) GLB1 fold change gene expression in 
control and senescent A549 cells 48 h post-transfection with different siRNAs. (d) Representative 
images of SA-β-Gal staining of control and palbociclib-induced senescent SK-Mel-103 cells 48 h after 
transfection with scrambled siRNA, siRNA 1 and siRNA 2. Scale bar = 200 μm. (e) Percentage of SA-β-
Gal-positive cells in conditions presented in (d). Bars represent mean ± SD (n = 3). (f) GLB1 fold 
change gene expression in control and senescent SK-Mel-103 cells 48 h post-transfection with 
different siRNAs.  
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Figure 3. (g) Quantification of cell viability upon 48 h Navitoclax treatment of control and cisplatin-
induced senescent A549 cells (10 μM Navitoclax) (left) and control and palbociclib-induced 
senescent SK-Mel103 cells (7.5 μM Navitoclax) (right) previously transfected with different 
experimental siRNAs against GLB1. (h) Quantification of cell viability upon 48 h Navitoclax treatment 
of control and cisplatin-induced senescent A549 cells (10 μM Nav-gal) (left) and control and 
palbociclibinduced senescent SK-Mel103 cells (7.5 μM Nav-gal) (right) previously transfected with 
different experimental siRNAs against GLB1. All bars represent mean ± SEM (n = 3). One-way ANOVA 
followed by Tukey's post-tests were performed to calculate the significance of the results; *p < .05, 
**p < .01, ***p < .001. 
7.3.3 Nav-gal induces apoptosis of senescent cells while preserving 
viability of nonsenescent cells 
The use of Navitoclax has been described to induce apoptosis preferentially in 
senescent cells through inhibition of the BCL-2-regulated pathway.13 To assess 
whether Nav-gal and Navitoclax killed senescent cells by the same end 
mechanism, cisplatin-induced senescent lung cancer A549 cells and palbociclib-
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induced senescent melanoma SK-Mel-103 cells were treated with Navitoclax or 
Nav-gal (or vehicle) in parallel, with automated realtime measurement of 
apoptosis study using a live-cell analysis system. Figure 4a,b and Figure S3A–D 
show that treatment with either Navitoclax or Nav-gal induced apoptosis 
preferentially in chemotherapy-induced senescent cells (as inferred from an 
increased annexin V signal). Importantly, and consistent with the results above 
(Figure 2a,b), the induction of apoptosis was lower in control nonsenescent cells 
treated with Nav-gal compared with Navitoclax (both at a high dose; 10 μM), 
particularly at later time points. While over 70% of nonsenescent A549 cells 
presented a strong signal for annexin V after 36 h of treatment with Navitoclax, 
this was true for only ~30% of the cells after treatment with the same dose of 
Nav-gal (Figure 4a,b and Figure S3A). Consistent effects were observed with the 
melanoma cell line SK-Mel-103 (Figure S3B–D). These results indicate that Nav-gal 
kills senescent cells by inducing apoptosis and that it protects against 
nonsenescent cell death to a higher extent than Navitoclax 
7.3.4 Cisplatin and Nav-gal have additive antitumour effects when 
used concurrently and sequentially 
Effective anti-cancer treatments have enhanced clinically beneficial effects when 
given in combination, including in NSCLC. We therefore next sought to ascertain 
the efficacy of concurrent cisplatin and Nav-gal treatment in vitro. We first used 
clonogenic assays to determine the efficacy of the combination of senescence-
inducing cisplatin and Navitoclax, Nav-gal or vehicle, administered concomitantly 
to A549 cells. Compared with monotherapies, the combination of cisplatin and a 
senolytic drug was substantially more effective at inhibiting cell proliferation 
(Figure 4c-f). From 0 to 2 μM cisplatin, as the concentration of both Navitoclax 
and Nav-gal increases, additional impairment of cell growth was observed. There 
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was also a significant reduction in the concentration of Nav-gal required to 
produce growth inhibition in 1 μM cisplatin versus 0 μM cisplatin (Figure S3G). 
Similar to the IC50 experiments (Figure 2a,b), a higher dose of Nav-gal than 
Navitoclax was required to achieve the same effect, likely due to the requirement 
for Nav-gal processing and activation by lysosomal β-Gal activity. While both 
senolytic drugs showed an additive effect in combination with cisplatin, increasing 
doses of Nav-gal exhibited coefficients of drug interactions (CDIs) <1 and closer to 
0 in combination with 1 μM cisplatin (Figure 4g), which suggests that the 
combination of drugs are likely to be synergistic.32  
Figure 4. The galacto-conjugated prodrug Nav-gal shows an enhanced effect when combined to 
senescence-inducing cisplatin treatment and a lower induction of apoptosis of nonsenescent cells. 
(a) Representative images of cell viability showing staining for Annexin V (red) of control or cisplatin-
induced senescent A549 cells, exposed to vehicle, Navitoclax (10 μM) or Nav-gal (10 μM) treatment 
over time. Red scale bar = 300 μm; black scale bar = 100 μm. (b) Average percentage of Annexin V-
positive cells in control and cisplatin-induced senescent A549 cells exposed to vehicle (top), 
Navitoclax (10 μM; middle) or Nav-gal (10 μM; bottom) treatment over time. Data represent mean ± 
SD (n = 3), where for each biological repeat the percentage of Annexin V-positive cells was 
calculated in 3 independent technical repeats per experimental condition. Statistical significance 
was calculated using two-tailed Student's t tests; *p < .05, **p < .001. 
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Of note, these observations were also validated in the context of a sequential 
treatment, where colonies were first exposed to increasing concentrations of 
cisplatin for 7 days, followed by 7 days of senotherapy (Figure S3E,F). 
Figure 4. (c, d) Representative images of clonogenic survival of A549 cells exposed to increasing 
concomitant concentrations of cisplatin (CDDP) and (c) Navitoclax or (d) Nav-gal as specified in axis. 
(e, f) Numerical heat map representation of normalized mean clonogenic potential after 10 days of 
increasing concomitant treatment with CDDP and (e) Navitoclax or (f) Nav-gal, where 1 = maximum 
clonogenic potential corresponding to untreated condition (n = 3). (g) Co-coefficient of drug 
interaction (CDI) value trend of Navitoclax and Nav-gal across 0.5 μM cisplatin treatment (left) and 1 
μM cisplatin treatment (right). CDI < 1 (yellow area) indicates a synergistic effect, where CDI values 
closer to 0 correlate to higher synergy between the drugs concomitantly used. Data represent mean 
± SD (n = 3). 
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7.3.5 Therapeutic activity of Nav-gal in xenografts and orthotopic models 
of NSCLC 
In order to validate the efficiency of the prodrug Nav-gal in combination with 
senescence-inducing chemotherapy in vivo, we used a model whereby A549 cells 
were transplanted subcutaneously into the flanks of severe combined 
immunodeficient (SCID) mice. In a first approach, we aimed to assess the 
induction of senescence in tumour-bearing mice treated with cisplatin. 
Histological analyses of the tumours collected after treatment showed evidence 
of senescence induction upon cisplatin administration (as inferred from SA-β-Gal 
positivity) (Figure 5a). The effects of concomitant treatment with cisplatin and 
each senolytic were then investigated. Once tumours reached an average volume 
of 100 mm3, mice were treated with cisplatin and daily doses of Navitoclax and 
Nav-gal, alone or in combination, for 17 days (as shown in Figure 5b). Importantly, 
both drugs improved the tumour growth inhibition of cisplatin (Figure 5c). The 
combination of cisplatin with either Navitoclax or Nav-gal had comparable effects 
on tumour growth inhibition, but both showed statistically significant differences 
with control and monotherapy groups. In contrast, Navitoclax and Nav-gal had no 
appreciable effect on tumour growth when administered in the absence of 
cisplatin, indicating that their therapeutic activities require concomitant induction 
of senescence by cisplatin in this model system. Consistently, histological analyses 
of the tumours revealed that cisplatin treatment results in increased p21 positivity 
(correlating with Western blot analyses of cisplatin-treated cells in vitro, Figure 
S2B) and decreased Ki67 positivity, which together constitute a hallmark of 
senescent cells (Figure 5d,e). Treatment with cisplatin and either Navitoclax or 
Nav-gal exhibited reduced levels of p21 and Ki67 positivity, alongside a strong 
TUNEL signal, strongly suggesting that apoptosis of senescent cells facilitates the 
anti-tumour effect. Additionally, a therapeutic effect of both Navitoclax and Nav-
gal in tumour growth was observed in a sequential treatment after one week of 
cisplatin administration, suggesting a potential application as adjuvant therapy for 
clearing senescent cells (Figure S4A,B). To obtain further evidence of the 
therapeutic potential of Nav-gal in combination with senescence-inducing 
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chemotherapy in a more physiological context, we used an orthotopic model of 
NSCLC. Here, wild-type C57BL/6J mice were transplanted (via tail vein injection) 
with a syngeneic luciferase-expressing KP lung adenocarcinoma cell line 
(L1475luc).31 Once tumours were established in the lungs, baseline luciferase 
signals were obtained and mice were then treated for 10 days with cisplatin 
alone, cisplatin and Nav-gal in combination, or their vehicles in combination, using 
the experimental scheme shown in Figure S5A. Representative images of the 
luciferase signal at initial and end-points are shown in Figure S5B. Luciferase signal 
monitoring demonstrated that concomitant treatment of the mice with cisplatin 
and Nav-gal significantly decreased tumour burden (Figure S5C) compared with 
cisplatin monotherapy. Histological analysis of the lungs showed high burden of 
senescent cells only in cisplatin-treated mice (as evidenced by increased SA-β-Gal 
and p21 levels), and decreased SA-β-Gal and p21 levels and higher TUNEL staining 
in mice concomitantly treated with cisplatin and Nav-gal, indicating enhanced 
apoptosis of senescent cells (representative areas are shown in Figure S5D).  
Figure 5 Concomitant treatment with the prodrug Nav-gal and cisplatin significantly inhibits tumour 
growth in a human lung cancer xenograft mouse model. (a) Representative images of A549 
xenografts stained for SA-β-Gal activity (in blue) after treatment with cisplatin or vehicle. (b) 
Schematic representation of concomitant treatment on A549-xenograft-bearing mice. (c) Tumour 
volume of A549 xenografts in mice concomitantly treated with cisplatin and Navitoclax or Nav-gal 
(as described in (b); n ≥ 10 tumours per group. Data represent mean ± SEM.  
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Taken together, these results demonstrate that the combination of senescence-
inducing therapy with senotherapy is highly effective in inhibiting tumour growth 
in vivo, providing preclinical proof-of-principle of the therapeutic benefits of using 
Nav-gal as a potent prodrug with senolytic activity. 
Figure 5. (d) Representative histological images of tumours at the end of concomitant treatment, 
stained for Ki67 and p21 expression, and labelled using TUNEL staining. Scale bar = 100 μm. (e) 
Percentage of Ki67- (top), p21- (middle) and TUNEL-positive (bottom) cells in tumours from animals 
treated with vehicle, cisplatin, or cisplatin and Navitoclax or Nav-gal concomitantly (n ≥ 5 tumours 
per group). For quantification, a total of 4 fields per tumour was analysed, covering most of the total 
tumour area. Two-way ANOVA followed by Bonferroni post-tests was performed to calculate the 
significance of the results; *p < .05; **p < .01; ***p < .001. 
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7.3.6 Nav-gal has reduced platelet toxicity when compared with 
Navitoclax 
Thrombocytopenia is a major dose-limiting, and clinically important, toxicity that 
is produced by Navitoclax in human patients.22,33 A potential benefit for galacto-
conjugation of senolytic drugs is the reduction of their associated toxicities, and 
the potential widening of their therapeutic windows. To determine whether 
galacto-conjugation affected platelet toxicity, we performed ex vivo experiments 
with both human and murine blood samples where we exposed the whole blood 
to increasing concentrations of either Navitoclax or Nav-gal, using fluorescein-
labelled annexin V to identify apoptotic platelets by flow cytometry34 (Figure 
S6A,B). As observed in Figure 6a,b for human blood and in Figure 6c,d for mouse 
blood, when samples were exposed to the same concentrations of Navitoclax and 
Nav-gal, the proportion of platelets with annexin V signal was significantly higher 
after exposure to Navitoclax than with Nav-gal. This effect persists in both 
models, despite a significant difference in platelet sensitivity to BCL-2 family 
inhibition between each model. To determine whether Nav-gal also protected 
platelet levels at therapeutic doses in vivo, we first examined the platelet count of 
wild-type C57BL/6J treated daily with senotherapy for a total of 10 days (Figure 
6e). As shown in Figure 6f, daily administration of Navitoclax resulted in severe 
thrombocytopenia after only 5 days of treatment, independently of the route of 
administration. Remarkably, Nav-gal treatment did not cause thrombocytopenia 
in the mice and led to platelet count levels comparable to those of vehicle-treated 
individuals, showing reduced platelet toxicity compared to Navitoclax. In order to 
validate our findings in the context of an in vivo cancer model, the platelet count 
was also assessed at end-points of the concomitant treatment of xenograft-
bearing mice described in Figure 5b-d. Notably, as shown in Figure 6g,h, no 
significant additional thrombocytopenia was observed in the group treated with  
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Figure 6 Nav-gal reduces thrombocytopenia in mice undergoing chemotherapeutic and senolytic 
treatment and reduces platelet apoptosis in mouse and human blood ex vivo, compared to 
Navitoclax. (a) Blood from healthy human volunteers was collected and treated ex vivo with 60, 20 
and 6.66 μM Navitoclax or Nav-gal as described. Apoptosis was analysed after Annexin V-FITC 
antibody incubation by flow cytometry. Graphs show proportion of apoptotic platelets upon each 
treatment based on scatter signals and Annexin V expression signal after gating for CD41-positive 
cells. (b) Percentage of Annexin V-positive platelets in human blood after treatment with 60, 20 and 
6.66 μM Navitoclax or Nav-gal. Bars represent mean ± SD (n = 3). (c) Blood from wild-type C57BL/6J 
mice was collected and treated ex vivo with 0.72, 0.24 and 0.08 μM Navitoclax or Nav-gal as 
described. Apoptosis was analysed after Annexin V-FITC antibody incubation by flow cytometry. 
Graphs show proportion of apoptotic platelets upon each treatment based on scatter signals and 
Annexin V expression signal after gating for CD41-positive cells. (d) Percentage of Annexin V-positive 
platelets in mouse blood after treatment with 0.72, 0.24 and 0.08 μM Navitoclax or Nav-gal. Bars 
represent mean ± SD (n = 5).  
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cisplatin and Nav-gal (cf. Navitoclax). We also found that Nav-gal reduced platelet 
toxicity, either in combination with cisplatin or as monotherapy, when 
administered in a sequential manner (Figure S4A–C), providing further evidence of 
platelet protection in vivo. These results confirm that the galacto-conjugation of 
Navitoclax to produce the Nav-gal prodrug serves as an effective strategy to 
decrease Navitoclax-driven thrombocytopenia at physiologically relevant 
concentrations capable of halting cancer growth. Altogether, we conclude that 
galacto-conjugated Navitoclax is effective in clearing senescent cells in vivo and 
can reduce its associated toxicities.  
Figure 6. (e) Wild-type C57BL/6J mice were treated daily with Navitoclax by oral gavage (o.g.) (100 
mg/kg body weight), with Navitoclax administered by i.p. injection (85 mg/kg body weight) or with 
Nav-gal (85 mg/kg body weight) for 10 consecutive days. Blood was collected on day 0, 5 and 10 by 
superficial vessel puncture and platelet count was analysed. (f) Platelet count on day 0, 5 and 10 
during the treatment of wild-type C57BL/6J mice in each experimental condition as described in (e) 
(vehicle, n = 4; Navitoclax o.g., n = 9; Navitoclax i.p., n = 8; Nav-gal, n = 8). Bars represent mean ± 
SEM. (g) SCID mice bearing A549-derived xenografts were treated with cisplatin (CDDP, 1.5 mg/kg 
body weight three times a week) and concomitant daily senotherapy (Navitoclax [100 mg/kg body 
weight] or Nav-gal [85 mg/kg body weight]) as shown in this schematic representation. Blood was 
collected after treatment by cardiac puncture and, platelet count was analysed. (h) Platelet count in 
each experimental condition described in (g) upon end of treatment in vivo (vehicle and CDDP, n = 5; 
CDDP + Navitoclax, n = 4; CDDP + Nav-gal, n = 6). Data represent mean ± SEM. Two way ANOVA 
followed by Bonferroni post-tests or one-tailed t tests was performed to calculate the significance of 
the results; * p < .05;***p < .001; ****p < .0001 
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7.4 Discussion 
In the last decade, the use of novel genetically engineered mouse models has 
demonstrated that the selective elimination of senescent cells attenuates a 
number of age-related pathologies and promotes the healthspan and lifespan of 
mice.35 These observations resulted in the development of senotherapies—
therapies aimed at interfering with cellular senescence, either by killing senescent 
cells (senolytics) or by inhibiting the SASP (senomorphics or senostatics).12 
However, specifically targeting senescent cells still remains a considerable 
challenge in most cases, and senotherapies are not exempt from both on- and off-
target toxicities, due to the activity of these agents in normal cells. Here, we 
report a versatile methodology for the generation of prodrugs that permits a 
more selective senolytic activity. We show that galactoconjugation of the BCL-2 
family inhibitor Navitoclax allows therapeutically relevant activity in subcutaneous 
tumour xenografts and orthotopic mouse models of chemotherapy-induced 
senescence in the context of lung carcinoma. In addition, this strategy reduces 
Navitoclax-associated thrombocytopenia in treated mice, and platelet apoptosis 
in human and murine blood samples. Targeting cellular senescence by galacto-
conjugation relies on the high levels of lysosomal β-Gal (SA-β-Gal) activity present 
in multiple types of senescent cells. Although SA-β-Gal is an imperfect marker of 
senescence, diseased tissues are often positive for this marker, particularly when 
senescent cells accumulate and persist in damaged areas.23,36 To exploit the 
accumulated pathological SA-β-Gal activity, we previously used beads with a 
mesoporous silica core that were functionally capped with a homogeneous 
coating of galacto-oligosaccharides, thereby allowing the encapsulation of 
cytotoxic drugs, including doxorubicin and Navitoclax, as well as fluorescent 
tracers for the detection of senescent cells. This nanotechnology enabled 
preferential cargo release within senescent cells, and the efficacy of this approach 
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was validated in models of bleomycin-induced pulmonary fibrosis and palbociclib-
treated melanoma and NSCLC tumours.26 However, despite the emergent interest 
in the development of nanomedicine and the considerable technical success of an 
increasing number of nanotechnologies in preclinical models, only a small number 
of formulations have reached clinical translation. The current limitations stem 
from an incomplete understanding of nano-bio interactions, potential toxicities, 
and challenges regarding biodistribution, such as systemic trafficking, presence of 
physiological barriers, mechanisms of cellular uptake, pharmacokinetics/ 
pharmacodynamics (PK/PD), and routes and timelines of elimination.37 In order to 
simplify the delivery of drugs to the lysosome of senescent cells, we recently 
created an OFF-ON two-photon fluorescent probe conjugated with an acetylated 
galactose for tracking cellular senescence in vivo.27 Acetylation is a widely used 
technique to markedly increase cellular permeabilization and uptake of N-
acetylated amino sugars.28 We show here that conjugation of Navitoclax with a β-
Gal activity-driven, cleavable acetylated galactose results in an effective prodrug 
that enhances its selective senolytic activity (over the parent drug) in a variety of 
cell types and senescence triggered by different stimuli, suggesting a potentially 
universal approach for senescent cell targeting. This includes cisplatin-induced 
senescence in human (A549) and mouse (KP) lung cancer lines; human melanoma 
(SK-Mel-103) and mouse mammary gland (4T1) cancer cell lines responsive to 
palbociclib; doxorubicin-induced senescent colorectal carcinoma cells (HCT116); 
mouse lung fibroblasts (MLg cells) subjected to X-ray radiation and human lung 
fibroblasts undergoing oncogene-induced senescence (ER:Mek IMR90 cells). Since 
Navitoclax is a potent small-molecule inhibitor of BCL-2, BCL-XL, and BCL-W 
proteins that exerts its killing activity by inducing apoptosis,38 we also tested 
whether this underlying mechanism of cell death is conserved for Nav-gal. 
Similarly to Navitoclax, we observed that Nav-gal induces the appearance of 
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annexin V-positive cells in two models of chemotherapy-induced senescence, 
namely cisplatin-induced senescent A549 lung cancer cells and palbociclib-
induced senescent SK-Mel-103 melanoma cells, thereby indicating that senolysis 
by Nav-gal is driven by the implementation of the apoptotic programme. After 
validating the use of Nav-gal with senescent cancer cells in culture, we focused on 
two in vivo models of lung carcinogenesis subjected to senescence-inducing 
chemotherapy. We showed that simultaneous administration of Nav-gal with the 
standard-of-care senescence-inducing cisplatin (widely used in the management 
of NSCLC patients) resulted in reduced tumour burden in SCID mice bearing 
subcutaneous tumour xenografts comprised of human A549 lung cancer cells. 
Concomitant treatment with cisplatin and Nav-gal also reduced tumour burden in 
an orthotopic transplantation model using murine KP lung adenocarcinoma cells. 
Nav-gal administration showed a strong effect in reducing tumour growth during 
both sequential and concomitant treatment with cisplatin. Combination 
treatment suggests an additive/synergistic effect between cisplatin and Nav-gal, 
as observed in our clonogenic assays and further confirmed by the calculated 
coefficient of drug interaction (CDI). It is important to note that neither Navitoclax 
nor Nav-gal had any relevant impact on tumour burden in the absence of cisplatin 
in our murine models, strongly suggesting a therapeutic activity restricted to the 
induction of senescence or whenever tumours contain senescent areas, but not in 
fully proliferative tumours. These observations reinforce the concept of Nav-gal as 
a senolytic prodrug and, more generally, open up the possibility of using 
senotherapies as promising adjuncts to treat cancer in combination with 
senescence-inducing chemotherapies. The eradication of senescent cancer cells 
by Nav-gal may also prevent tumour progression by mitigating the senescent 
secretome (SASP) and its broad range of potential protumorigenic effects.6 In this 
regard, cancer therapies can induce senescence not only in cancer cells but also in 
Chapter 7 
258 
stromal cells, and this is also the case in lung cancer patients subjected to 
platinum- and taxane-based chemotherapy regimens.10 Stromal senescence 
appears to establish an immunosuppressive microenvironment that influences 
and promotes tumorigenesis39 and can also be a fundamental driver of the 
metastatic niche.9 Future studies will examine the impact of Nav-gal on stromal 
senescence. Taken together, our data reinforce the concept that combination 
treatments comprised of senescence-inducing radio/chemotherapy and senolytics 
might result in potent approaches for precision cancer management in the near 
future. As with many targeted agents, Navitoclax presents clinically important and 
dose-limiting haematological toxicities in clinical trials, including 
thrombocytopenia,22 presenting particular challenges when given in combination 
with cytotoxic chemotherapies which also have dose-limiting haematological 
toxicities. For Navitoclax, this occurs because of the importance of BCL-XL in 
platelet survival, and the gradual reduction of its levels by Navitoclax promotes a 
change in the molecular clock that determines platelet lifespan leading to the pro-
apoptotic activity of BAK.40 In addition to thrombocytopenia, the first trial to 
evaluate Navitoclax in lymphoid malignancies resulted in grade III transaminitis 
and gastrointestinal bleed in a proportion of patients subjected to a continuous 
dosing schedule.33 The modification of Navitoclax with an acetylated galactose 
may prevent the exposure of healthy (nonsenescent) cells to the inhibitory activity 
of BCL-2 family protein members and, thereby, reduce unwanted side effects. In 
support of this, our IC50 experiments with A549 cells treated with cisplatin 
indicated that the enhanced senolytic index of Nav-gal when compared to 
Navitoclax is mainly due to reduced cytotoxicity in the absence of senescence 
induction, suggesting that the prodrug is not efficiently activated in nonsenescent 
A549 cells. Also, we noted that although the percentage of annexin V-positive 
senescent cancer cells at a high concentration of both Navitoclax and Nav-gal is 
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similar and results in the complete eradication of these cells, nonsenescent cancer 
cells were substantially more protected from the induction of apoptosis when 
exposed to Nav-gal, indicating enhanced selective sensitivity for Nav-gal for 
senescent cells. Importantly, we have observed that Nav-gal results in less 
thrombocytopenia (compared with Navitoclax) in daily-treated mice. We also 
show that Nav-gal reduces apoptosis in platelets, using both human and mouse 
blood samples. A recent study has shown that another Navitoclax derivative, 
namely DT2216, exerts anti-tumour activity by targeting BCL-XL to the VHL E3 
ligase for proteolytic degradation.41 However, distinctly to Nav-gal, DT2216 has 
not been designed for targeting senescent cells, but for reducing 
thrombocytopenia (as platelets are characterized by poor VHL E3 ligase 
expression) while maintaining anti-cancer properties. In addition, DT2216 
specifically targets BCL-XL, but not BCL-2 or BCL-W, which may also hinder its 
potential senolytic activity. In summary, we have synthesized a potent senolytic 
prodrug that can be used to kill multiple types of senescent cells. We propose 
galacto-conjugation as a versatile strategy that might be expanded to other 
cytotoxic agents and senolytic drugs to develop more specific, next-generation 
senolytics. As a proof-of-principle, we show that galacto-conjugated Navitoclax 
(Nav-gal) selectively kills a variety of human and murine cell types undergoing 
senescence by different stressors in vitro and that it has therapeutic efficacy in 
combination with cisplatin in murine NSCLC models. Importantly, we also 
demonstrate that galacto-conjugation of senolytics can reduce potential toxicities 
of the conjugated drug. The development of galacto-conjugated prodrugs has 
considerable promise for improving cancer treatment, as well as other human 
senescence-related disorders.  
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7.5 Experimental procedures 
7.5.1 Synthesis, characterisation and hydrolysis reaction studies 
For the synthesis of Nav-gal prodrug, 40 mg (0.04 mmol) of Navitoclax 
(Eurodiagnostico), 25 mg (0.06 mmol) of 2,3,4,6-tetra-O-acetyl-α-D-
galactopyranosyl-bromide (Sigma) and 10.5 mg (0.07 mmol) of K2CO3 (Sigma) 
were mixed. Anhydrous acetonitrile (Sigma) was added, and the mixture was 
stirred at 70°C for 3 h under argon-enriched atmosphere. The solvent was 
eliminated under vacuum. The product was purified by flash chromatography on 
silica gel (Sigma), from hexane-ethylacetate (3:7 v/v; Scharlab) to hexane-
ethylacetate (7:3 v/v) used as eluent. Purified Nav-gal was obtained as a yellow 
powder in 35% yield. For large stocks used in mouse experiments, the reactions 
were performed in different batches. Once the desired amount was obtained, all 
batches were pooled and purified on a single flash chromatography column as 
described above.  
7.5.2 Characterisation of Nav-gal prodrug 
Nav-gal was characterised by conventional techniques. For samples preparation, 
pure Nav-gal was dissolved in deuterochloroform (CDCl3; Sigma) and transferred 
to a Wilma NMR tube (Sigma). Samples were immediately analysed by proton 
nuclear magnetic resonance (1H-NMR), Carbon-13 nuclear magnetic resonance 
(13C-NMR) and homonuclear bidimensional correlated spectroscopy (COSY NMR). 
NMR spectra were acquired with a Bruker FT-NMR Avance 400 (Ettlingen, 
Germany) at 300 K and analysed with MestReNova 6.0 software. Chemical shifts 
are expressed as δH (ppm) relative tetramethylsilane (TMS). Attenuated total 
reflectance (ATR) was performed in a Bruker Tensor 27 FT-IR (Ettlingen, Germany) 
at room temperature and analysed with OPUS Data Collection Program (V1.1). 
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Finally, high resolution mass spectrometry (HRMS) was recorded with an ABSciex 
TRIPLETOF T5600. 
7.5.3 Hydrolysis reaction of Nav-gal studies 
For hydrolysis reaction studies, aqueous solutions of Navitoclax and Nav-gal at a 
concentration of 10–5 M (pH 7) in 0.01% DMSO were prepared. Human β-Gal 
(Biotechne, R&D Systems) was then added to Nav-gal solutions to a final 
concentration of 8 ng/μl, and chromatograms were acquired after complete 
reaction (λexc = 365 nm) with a Waters 1525 binary HPLC pump equipped with a 
Waters 2990 diode array detector. Chromatograms were obtained using Empower 
3 software. Conditions: KromasilC18 column, 0.9 ml/min, (H2O (0.1% acetic acid): 
MeOH gradient elution: 50:50 3 min, 40:60 7 min, 30:70 10 min, 20:80 5 min, 
10:90 3 min, 0:100 3 min. Data analysis was performed using OriginPro8 software. 
7.5.4 Cells and reagents 
The human lung carcinoma cell line A549 was obtained from the European 
Collection of Authenticated Cell Cultures (ECACC). SKMEL-103 (human 
melanoma), 4T1 (breast cancer), HCT116 (human colorectal carcinoma) and MLg 
(mouse lung fibroblastic) cell lines were obtained from the American Type Culture 
Collection (ATCC). The murine KP lung adenocarcinoma cell line L1475 was 
derived from KrasLSL-G12D/+;p53Fx/Fx mice42 and transduced with MSCV-
luciferase-hygromycin retrovirus, as previously described.31 A549, SK-MEL-103, 
4T1 and L1475(luc) cell lines were maintained in DMEM, and supplemented with 
10% FBS (Sigma). HCT116 cells were grown in McCoy's 5A medium (Thermo Fisher 
Scientific) supplemented with 10% FBS. MLg cells were cultured in DMEM-F-12 
culture media (Sigma) supplemented with 2 mM l-Glutamine and 10% FBS. 
ER:Mek IMR90 cells were cultured in phenol red-free DMEM (Sigma) 
supplemented with 10% FBS, 2 mM l-Glutamine and 1 mM sodium pyruvate 
(Sigma). All cells were incubated in 20% O2 and 5% CO2 at 37°C. Cells were 
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routinely tested for Mycoplasma using the universal mycoplasma detection kit 
(ATCC) or by RNA-capture ELISA. For senescence induction, A549 cells were 
treated with 15 Μm of cisplatin (Stratech) for 10 days. SK-MEL-103 and 4T1 cells 
were treated with 5 μM palbociclib (Eurodiagnostico) for 7 days. HCT116 cells 
were treated with 100 nM doxorubicin (Carbosynth) for 72 h. MLg cells were 
irradiated with 10 Gy and used for viability assays 10 days later. ER:Mek IMR90 
cells were treated with 200 nM 4-hydroxytamoxifen for 72 h and used for viability 
assays 2 days later. For experiments with cells, cisplatin (Stratech) was 
reconstituted in sterile PBS; palbociclib (Eurodiagnostico), Navitoclax (Stratech) 
and Nav-gal were reconstituted in DMSO. For in vivo experiments, cisplatin was 
reconstituted in saline; Navitoclax was formulated in 10% ethanol, 30% 
polyethylene glycol 400 and 60% Phosal PG, and Nav-gal was reconstituted in 
DMSO and further diluted in saline. 
7.5.5 GLB1 downregulation 
For transient downregulation of GLB1, a total of 30,000 control or 50,000 
senescent A549 and SK-MEL-103 cells were plated per well in a 24-well plate. The 
next day, cells were transfected with TriFECTa® Kit DsiRNA Duplex siRNAs 
(Integrated DNA Technologies) hs.Ri. GLB1.13.1 (siRNA1), hs.Ri.GLB1.13.3 
(siRNA2) or scrambled siRNA, using Lipotectamine RNAiMAX Reagent (Thermo 
Fisher Scientific) as per manufacturer's instructions. After 48 h, RNA was extracted 
using the RNeasy Mini Kit (Qiagen) and cDNA was synthesized with the High-
Capacity RNA-to-cDNA™ Kit (Thermo Fisher Scientific). Gene expression of GLB1 
and ACTB genes was measured by quantitative real-time PCR performed on a 
QuantStudio thermocycler (Applied Biosystems) following Luna® Universal qPCR 
Master Mix (New England Biolabs) protocol and amplification parameters, and 
using predesigned KiCqStart® SYBR® Green Primers H_GLB1_1 and H_ACTB_1 
pairs (Sigma-Aldrich). Relative quantification was carried out using 2−ΔΔCt 
methodology. 
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7.5.6 Cell viability and apoptosis analysis 
For A549, SK-MEL-103, 4T1, HCT116 and ER:Mek IMR90 cell lines, control and 
senescent cells were seeded in flat-bottom-clear 96-well plates at a density of 
6,000–8,000 and 4,000–6,000 cells per well, respectively. The following day cells 
were treated with serial dilutions of Nav-gal or Navitoclax in 0.2% FBS-containing 
media. Viability was assessed 48 or 72 h later after two hours of incubation at 
37°C with CellTiter-Glo® Luminescent Cell Viability Assay (Promega) or CellTiter-
Blue® Cell Viability Reagent (Promega). Raw data were obtained by measuring 
luminescence in a VICTOR Multilabel Plate Reader (Pelkin Elmer) or fluorescence 
at an excitation/emission wavelength of 560 nm/590 nm in an Infinite 200 PRO 
Multimode Spectrophotometer (TECAN). For MLg cells, control and senescent 
cells were seeded in a 12-well plate at a density of 80,000 and 60,000 cells per 
well respectively, and cells were treated with three to five different increasing 
concentrations of Nav-gal or Navitoclax on the following day. After 72 h, viability 
was assessed with CellTiter-Blue® Cell Viability Reagent (Promega) as described 
above. To determine the induction of apoptosis after the treatment with 
Navitoclax and Nav-gal, 4,000 senescent and 6,000 nonsenescent A549 or SK-Mel-
103 cells were seeded in 96-well plates. 24 h later, annexin V Fluorescent Reagent 
(Essen Bioscience) was added to the media, and after a first scan, the cells were 
treated with vehicle (DMSO), 11 μM Navitoclax or 11 μM Nav-gal for 48 h. Images 
were collected every 2 h with an Incucyte® S3 Live-Cell Analysis System 
microscope (Essen Bioscience) over time. A total of 2 pictures per well were 
analysed using the IncuCyte ZOOM™ software analyser, and total and annexin V-
positive cells were counted using ImageJ software. 
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7.5.7 Clonogenic assay 
For clonogenic potential analysis, 10,000 A549 cells were seeded per well in a 6-
well plate and allowed to attach overnight. In a first approach (concomitant 
treatment), cells were then treated with increasing and concomitant 
concentrations of cisplatin and Navitoclax or Nav-gal. In a second approach 
(sequential treatment), cells were first treated with increasing concentrations of 
cisplatin for 7 days, and then Navitoclax or Nav-gal were added for 7 additional 
days. Fresh drug was added every 2–3 days, and 10 days later, colonies were 
washed with PBS and fixed with 4% PFA for 10 min. They were then permeabilized 
using ice-cold methanol for 20 min, and left to dry. Colonies were then stained 
with 0.5% crystal violet for 30 min, and excess was removed by thoroughly 
washing three times with deionised water. Colonies were imaged using a BioRad 
GelDoc XR+ machine (BioRad Technologies). To calculate mean clonogenic 
potential, staining of colonies was subsequently diluted in 10% acetic acid and 
optical density (OD) was measured at 595 nm using an Infinite 200 PRO 
Multimode Spectrophotometer (PECAN) microplate reader. The blank (10% acetic 
acid) was subtracted from each OD measurement, and the average value for each 
experimental condition was calculated and normalized against clonogenic 
potential value obtained in no-treatment condition. To analyse the synergistic 
effect of the concomitant treatment of cisplatin and the senolytics Navitoclax and 
Nav-gal, we calculated the co-coefficient of drug interaction (CDI) using the 
normalized clonogenic potential values of the individual and concomitant 
treatments at different concentrations. CDIs were calculated as ratios following 
the formula CDI = (AB)/(AxB), where AB is the clonogenic potential value of the 
concomitant treatment with the two drugs combined at a specific concentration, 
and A and B are the clonogenic potential values of the individual treatments of 
each drug at such concentration. Following this formula, a CDI > 1 indicates that 
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the drugs are antagonistic, a CDI = 1 indicates that the drugs are additive and a 
CDI < 1 indicates that the drugs are synergistic, with values closer to 0 indicating 
higher synergy between the drugs. This effect can depend on the ratio and 
molarity of drugs used, and for this reason, CDIs were calculated and plotted at 
different molar ratios of cisplatin and Navitoclax or Nav-gal. 
7.5.8 Immunoblotting 
Cell lysis was performed using RIPA buffer (Sigma) supplemented with 
phosphatase inhibitors (PhosSTOP™ EASYpak Phosphatase Inhibitors Cocktail, 
Roche) and protease inhibitors (Complete™ Protease Inhibitor Cocktail, Roche). 
Proteins were quantified and separated by SDS-PAGE and transferred to 
polyvinylidene difluoride (PVDF) membranes (Millipore) according to standard 
protocols. Membranes were immunoblotted with antibodies against p21 and p53 
from Santa Cruz Biotechnology, and phospho-Rb (pRBS780) from Cell Signaling. 
After incubation with the primary antibody overnight, membranes were washed 
and incubated with secondary HRP conjugated AffiniPure antibodies (Jackson 
ImmunoResearch) for 1 h at room temperature and subsequently incubated with 
Enhanced Chemiluminescence Detection solution (Amersham). Membranes were 
plaed on X-ray films and processed using a Xograph Compact X4 automatic 
processor. 
7.5.9 Mouse experiments 
All mice were treated in strict accordance with the local ethical committee 
(University of Cambridge Licence Review Committee) and the UK Home Office 
guidelines. For the orthotopic model experiment, 5–6 weeks old C57BL/6J mice 
were transplanted in the lungs with 3 × 105 syngeneic luciferase-expressing KP 
(L1475(luc)) lung tumour cells via tail-vein injection. All mice were maintained in 
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ventilated cages within a specific pathogen free animal facility. Luminescence 
values were recorded 5 days later after i.p. injection with D-luciferin (150 mg/kg 
body weight, PerkinElmer) using an IVIS Spectrum Zenogen machine (Caliper Life 
Sciences) and analysed with Living Image software, and then randomized into the 
different experimental groups. Mice were treated with either vehicle, 1 mg/kg 
CDDP (via i.p. injection) every 3 days and 85 mg/kg Nav-gal (via i.p. injection) for 
two consecutive days after each CDDP administration. Luminescence values were 
recorded again as described above on day 5 and 15, when treatment was finished, 
all mice were culled by anaesthetic overdose, and lungs were collected for 
subsequent histological analyses. To establish subcutaneous tumour xenografts, 
5–7 weeks old SCID (CB17-Prkdcscid/J) females were injected subcutaneously with 
4 × 106 A549 cells in each flank. Tumours were measured with callipers every 2–3 
days, and the tumour volume was calculated with the formula length × width2/2. 
When tumour volume reached an average of 100 mm3, mice were randomised 
and assigned to one of the control or therapy groups. Therapy was initiated with 
either vehicle, 1.5 mg/kg cisplatin (CDDP, via intraperitoneal (i.p.) injection) three 
times per week, 100 mg/kg Navitoclax (via oral gavage) 5 days ON/2 days OFF, 85 
mg/kg Nav-gal (via i.p. injection) 5 days ON/2 days OFF, or a combination of the 
mentioned drugs. Mice were culled by cervical dislocation after 3 weeks of 
treatment. For platelet toxicity analysis, wild-type C57BL/6J mice were treated 
daily with 100 mg/kg Navitoclax (via oral gavage), 85 mg/kg Navitoclax (via i.p. 
injection) or 85 mg/kg Nav-gal (via i.p. injection) for 10 consecutive days. To 
analyse platelet count in mice, blood was collected by cardiac puncture during 
isoflurane anaesthesia in xenograft experimental mice, and by superficial vessel 
puncture in wild-type C57BL/6J experimental mice. Blood was collected into 
anticoagulating Microvette® tubes (Sarstedt), and platelet levels were 
immediately measured using a Scil Vet abc Plus hematology analyser (Horiba). 
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7.5.10 Histology 
SA-β-Gal staining was performed in frozen tissue sections using the Senescence β-
Gal Staining kit (Cell Signaling), following the manufacturer instructions. Briefly, 
whole tissue was fixed at RT for 15 min with a 2% formaldehyde and 0.2% 
glutaraldehyde, washed and incubated for 6 h at 37°C with the staining solution 
containing X-gal in N,N-dimethylformamide (pH 6.0). Tissues were subsequently 
counterstained with nuclear fast red, dehydrated and mounted. For 
immunohistochemistry, 5 mm paraffin sections were deparaffinised and re-
hydrated, and slides were incubated with anti-p21 (Abcam) and Ki67 (Abcam) 
antibodies at 4°C overnight, or processed for TUNEL staining using the DeadEnd™ 
fluorometric TUNEL System (Promega) as per manufacturer's instructions. 
Immunohistological reaction was of p21, and Ki67 was developed using 3,3-
diaminobenzidine tetrahydrochloride (DAB), and nuclei counterstained with 
haematoxylin. For immunofluorescence, frozen tissue sections were either 
processed for TUNEL staining using the above mentioned kit or alternatively fixed 
in 4% PFA for 10 min, permeabilised with 0.5% Triton™ X-100 for 3 min and 
subsequently blocked with Normal Donkey Serum for 1 h at room temperature. 
They were then probed with anti-p21 (Abcam) and Ki67 (Abcam) antibodies at 4°C 
overnight. The following day, sections were incubated with Anti-Rat IgG 555 and 
Anti-Rabbit IgG 488 secondary antibodies (Cell Signaling Technologies), briefly 
incubated in DAPI-containing PBS, and mounted using Fluoromount-G™ Mounting 
Medium. Images were obtained using an AxioScan Slide Scanner (Zeiss) and 
processed with ZEN 2 Blue Edition software (Zeiss). Positive signal for p21, Ki67 
and TUNEL was quantified with ImageJ. 
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7.5.11 Platelet apoptosis analysis 
For human platelets apoptosis assay, blood from three healthy volunteers was 
extracted according the UPV ethics procedures and processed essentially as 
shown in reference 34. For mouse platelet apoptosis assay, blood from five wild-
type C57BL/6J mice was collected by cardiac puncture in accordance with the 
University of Cambridge ethical committee and the UK Home Office guidelines. 
Samples were collected in nonvacuum citrate tubes (DH medical material), and 
blood in control tubes was diluted in Tyrodes Buffer. Blood in treated samples was 
mixed with 2X drug solution (either Navitoclax or Nav-gal) in RPMI (10% FBS). 
Control and treated specimens were incubated for 5 h in 20% O2 and 5% CO2 at 
37°C. Treated samples were diluted in Tyrodes Buffer, and then all specimens 
were mixed with AnexinBinding Buffer (Thermo Fisher Scientific) and incubated 
for 10 min with Annexin V-FITC (Immunostep) and CD-41-PE (Immunostep) 
conjugated antibodies. A23187 (Sigma), a calcium ionophore, was also added in 
parallel control samples to induce cell death and be used as a positive control. 
Samples were finally diluted in Annexin Binding Buffer (Thermo Fisher Scientific), 
and data were acquired using an FC500 MPL Flow Cytometer (Beckman-Coulter) 
for human samples and an LSR Fortessa cell analyser running the FACSDiva 
software (BD Biosciences) for mouse samples. FlowJo 10.3 software was used to 
analyse the results. 
7.5.12 Statistical analysis 
Statistical analyses were performed as described in the figure legend for each 
experiment. Statistical significance was determined by one- and two-way ANOVA, 
Student's t tests and Bonferroni post hoc tests using Prism 5 software (GraphPad) 
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as indicated. A p-value below .05 was considered significant and indicated with 
asterisk:*p < .05, **p < .01 and ***p < .005. 
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7.11 Supporting Information 
Figure S1. Molecular characterisation of pro-drug Nav-gal. (A) Schematic chemical structural 
representation of synthesis of Nav-gal prodrug. (B-C) Chemical shifts of the signals of proton (B) and 
carbon (C) atoms of Nav-gal observed in 1H and 13C NMR recorded in a 400MHz NMR spectrometer 
using deuterated chloroform (CDCl3) as solvent. 1H NMR (400 MHz, CDCl3) δ = 8.25 (d, J=2.19Hz, 1H), 
7.98 (d, J=9.18Hz, 1H), 7.86 (dd, J= 2.19, 9.18Hz, 1H), 7.41-7.26 (m, 5H), 7.03 (d, J=8.43,2H), 7.01 (d, 
J=8.43Hz,2H), 6.80 (d, J=9.4Hz, 2H), 6.65 (d, J=9.4Hz, 2H), 5.71 (d, J=8.24 Hz,1H), 5.48 (dd, J=10.37, 
8.24 Hz, 1H), 5.41 (d, J=2.72 Hz, 1H), 5.07 (dd, J=3.41, 10.4 Hz, 1H), 4.09-4.06 (m, 1H), 4.00-3.94 (m, 
2H), 3.80 (t, J=4.51 Hz, 4H), 3.28 (t, J=5.15 Hz, 4H), 3.10-2.92 (m, 3H), 2.73 (s, 2H), 2.43-2.14 (m, 
12H), 2.04 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.99 (s,3H), 1.82 (s, 2H), 1.69-1.50 (m, 2H), 1.4 (m, 3H), 
0.99 (s, 6H) ppm. (c) 13C NMR (400 MHz, CDCl3) δ =170.24, 170.48, 170.26, 170.05, 169.21, 154.90, 
151.31, 141.97, 135.55, 134.93, 133.63, 132.22, 131.34,  131.30, 131.29, 131.15, 129.83, 129.49, 
129.44, 129.41, 129.39, 128.46, 127.62, 127.52, 113.60, 113.38, 112.67, 94.76, 90.80, 71.72, 70.76, 
68.64, 68.35, 66.92, 60.68, 54.59, 53.79, 53.74, 53.56, 52.42, 50.86, 50.95, 46.82, 41.64, 41.00, 
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Figure S1. (D) Homonuclear bidimensional correlated spectroscopy 1H-1H (2D) COSY NMR (400MHz, 
CDCl3). Signals outside of the diagonal arises from the protons that are coupled together in 
neighbouring carbons. (E) Attenuated total reflectance (ATR) spectra of Nav-gal and Navitoclax 
compounds, the signal centered at ca. 1795 cm-1 are assigned to the C=O stretching vibration 
present in Nav-gal structure. (F) The high resolution mass spectra shows molecular fragments 
obtained after Nav-gal ionization corroborating the chemical structure of Nav-gal. HRMS-EI m/z: 
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Figure S2. Assessment of the induction of cellular senescence in cell lines used for in vitro 
experiments. (A) Representative images of SA-β-gal staining of control and cisplatin-induced 
senescent A549 cells, palbociclib-induced senescent SK-Mel-103 cells, cisplatin-induced senescent 
KRasG12D/WT;p53-/- lung cancer cells (L1475(luc)), palbociclib-induced 4T1 senescent cells, 
doxorubicin-induced senescent HTC116, irradiation-induced MLg fibroblastic cells and 
hydroxytamoxifen-treated ER:Mek IMR90 cells. (B) Quantification of SA-β-gal positive cells of control 
and senescent cells. (C) Western blot analysis of the expression of phospho-retinoblastoma (p-Rb), 
p53 and p21 in control and senescent cells.  
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Figure S3. The galacto-conjugated pro-drug Nav-gal shows a lower induction of apoptosis of non-
senescent melanoma SK-Mel-103 cells and lung cancer A549 cells, and significantly decreases 
clonogenic potential in combination with cisplatin. (A) Average percentage of Annexin V-positive 3 
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cells in control (left) or cisplatin (CDDP)-induced senescent A549 cells (right) exposed to Navitoclax 
(10 μM) or Nav-gal (10 μM) treatment over time. (B) Representative images of cell viability depicting 
staining for Annexin V (green) of control or palbociclib-induced senescent SK-Mel-103 cells, exposed 
to Navitoclax (10 μM) or Nav-gal (10 μM) treatment over time. Scale bar at lower magnification = 
300 μm. Scale bar at higher magnification = 100 μm. (C) Average percentage of Annexin V-positive 
cells in control (top) or palbociclib-induced senescent SK-Mel-103 cells (bottom) exposed to 
Navitoclax (10 μM) or Nav-gal (10 μM) treatment overtime. (D) Same as in (C) but directly 
comparing the effect in control and senescent cells of Navitoclax (top) or Nav-gal (bottom) 
treatment. (E) Representative images of clonogenic survival of A549 cells exposed to increasing 
concentrations of CDDP for 7 days followed by the treatment of Navitoclax (left) or Nav-gal (right) as 
specified in axis for 7 days (sequential treatment). (F) Numerical heat-map representation of 
normalised mean clonogenic potential after 7 days of CDDP treatment followed by 7 days of 
senotherapy treatment navitoclax (left) or Nav-gal (right), where 1 = maximum clonogenic potential 
corresponding to CDDP 0.5 μM condition (n=2). (G) Normalised mean clonogenic potential of A549 
cells upon increasing concentrations of Navitoclax (left) or Nav-gal (right) as a single or combined 
treatment with CDDP. In (E) data represent mean ±SEM (n=3), and in (A, C and D) data represent 
mean ± SD (n=3), where for each biological repeat the percentage of Annexin V-positive cells was 
calculated in 3 independent technical repeats per experimental condition. Statistical significance 
was calculated using two-tailed Student’s t-tests; *p < 0.05, **p < 0.001.  
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Figure S4. Sequential Nav-gal treatment after chemotherapy decreases tumour volume and 
platelet toxicity compared to Navitoclax. (A) A549-xenograft-bearing mice were first treated for a 
week with cisplatin (CDDP, 1.5 mg/kg three times a week) and then treated daily with Navitoclax 
(100 mg/kg body weight) or Nav-gal (85 mg/kg body weight) or their vehicles until end-point. Blood 
was then collected by cardiac puncture and the platelet count in each group was analysed. (B) 
Tumour volume of A549 xenografts in mice treated as described in (A) over time. (C) Platelet count 
in each experimental condition upon end of treatment in vivo (vehicle, Navitoclax, Nav-gal and 
CDDP + Navitoclax, n=5; CDDP and CDDP + Nav-gal, n=3). Data represent mean ± SEM. Two-way 
ANOVA followed by Bonferroni post-tests or one-tailed t-tests were performed to calculate the 
significance of the results; * p < 0.05.  
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Figure S5. Concomitant treatment of lung tumours with pro-drug Nav-gal and cisplatin 
significantly decreases tumour burden in an orthotopic lung cancer mouse model. (A) Murine KP 
lung cancer cells were orthotopically transplanted in the lungs of C57BL/6J mice via tail-vein 
injection. After 5 days, animals were imaged and randomised into different groups following 
luciferase signal analysis, and subsequently treated with either vehicle (n=4), cisplatin (1 mg/kg body 
weight; n=5) or cisplatin and Nav-gal (85 mg/kg body weight; n=6) as shown in the schematic 
representation. Mice 4 were imaged at day 10 and 15 post-transplantation and lungs were collected 
at end-point for histological analysis. (B) Representative images of luciferase activity signal at day 5 
(start of treatment) and 15 (end of treatment) of each experimental group are shown. (C) Fold-
change of relative luciferase activity of each group over-time.  
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Figure S5. (D) Representative histological images of lung sections of each experimental group 
stained for SA--gal activity (in blue), p21 (red), TUNEL (green) and ki67 (red). Data in (C) represent 
mean ± SEM, and statistical significance was calculated by one-way ANOVA followed by Bonferroni 
post-tests.  
Figure S6. Gating strategy for the analysis of Annexin V-positive platelets (apoptotic platelets) in 
samples from (A) human and (B) mouse blood. Total platelet events were gated based on scatter 
Chapter 7 
signals (SSC-A vs FSC-A) and then free platelets were gated through CD41 expression. The 
percentage of apoptotic platelets was determined by analysing the Annexin V-positive population. 
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The function of cellular senescence is to prevent damaged or stressed cells 
from proliferating. However, normal ageing or certain conditions can cause 
senescent cells to accumulate in tissues, thereby promoting inflammation and 
tissue ageing. Research around senescence has expanded in recent years, 
particularly with respect to strategies to modulate senescence and to detect and 
eliminate senescent cells. A number of new advances in the field of 
senotherapeutics are expected in the following years. In terms of detection, both 
chromogenic and fluorogenic probes are especially appealing as simple systems to 
detect cellular senescence. However, one general drawback of existing probes is 
that, even in realistic in vivo models, the staining is visualized only after the animal 
is euthanized or probes are tested in animal models that were not directly related 
to senescence (using a lacZ gene transfection, which results in high levels of 
bacterial β-Gal expression in the cell cytoplasm, unlike the lysosomal β-Gal activity 
associated with senescent cells). When this thesis started, there were very few 
examples of non-invasive or less invasive probes to detect the presence of 
senescent cells in realistic in vivo models. Such probes would be highly desirable, 
as they would allow monitoring the fate of senescent cells in real time. If these 
probes were accessible, we envision advances in detection cellular senescence in 
combination with classical imaging techniques, such as computed tomography, 
magnetic resonance imaging and positron emission tomography. Beyond small 
molecules, there is a marked interest in the development of (bio)molecules or 
nanoparticles that selectively release tracers in senescent cells or nanoparticles 
that selectively “interact” with senescent cells. Development of new systems for 
detection would benefit both fundamental senescence research as well as applied 
research into monitoring the efficacy and mechanisms of senolytics. Selective 
probes are expected to help detecting senescent cells in aged or damaged tissues 
and to become suitable tools to monitor the action of senolytics in multiple, age- 
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related disorders and assess treatment response. One of the main questions in 
the senotherapeutics field is how to differentiate senolytic and senomorphic 
compounds in in vivo models. A detailed understanding of senescence will allow 
us to rationally develop new probes and come closer to answering this important 
question. 
In this context, this PhD thesis has attempeted to contribute to this field by 
designing three new probes, a nanodevice based on gated mesoporous silica 
nanoparticles for the detection of cellular senescence and a pro-drug to kill 
senescent cells. All probes and materials have been succefully tested in vivo in 
various models of cellular senescence.  
At this respect, in the third chapter, a new molecular two-photon probe for the 
detection of cellular senescence in vivo is developed (AHGa). The probe consists 
of a naphthalimide fluorophore, with an L-histidine methyl ester linker and an 
acetylated galactose attached to one of the aromatic nitrogen atoms of L-
histidine. Probe AHGa is hydrolyzed in senescent cells, resulting in enhanced 
fluorescent emission intensity. The probe presents greater selectivity in vivo 
against senescent SK-Mel-103 human melanoma cells (chemotherapeuthically 
induced) than against control cells. Besides, in vivo detection of cellular 
senescence is assessed in xenografted mice with senescence inducing 
chemotherapy. 
The fourth chapter describes another two-photon probe (HeckGal) containing 
a new fluorophore with higher excitation and emission wavelength (in the NIR 
zone) which presents great versatility and is able to detect senescent cells in 
different types of cell lines with different induction methods of senescence. 
Moreover, HeckGal detects senescent cells in vivo in palbociclib-treated 
orthotopic model of mouse breast cancer and in a mouse model of renal fibrosis.  
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As mentioned avobe, there is a real need for non-invasive and easily-readout 
probes for cellular senescence detection. We deal with this problem in the fifth 
chapter, through the design of a renally clearable probe. Specifically, cellular 
senescence is detected using a new cyanine-7-based diuretic probe containing 
sulfonic acid moieties (Cy7Gal) that is hydrolyzed in senescent cells into the highly 
emitting fluorophore Cy7. The burden of senescence is quantified in vivo by direct 
measurement of urine fluorescence in a palbociclib-treated orthotopic model of 
mouse breast cancer, in naturally aged mice and in mice with accelerated 
senescence. Cy7Gal is the first example able to detect cellular senescence in vivo 
in urine and may serve as a basis for the development of new molecular probes 
for the easy diagnosis of different diseases, as well as for the monitoring of 
therapeutic treatments of patients. 
The sixth chapter is the last one devoted to cellular senescence detection. In 
this chapter, NB-loaded MSNs capped with a galactohexasaccharide is developed 
(S3). NB is highly emissive with a remarkable band at 672 nm, yet this 
fluorescence is quenched inside the pores of the S3 nanoparticles (due to π-
stacking interactions). On the other hand, the galactohexasaccharide cap in S3 
confers the nanoparticles specific selectivity for senescent cells, which 
overexpressed SA-β-Gal. This enzyme is able to hydrolize the 
galactohexasaccharide cap with the subsequent release of NB, which results in a 
marked emission enhancement. S3 optically detects cellular senescence in vitro in 
SK-Mel-103 and 4T1 senescent cells, and in vivo in a palbociclib-treated BALB/cByJ 
mice bearing breast cancer tumor.  
Finally, chapter seven describes the preparation of the pro-drug Nav-gal by 
combining the well-known senolytic drug Navitoclax and a galactose unit. Nav-gal 
is not able to inhibit the antiapoptotic proteins of the BCL-2 family when linked to 
sugar. However, upon diffusion to the lysosome of senescent cells, SA-β-Gal 
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hydrolyzes the glycosidic bond in Nav-gal, yielding free navitoclax. Nav-gal is 
validated in vitro in different senescent cell lines in in vivo in a mouse lung cancer 
model. Moreover, thrombocytopenia is reduced with Nav-gal when compared 
with Navitoclax.  
The development of probes, nanomaterials and prodrugs to target senescent 
cells in vivo is a promising strategy to detect and treat aging-related diseases. 
However, taking into the account that these systems are still in the initial stages of 
biomedicine applications, some drawbacks still need to be overcome and for 
instance the potential effects in the organism have to be completely analyzed. The 
benefit-to-risk ratio has to be studied and more research efforts are needed to 
finally use probes and senolytic drugs in clinical applications. Several new 
advances in the field of cellular senescence detection and treatment are expected 
in the near future. It is our hope that the results achieved in this PhD thesis open 
new research opportunities and inspire the development of new smart probes 
and pro-drugs for their application in the field of cellular senescence, as well as in 
other biomedical unresolved needs.  
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